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During the past two decades, gold(III), platinum(II), palladium(II) and ruthenium(II) 
compounds have been investigated as potential anticancer drugs. Our group at Brooklyn College 
reported on the cytotoxic properties of neutral and cationic gold(III), palladium(II) and 
platinum(II) complexes with iminophosphoranes (IM) or iminophosphine ligands of the general 
formula R3P=NR’. These IM ligands have been very useful to synthesize and stabilize 
compounds of d
8
 transition metals which displayed higher toxicity against leukemia, prostate 
cancer and ovarian cancer cells when compared to normal T-lymphocytes. They also seemed to 
have a mode of action different from that of cisplatin.  
This thesis describes the synthesis of coordination and organometallic, gold(III), 
platinum(II), palladium(II) and ruthenium(II) complexes with different iminophosphorane 
ligands, the study of their stability in solution by different techniques and of their interaction 
with biological targets (mostly DNA and HSA). I have also included data on the biological 
activity of these compounds (in vitro and for selected complexes in vivo) to understand their 
potential as cancer chemotherapeutics. Most of these compounds have displayed excellent 
anticancer properties by a mode of action different from that currently accepted for cisplatin and, 
in some cases, have displayed a lower toxicity, better activity or better permeability in vivo. 




In Chapter III, I describe the synthesis and characterization of a series of coordination 
gold(III), palladium(II), and platinum(II) complexes with a luminescent IM ligand derived from 
8-aminoquinoline [Ph3P=N-C9H6N]. The coordination palladium(II) and platinum(II) 
compounds can evolve further, under appropriate conditions, to give stable cyclometalated endo 
species [M{κ
3
-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl] (M = Pd, Pt) by C-H activation of the phenyl 
group of the PPh3 fragment. The compounds have been evaluated for their antiproliferative 
properties in a human ovarian cancer cell line (A2780S), in human lung cancer cells (A-549) and 
in a non-tumorigenic human embryonic kidney cell line (HEK-293T). Most compounds have 
been more toxic to the ovarian cancer cell line than to the non-tumorigenic cell line. The new 
complexes interact with human serum albumin (HSA) faster than cisplatin. Studies of the 
interactions of the compounds with DNA indicate that, in some cases, they exert anticancer 
effects in vitro based on different mechanisms of action with respect to cisplatin. The stability of 
cyclometallated compounds is markedly higher than that of coordination complexes. 
In Chapter IV, I describe the synthesis, characterization and stability studies of new 
organometallic gold(III) and platinum(II) complexes containing cyclometalated IM ligands. Most 
compounds are more cytotoxic to a number of human cancer cell lines than cisplatin. A cationic 
Pt(II) derivative ([Pt{κ
2
-C,N-C6H4(PPh2=N(C6H5)(COD)](PF6))  displays IC50 values in the sub-
micromolar range. Its cell death mechanism is mainly through caspase-dependent apoptosis but it 
triggers caspase-independent cell death when apoptosis is blocked. Permeability studies by two 
different assays: in vitro caco-2 monolayers and a rat perfusion model have revealed a high 
permeability profile for this compound (comparable to that of metoprolol or caffeine) and an 





Lastly in Chapter V, I describe the synthesis, characterization and stability studies of a 
series of organometallic ruthenium(II) complexes containing iminophosphorane ligands. These 
cationic compounds with chloride as counterion are highly soluble in water (70-100 mg/mL). 
Most compounds (especially the highly water-soluble compound- ([(η
6
-p-cymene)Ru{(Ph3P=N-
CO-2-N-C5H4)-κ-N,O}Cl]Cl) are more cytotoxic to a number of human cancer cell lines than 
cisplatin. Initial mechanistic studies indicate that the cell death type for these compounds is 
mainly through canonical or caspase-dependent apoptosis, non-dependent on p53, and that the 
compounds do not interact with DNA or inhibit protease cathepsin B. In vivo experiments of 
([(η
6
-p-cymene)Ru{(Ph3P=N-CO-2-N-C5H4)-κ-N,O}Cl]Cl) on MDA-MB-231 xenografts in 
NOD.CB17-Prkdc SCID/J mice showed an impressive tumor reduction (shrinkage) of 56% after 
28 days of treatment (14 doses of 5 mg/kg every other day) with low systemic toxicity. 
Pharmacokinetic studies showed a quick absorption in plasma with preferential accumulation in 
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1.1. Cancer, statistics and current treatment 
 
Cancer is a major public health problem in the United States and all over the world. It is 
currently the second leading cause of death in the United Sates, and is expected to surpass heart 
disease as the leading cause of death in the nearby future.
1
 In the U.S. alone, more than one 
million people get cancer each year. Although there are many kinds of cancers, cancer starts 
when normal cells in a part of the body grow out of control. Cells become cancerous due to DNA 
damage. In normal cells when DNA gets damaged, the cells either repair the damage or die. In 
cancer cells however, the damaged DNA is not repaired and the cells do not die like the normal 
cells. The cells go instead on making new ones that the body does not need. In most cases, the 
cancer cells form a tumor and over time the tumors can replace normal tissues, crowd it or push 
it aside. Very often cancer cells travel to other parts of the body where they can grow and form 
new tumors in a process called metastasis.
2
  
Nevertheless, not every cancer is the same. Some cancers, like leukemia, rarely form 
tumors and instead involve the blood and the blood-forming organs and circulate through other 
tissues where they grow. Moreover, different cancers can behave very differently. They can grow 
at different rates and respond to different treatments. Prostate cancer for instance is the second 
leading cause of cancer death among men in the US, whereas breast cancer is more common in 
women. At the same time, one particular cancer can differ in how it affects a particular organ. 
Lung cancer for example, has three main types, such as non-small cell lung cancer, which is the 
most common type of lung cancer accounting for about 85% of all lung cancers; small cell lung 
cancer, also called oat cell cancer accounting for about 10-15% of all lung cancers and this type 
of cancer tends to spread more quickly; and lung carcinoid tumor which occurs for fewer than 
5% of lung cancers. When it comes to breast cancer, different types can be identified depending 
how the cancerous cells look under the microscope. Most breast cancers are carcinomas that start 





Table 1. Ten leading cancer types for the estimated new cancer cases and deaths by sex in the 
United States for 2015.
1,2 
 




Prostate 220,800 26% Breast 231,840 29% 
Lung & bronchus 115,610 14% Lung & bronchus 105,590 13% 
Colon & rectum 69,090 8% Colon & rectum 63,610 8% 
Urinary bladder 56,320 7% Uterine corpus 54,870 7% 
Malenoma of the skin 42,670 5% Thyroid 47,230 6% 
Non-Hodgkin lymphoma 39,850 5% Non-Hodgkin lymphoma 32,000 4% 
Kidney & renal pelvis 38,270 5% Malenoma of the skin 31,200 4% 
Oral cavity & pharynx 32,670 4% Pancreas 24,120 3% 
Leukemia 30,900 4% Leukemia 23,370 3% 
Liver & intrahepatic bile duct 25,510 3% Kidney & renal pelvis 23,290 3% 
All sites 848,200 100% All sites 810,170 100% 






Lung & bronchus 86,380 28% Lung & bronchus 71,660 26% 
Prostate 27,540 9% Breast 40,290 15% 
Colon & rectum 26,100 8% Colon & rectum 23,600 9% 
Pancreatic 20,710 7% Pancreatic 19,850 7% 
Liver & intrahepatic bile duct 17,030 5% Ovary 14,180 5% 
Leukemia 14,210 5% Leukemia 10,240 4% 
Esophagus 12,600 4% Uterine corpus 10,170 4% 
Urinary bladder 11,510 4% Non-Hodgkin lymphoma 8,310 3% 
Non-Hodgkin lymphoma 11,480 4% Liver & intrahepatic bile duct 7,520 3% 
Kidney & renal pelvis 9,070 3% Brain & other nervous system 6,380 2% 
All sites 312,150 100% All sites 277,280 100% 
      
3 
 
1.1.1. Prostate cancer  
According to the latest American Cancer Society (ACS) estimates in the United States for 
2015, about 220,800 new cases of prostate cancer will be diagnosed and about 27,540 men will 
die of prostate cancer (Table 1).
2 
The mortality due to prostate cancer has however steadily 
declined between 1999 and 2003, which among several factors, may be attributable to earlier 
detection and improved treatment of cancer.
 
In the past few years, several targeted therapeutic 
agents have been developed and clinically used for the treatment of prostate cancer.
3
 Current 
therapeutic treatments for metastatic castration-resistant prostate cancer includes abiraterone (a, 
Zytiga® in Figure 1). Abiraterone was approved by the FDA in April 2011 and by the EMA 
since September 2011 for the treatment of metastatic castration-resistant prostate cancer and has 
been found to be effective as a second-line treatment with increased survival.
2,4
  
1.1.2. Triple-negative breast cancer 
Over the past several years, progress has been made in breast cancer research, including 
the discovery of the role of three proteins associated with breast cancer growth. These proteins 
include estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth 
factor receptor 2 (HER2). Researchers have been successful in creating therapies specifically for 
those three proteins, called targeted therapy. Patients diagnosed with triple-negative breast 
cancer lack these three proteins on the tumor cells that are responsible for breast cancer growth. 
This makes the triple-negative breast cancer difficult to treat. Moreover, triple-negative breast 
cancer is more aggressive than other cancers and more likely to recur than any other types of 
breast cancer. One of promising chemotherapeutic drugs for triple-negative breast cancer is a 
drug called glembatumamab vedotin (CDX-011, b in Figure 1), an antibody-drug conjugate that 
targets gpNMB-containing cells, with the goal of killing the cancer cells. gpNMB is a specific 
protein over-expressed in breast cancer and other tumor types that is believed to be involved in 







Figure 1. Current therapeutic treatments for leukemia, prostate, pancreas, lung, ovarian and 
triple-negative breast cancer. 
 
1.1.3. Lung cancer 
Lung cancer, both small cell and non-small cell, is the second most common cancer in 
both men and women in the United Sates. Lung cancer accounts for about 13% of all new cancer 
cases. According to the ACS estimates in the US, in 2015 about 221,200 new cases of lung 
cancer will occur and an estimate of 158,040 people will die of lung cancer (Table 1). Lung 
cancer mainly occurs in older people, with 2 in 3 diagnosed people being 65 of age or older and 




statistics in people with lung cancer vary depending on the stage of the cancer when it is 
diagnosed. Chemotherapeutics drugs used for small- and non-small cell lung cancer include 
cisplatin (c), carboplatin (d, Paraplatin®) and etoposide (e, Toposar®). Paclitaxel (f, Taxol
®
) is 
also used for treatment of non-small cell lung cancer (Figure 1).
2
 While all the drugs are 
administrated intravenously, etoposide can be administrated also orally. Drugs that are 
administrated through a vain as an infusion could be irritants that can cause inflammation of the 
vein through which it is given. If the medication escapes from the vein it can cause tissue 
damage.
6
 More detailed explanation and description on platinum drugs will be addressed in 
section 1.2.  
1.1.4. Leukemia  
There are four different types of leukemia, depending on the type of cells where they 
initiate, how quickly they grow, which people they affect (adults or children) and how they are 
treated. The types of leukemia include: acute lymphocytic (or lymphoblastic) leukemia (ALL), 
chronic lymphocytic leukemia (CLL), acute myeloid (or myelogenous) leukemia (AML) and 
chronic myeloid leukemia (CML). Acute lymphoblastic leukemia is the most common type of 
leukemia among children and the risk of developing is highest under the age of 5. According to 
the American Cancer Society in the United States, in 2015 there will about 54,270 new cases of 
all kinds of leukemia and approximately 24,450 deaths (Table 1).
 
One of the promising drugs for 
treatment of chronic lymphocytic leukemia CTT is bendamustine (g, Treanda®) (Figure 1), 




1.1.5. Ovarian cancer 
The ovaries are made up of three main kinds of cells and each type of cell can develop 
into a different type of tumor. These tumors include epithelial, germ cell, and stromal tumors. 
Most ovarian tumors are epithelial cell tumors. The majority of these tumors are benign (non-
cancerous) and never spread beyond the ovary and can be treated by removing either the ovary or 
the part of the ovary that contains the tumor. Approximately 21,000 women each year are affects 




States, in 2015 there will about 14,180 women will die of ovarian cancer. Chemotherapeutics 
used for ovarian cancer include cisplatin (c), carbolatin (d), etoposide (e) and albumin bound 





1.1.6. Pancreatic cancer 
Not all growths in the pancreas are cancerous. Some of them are benign while others 
might become cancer over time if left untreated. Since more people are getting imaging tests 
such as CT scans more frequently than in the past, these types of pancreatic growths are now 
being found more often. Pancreatic cancer involves two types of cells, exocrine and endocrine 
cells, which form different types of tumors. These tumors have distinct risk factors and causes, 
have different signs and symptoms, are diagnosed using different tests, are treated in different 
ways, and have different outlooks. Therefore it is important to distinguish between exocrine and 
endocrine cancers of the pancreas in order to address appropriate treatment. Approximately 
48,000 people each year are affected by pancreatic cancer in the United States; both male and 
female (Table 1) and acccording to the ACS statistics in the United States, in 2015 there will 
about 40,560 people will die of pancreas cancer. Chemotherapeutics used for pancreas cancer 
include cisplatin (c), oxaliplatin (h), albumin bound paclitaxel and paclitaxel (i).
2 
1.1.7. Limitations of the current existing chemotherapeutic treatments for the above 
described cancers 
 
The preparation of some of the listed chemotherapeutics can be sometimes challenging. 
For instance, the current commercial preparation of bendamustine entails at least nine synthetic 
steps, involving the use of several hazardous reagents such as thionyl chloride. The treatment 
cost for bendamustine is extremely costly as well. Single dose of the drug cost aproximetly 
$4.320 and the entire treatment could be as expensive as $80,000.
8
 The process of preparation of 
abiretarone involves multiple steps, including the use of Pd(II) catalysts through Suzuki or 
Negashi coupling, and long purification processes. Even though a more recent advancement in 
the preparation of abiretarone has been made with a reduced reaction time, it involves multiple 
crystallizations in order to enable large-scale synthesis. Furthermore, the process also engages 




anhydride on a rotary evaporator at higher temperature, leading to a laborious work-up with 
decrease in the yield and purity of the product.
9
  
In addition, patients who received Zytiga® and prednisone combination have a median 
overall survival of 14.8 months, which is only 4 months more from the patients that did not 
receive the treatment.
10
 Clinical trials for Taxol® in advanced ovarian cancer, showed that the 
survival impact is an average prolongation of one year in survival, which is a modest dramatic 
result for patients with advanced disease. In case of Taxol® for non-small-cell lung cancer, it 
prolongs the survival by approximately two months compared to a standard chemotherapy 
treatment consisting of cisplatin and etoposide.
11 
Additionally, the major drawbacks of these drugs are side effects, such as nausea, 
vomiting, hair loss or vision problems. Cisplatin and bendamustine can cause major damage to 
the kidneys
2,12,13
 and because of the way etoposide acts on cells in the body, it may increase the 
risk of getting a second type of cancer, such as leukemia.
2
 Paclitaxel can cause allergic reactions 
or condition known as hand-foot syndrome, causing pain, numbness or swelling in the hands or 
feet, while albumin bound paclitaxel can affect heart rhythm, as well as lung inflammation.
2 
There is therefore, a real need for new chemotherapeutics that can overcome the major 
drawbacks of already existing drugs for the cancers listed above.  
 
1.2. The foundation of platinum-based drugs, as cancer chemotherapeutics - limitations 
and resistance 
 
The accidental discovery of cisplatin (cis-diamminedichloroplatinum(II)) over 40 years 
ago by Barnett Rosenberg (a Brooklyn College ‘62 alumnus) and its clinical approval in 1978, 
revolutionized cancer chemotherapy that represents a major landmark in the history of successful 
anticancer drugs.
13,14
 This discovery led to the synthesis and biological evaluation of hundreds of 
cisplatin analogues, such as carboplatin, oxaliplatin, picoplatin, as well as nedaplatin and 
lobaplatin (the last two being widely used in Asia) (Figure 2).
15
 However, only cisplatin and the 
follow-on drugs carboplatin (Paraplatin®) and oxaliplatin (Eloxatin®) have been approved 
worldwide as anticancer drugs and are still used to treat 40–80% of cancer patients.
12,15
 At 
present, cisplatin is one of the most effective drugs employed to treat testicular and ovarian 




oxaliplatin has been approved by the FDA in 2002 for treating colorectal cancer. Despite the 






Figure 2. Platinum-based chemotherapeutic agents. 
 
 
The primary target for cisplatin is DNA (Figure 3). The major mechanism of action is 
that cisplatin becomes activated intracellularly by the aquation of one of the two chloride leaving 
groups which allows cisplatin to covalently bind to guanines of the DNA, forming a DNA 
adduct. This activates various signal-transduction pathways, such as those involved in DNA-











Despite therapeutic success in the treatment of several types of tumors, the high 
effectiveness of platinum-derived drugs has faced certain limitations. Since DNA is the primary 
target for cisplatin, it can affect both sick and healthy cells. In addition, due to the affinity of 
platinum for the sulfur and selenium donor that are present in many proteins in the plasma and in 
the cellular environment, cisplatin can interact and disrupt the function of different proteins and 
enzymes, as confirmed by the fact that only 1% of the intravenously administrated drug actually 
reaches DNA.
 
This produces a variety of side effects such as neurotoxicity, nephrotoxicity, 
hepatotoxicity, ototoxicity, gastrointestinal disturbances, bone marrow suppression, hair loss and 
anemia.
13,15 
Another important concern is that cisplatin may induce acquired or intrinsic 
resistance.
15,16
 Cisplatin can bind to DNA through both interstrand and intrastrand cross-linking, 
thus hindering RNA transcription and DNA replication which subsequently triggers the cell 
death pathway. Unfortunately, its efficacy is frequently lost after several chemotherapeutic- 
cycles due to tumor cells resistance. Platinum drugs such as carboplatin, that bind to DNA in the 
same manner and generate the same kind of adduct as cisplatin probably induce cross-resistance 
to cisplatin. Another drawback is the fact that cisplatin only reaches DNA in low amounts where 






A number of platinum analogues have entered clinical trials in the past 30 years with two 
(carboplatin and oxaliplatin) having been approved by the FDA. Satraplatin and picoplatin have 
emerged after the development of carboplatin. Satraplatin was originally developed as an orally 
active version of carboplatin and early clinical trials demonstrated the feasibility of 
administrating a platin by the oral route. Satraplatin showed promising clinical activity in a trial 
of 50 patients with hormone-refractory prostate cancer. Phase III with this drug, involving 900 
patients who had failed previous chemotherapy, showed significant reduction of the risk in 
disease progression. The most recent data for Satraplatin has been submitted as a new drug 
application to the FDA and awaits approval.
13
  
In addition, picoplatin was designed to provide steric bulk around the platinum centre and 
showed to retain activity against a wide range of cisplatin-resistant and oxaliplatin-resistant cells 
in vitro. Picoplatin also demonstrated in vivo antitumor activity by both the intravenous and oral 
routes, as well as promising antitumor activity in phase II trials of ‘platinum sensitive’ ovarian 




Overcoming these limitations can be quite challenging in pharmaceutical research. 
Development of more active platinum-derived drugs
14,18-26
 with improved properties and with 
less side effects that can address the clinical problems
2,12,13,15
 related to the use of cisplatin and 
their follow-on drugs, carboplatin and oxaliplatin is extremely important. Nanotechnology may 
provide several advantages for drug delivery and accumulation of platinum compounds
27
 such 
as: 1) Control of drug solubility; 2) Modulation of drug distribution; 3) Targeting of specific 




















) have been encapsulated into polymer nanoparticles and tested in vitro or in 
vivo as potential cancer chemotherapeutics. All these formulations were proven to be beneficial 
with better activities in vitro or in vivo and lower nephrotoxicity than cisplatin. The synthetic 
strategies involved are nevertheless not straight forward and certainly not cheap. It would also be 
desirable to have metallodrugs more selective and effective than cisplatin to be delivered this 
way.  
A wide range of other transition-metal based drugs emerged as potential candidates and 
are currently investigated for future advancement.
14,15,35,36,39-43,45-51,53-57




organometallic compounds with properties bridged somewhat between inorganic and organic 
drugs have been recently considered as promising alternatives as cancer chemotherapeutics. One 
reason is that these cross-compounds combine the features of a metallic center and organic 
scaffolds and may be endowed with versatile stereochemistry having geometries ranging from 
linear to octahedral and sometimes even beyond, with a large number of stereoisomers in some 
cases. Another reason is that the redox properties of the resulting metal cations in vitro along 
with their ability to bind covalently to biological targets can make them good candidates in 
medicinal chemistry. Lastly, organometallic species are relatively lipophilic (more permeable) 
and can be functionalized with a variety of organic ligands that contain specific reactivity.
14
  
 In the following subsections, new coordination and mostly organometallic platinum(II), 
gold(III), palladium(II) and ruthenium(II and III) complexes are described as potential cancer 
chemotherapeutics.  
1.3. Platinum (II), gold(III), palladium(II) and ruthenium (II and III) compounds as 
alternatives chemotherapeutic agents 
1.3.1. Platinum(II) compounds 
From the different strategies employed (trans compounds, platinum(IV) pro-drugs, 





 Multiple efforts have been made to synthesize various and 
structurally different organoplatinum complexes exhibiting antitumor properties and with 
different mechanisms of action. Within this context, novel cyclometalated platinum-based 
complexes have been designed, synthesized and studied, with an emphasis on their potential 
interaction with DNA and favorable cytotoxicity against different cancer cell lines.
14
 The early 
development of this type of compounds for anticancer purposes focused on different bidentate C-
N cycloplatinated complexes having the general formula Pt(C-N)LX. By changing the structure 
of C-N ligands and other ancillary ligands, the kinetic, structural and electronic properties of 
cycloplatinated compounds can be appropriately tuned to enhance their activity.
18,19
 One such 
example is five coordinated cyclometalated Pt(II) complexes (A, Figure 4) containing chelating 




cisplatin. Moreover, this compound displayed proteasome inhibitory activity in human breast 




Figure 4. Recently developed platinum anticancer agents.
14,20-22 
 
 Cycloplatinated tridentate C-N-N complexes that are more stable under physiological 
conditions than cisplatin and its derivatives have been recently described by Che’s et al. (like B 
in Figure 4). This N-heterocyclic carbene platinum complex displayed in vitro cytotoxicity 
activity higher than that of cisplatin and inhibited tumor growth in a nude mice model. 
Surprisingly, B did not accumulate in the vicinity of DNA but preferentially accumulated in 
cytoplasmic structures including sites where active survivin, an inhibitor of apoptosis, is located. 
Most importantly, in vivo results showed that injection at 3 mg/kg considerably inhibited NCI-
H460 tumor growth, did not cause death of mice and induced no significant weight loss.
21
 
Moreover, a rhomboidal Pt(II)-based complex C was recently evaluated in vivo on the 
tumor growth rate in a breast cancer (MDA-MB-231) mouse xenograft model. Interestingly, 
substantial 64% reduction of the average tumor volume reduction burden was observed on the 
last day of the experiment.  In addition, the emissive properties of this complex open a possibility 






1.3.2. Gold(III) compounds 
 The successful development of antitumor platinum drugs has paved the way for studying 
other metal-based chemotherapeutic compounds with potentially improved properties. Gold was 
one of the first metals used as a treatment for disease thousands of years ago; however its 
exploitation in modern medicine was mainly restricted to the cure of rheumatoid arthritis since 
the mid-1930s.
15
 During the past decade gold complexes have gained increasing attention due to 
their strong tumor cell growth inhibiting effects generally achieved by exploiting non-cisplatin-
like pharmacodynamic and pharmacokinetic properties and mechanisms of action.
31-33
 Gold(III) 
compounds were initially chosen as an alternative to cisplatin since Au(III) is isoelectronic with 
Pt(II) and has a d
8
 configuration resulting in square-planar tetracoordinate complexes, which in 
theory should make them interact with DNA in a similar manner. The ligand exchange kinetics 
are relatively slow for both metals although they are slightly faster for Au(III) complexes. 
Unfortunately, their relatively poor chemical stability in solution slowed down research in this 
field until the mid-1990s when complexes stable in physiologically relevant conditions were 
developed.
15 
Since then, improved classes of gold(III) compounds have been reported with 
anticancer activities. They not only display high cytotoxicity against representative human tumor 
cell lines in vitro and tumors in vivo, but also show a mode of action different from that of 
cisplatin which allows them to be active in specific cell lines resistant to cisplatin. It has been 
proposed that the mechanism of action for Au(IIII) complexes is either purely DNA-independent 
or that the interaction with DNA in the intercalative mode is partly responsible for the cell death. 
Moreover, in most cases, Au(III) compounds display interactions with a variety of target proteins 
isolated or inside cells. Thus, they form effective bonds with serum proteins, such as albumin or 
with sulfur-containing proteins such as GSH and thioredoxin reductases (TrxR).
14,15
 The two 
main mechanisms known to date that are responsible for the biological activity of gold(III) 
compounds include reductive oxygen species (ROS) production and direct metal binding to the 
proteasome.
34 
 Among these compounds, gold(III)-dithiocarbamato AuD6 (E) and AuD8 (F) (Figure 5) 
were designed as anticancer gold(III)-based peptidomimetics. Both compounds were highly 
active against human MDA-MB-231 breast cancer cell lines in vitro, with AuD8 being more 
potent than AuD6 (IC50 = 6.5±0.6 µM). In vivo studies showed slightly higher antitumor activity 




days of treatment. In some mice, 85% inhibition after 13 days was observed. AuD68 was also a 





Figure 5. Representative gold(III) dithiocarbamate and cycloaurated complexes.
14,35-39 
 
Cinellu, Messori et al. developed a C,N,N-gold(III) complex (G, in Figure 5) that was 
stable under pseudo-physiological conditions and was cytotoxic against different ovarian cancer 
cell lines.
36
 Cycloaurated compound G displayed good activity and high selectivity against a 
panel of 12 human tumor cell lines while H was considerably more cytotoxic and had a high 
degree of selectivity against panel of 36 human tumor cell lines.
37
 Studies on the inhibitory 
effects on TrxR suggested that mitochondrial pathways were directly involved in the apoptotic 
process and the cytotoxicity. The interaction of G with Calf Thymus DNA showed to be weak 
and reversible in nature. Bovine serum albumin (BSA) studies reveled that Au-protein adduct 
was formed, which suggested coordination of the complex at the level of surface histidines. 
Interestingly, the gold(III) compounds formed small amounts of metal-protein adducts with 







In vivo studies in rats bearing HCC orthografts with the dinuclear gold(III) complex I  
(Figure 5) reported by Che et al. showed significant inhibition in tumor growth (77%). It was 
revealed that the complex inhibited thioredoxin reductase and induced endoplasmic reticulum 
(ER) stress. Particularly, I has also been subjected to acute and sub-chronic toxicity evaluation in 
nude mice and in beagle dogs, reveling no severe and irreversible side-effects in association with 
the consumption of the compound at its effective concentrations in these animal models. 
Furthermore, gold(III) complex did not induce obvious genotoxicity.
14,38,39
 
All these results indicate that gold(III) derivatives are therefore good candidates for 
further studies and some may be even suitable to enter phase I clinical trials. 
1.3.3. Palladium(II) compounds 
The coordination chemistry of palladium(II) is very similar to that of platinum(II); 
therefore palladium derivatives have been explored as an alternative to platinum-based 
compounds due to the structural and thermodynamic similarity between the two metal-based 
complexes. One of the features that distinguishes Pd(II) complexes from those of Pt(II) is the 
ligand exchange mechanism, which is 10
5
 times higher for Pd(II)-derivatives. This can cause fast 
hydrolysis of Pd(II)-based complexes associated with ligand dissociation by generating very 
active species that can easily interact with donor groups encountered in the bloodstream and 
cellular environment; thus preventing the drug from reaching its target. This makes palladium 
complexes generally inactive and somewhat toxic due to their higher reactivity. This process can 
be however avoided by using bulky chelating ligands and achieving higher stabilization with 
strongly coordinated ligands.
14,15
 Palladium(II) compounds have been therefore studied as 
anticancer agents in the past 15 years with relevant examples found in the family of 
organometallic compounds. 
The advantage of using Pd(II)-derived complexes over Pt(II) is their higher solubility.
15
 
Moreover, the higher stability of cyclopalladated compounds in physiological media and a lower 
toxicity to normal cells are all promising features for their biological applications.
40 
Organometallic Pd(II) complexes have been reported to have cytotoxicity activity against human 
cervical epitheloid carcinoma, human chronicmyelogenous leukemia, osteogenic sarcoma, 
malignant melanoma, breast cancer, lung cancer, glioma, human colorectal adeno-carcinoma, 











Cyclopalladated complexes are less toxic overall, which makes them very promising as 
antitumor compounds. A good example of such cyclopalladated compound is J in Figure 6, 
which showed to induce apoptotic cell death in human leukemia cells (HL-60 and Jurkat) by 
rapture of lysosomal membranes and release of cathepsin B into the cytoplasm.
14,41,42 
Travassos et al. reported on the biphosphinic cyclopalladated complex (K, C7a) that 
displayed promising antitumor properties against murine and cisplatin-resistant human tumor 
cells both in vitro and in vivo. This compound induced the central apoptotic pathway by a strong 
effect on mitochondria and interacted with thiol-containing protein groups in the mitochondrial 
membrane, by inducing Bax translocation from cytosol, colocalizing with mitochondrial tracker. 
Increase in cytosolic calcium concentration, mainly from intracellular compartment was 
observed, as well as a significant decrease of adenosine triphosphate (ATP) and 
caspse/endonuclease activation. Moreover, in preclinical studies of malenoma model, this 
dimeric complex was effective against primary and metastatic tumors, having low toxicity. Thus, 
cyclopalladated complex K is a promising tumor chemotherapeutic agent and was selected for 
further preclinical studies that include a gene therapy protocols in conjugation with plasmids.
43-45
  
Another study conducted on C7a (K) investigated therapeutic efficacy in patient-derived 
xenograft model of adult T-cell leukemia lymphoma (ATLL) and the mechanism of action in the 
human T lymphotropic virus type 1-positive and negative-T cell lines (HTLV-1). In vivo survival 
studies led to significant increase of survival in the treated mice. Moreover, C7a inhibited more 






Furthermore, this compound was also found to be highly effective to promote cell death in the 
K562 human leukemia cells through apoptotic cell death and associated to cytochrome c release 
and caspace activation. These results prove that C7a compound is a promising drug in the 
chronic myeloid leukemia (CML) antitumor chemotherapy.
47 
 
1.3.4. Ruthenium(II and III) compounds 
In the 1970s, Clarke et al. reported on a ruthenium complex, [Ru(NH3)5(purine)]
3+
, 
capable of inhibiting DNA and proteins synthesis in human nasopharyngeal carcinoma cells in 
vitro.
48
 This subsequently initiated interest in ruthenium complexes as potential anticancer agents 
and without a doubt, ruthenium became the star metal in the present search for chemotherapeutic 
alternatives to cisplatin.
15
 In the 1980s, chloro-ammine-Ru(III) compounds were found to have 
anticancer activity against rats, but their poor solubility limited their action. Soon after, a 
DMSO-Ru(II) species, cis-[RuCl2(dmso)4] was shown to be active against both primary and 
metastatic cancers, though less effective than cisplatin, but with fewer side effects compared 
with the platinum-based drugs. Since then a number of active ruthenium compounds in vitro and 
in vivo two of which have already entered clinical trials.
15
  
The emergence of ruthenium complexes as some of the most promising candidates for 
cancer therapy with metallodrugs can be attributed to their specific characteristics. First of all, 
ruthenium compounds can easily access three different oxidation states (II, III and possibly IV) 
in physiological solutions.
15,49
 Ruthenium II and III states can form six-coordinate octahedral 
species that can facilitate finer tuning of the steric and electronic properties of the complexes by 
intervening with the two “extra” axial ligands. They can also interact with macromolecules in a 
different manner that those derived from platinum.
49
 The rate of ligand exchange in ruthenium 




 per second, which gives 
the molecules high kinetic stability and preventing rapid equilibrium reactions. This helps the 
molecule to stay intact on its way to the target and it also remains viable throughout its 
interaction with the cell.
15
 And most importantly, ruthenium compounds are able to mimic iron 
in binding biologically relevant molecules such as albumin and transferrin, and as a consequence 












A number of ruthenium(III)-arene complexes showed high in vivo antitumor activity and  
have successfully completed phase I clinical trials and entered phase II.
14
 Those compounds 
include NAMI-A,
50,51





developed by Keppler et al. (Figure 7). KP1019 (indazolium trans-
[tetrachloridobis(1H-indazole)ruthenate(III)]) was found to be highly active against the rat colon 
cancer model, yielded efficacy with up to 95% reduction of tumor volume without any mortality 
(0%) and without any considerable weight loss (6%).
53
 KP1339 was also found to exhibit 
cytotoxic activities in various tumor types, such as colon carcinomas.
52
 
NAMI-A (imidazolium trans-[tetrachloridobis(1H-imidazole)(S-dimethyl 
sulfoxide)ruthenate(III)]) demonstrated to affect the process of metastasizing, rather than acting 
against the primary tumors or already established metastases. Its activity is most likely based on 
enhanced cell adhesion, inhibition of cancer cell motility and invasiveness, as well as on 
inhibition of neoangiogenesis in the tumor tissues.
53
  
I will detail in Chapter V a number of organometallic ruthenium(II) derivatives that have 







1.4. New drug design with iminophosphorane ligands 
Iminophosphorane (IM) ligands of the general formula R3P=NR’ are attractive substrates 
for coordination (N,N-) or cyclometallation (C,N-). They provide a C,N- or N,N- chelating 
backbone that stabilizes the resulting square-planar structure of d
8
 transition metal complexes 
and can also coordinate to d
6
 metals like Ru(II) (Chart 1). Incorporating phosphines in the 
skeleton of the IM pincer ligand is important since the phosphorus atom can serve as a 




H} NMR spectroscopy in order to study the stability and 
oxidation state of the compounds in vitro in different deuterated solvents. Furthermore, 
modifications to X ancillary ligands in these metallic compounds permits further functionality by 
ligand substitution.  
 





Figure 8. Examples of iminophosphorane ligands. 
 
Iminophosphoranes can be divided into three classes: stabilized, semi-stabilized and non-
stabilized (Figure 8), as a function of the carbanionic charge delocalization degree and the ability 
to delocalize this charge which is closely related to the nature of the substituents (Figure 9). For 
example, the stabilized iminophosphorane ligands are characterized by the presence of the C=O 
next to the P=N bond. This results in more stable structures due to the conjugation. The semi-
stabilized and non-stabilized classes lack the C=O and are therefore less stable.
54
 The main focus 
remains on using stabilized and semi-stabilized iminophosphorane ligands avoiding the least 
stable third class of IM ligands. 
 
 
Figure 9. Resonance structures for stabilized iminophosphorane ligands. 
  
There are many different methods in which iminophosphorane ligands can be prepared. 




organic azide in the presence of non-polar solvent, such a dichloromethane, at room temperature,  
releasing nitrogen gas and forming semi-stabilized IM (R
3
P + N3R’   R3P=NR’).
54
 The second 
method is the Pomerantz reaction, in which a tertiary phosphine reacts with a primary amide in 
the presence of di-tert-butylazodicarboxylate (
t
BuDAD) and polar solvent, such a 
tetrahydrofuran at 0ºC, forming stabilized IM (R
3
P + H3NC(O)R’   R3P=NC(O)R’) (Scheme 
1).
55
 A number of our IM were prepared by Pomerantz method which is the method of choice 
when amides are used. 
 
Scheme 1. Staudinger and Pomerantz reaction. 
 
1.5. Previous studies using iminophosphorane ligands 
 
Our research group in Brooklyn College has reported that non-toxic iminophosphorane or 
iminophosphane compounds serve as stabilizing (C,N- or N,N) chelating ligands in the 
preparation of anticancer organometallic and coordination d
8
 metal complexes (Figure 10).
56-60 
A 
series of neutral and cationic organo-gold(III) iminophosphorane complexes (like 1, in Figure 
10) showed higher toxicity against leukemia cells, including cells from patients with chronic 
leukemia CCL, while being less toxic to normal T-lymphocytes with IC50 values in the 




Thymus DNA and induce intracellular oxidative stress that provokes mitochondrial dysfunction. 
Complex 1 induces necrotic cell death and reactive oxygen species (ROS) production at the 




Figure 10. Selected cytotoxic gold(III), platinum(II) and palladium(II) complexes with IM 
ligands (1-6) prepared in our research group.
56-60 
 
Another study conducted in our research group involved the coordination of a water-
soluble IM ligand PTA=N-C(O)-2-N5H4(N,N-IM) to d
8
 metals, affording hydrophilic stable 
Pd(II) and Pt(II) compounds (like 2, in Figure 10). Compound 2 was highly cytotoxic in vitro 
against human T-cell leukemia Jurkat while being less toxic to normal T-lymphocites (PBMC). It 
was also 15 times more toxic to Jurkat shBak cell lines than cisplatin, indicating a cell death 
pathway that may be different from that of cisplatin. The interactions of compound 2 with Calf 
Thymus and plasmid (pBR322) DNA, revealed differences compared to cisplatin and with faster 
binding to HSA. It was demonstrated that compound 2 interacted with HSA in a reversible way 
which could be potentially beneficial to the antitumor activity in vivo of this compound.
58
    
In another project, a series of water-soluble and highly lipophilic organometallic Pd(II) 
complexes including the orthopalladated dimer [Pd(μ-Br){C6H4(C(O)N=TPA-kC,N)-2}]2 (3) and 




synthesized. Palladium compounds 3 and 4 displayed high cytotoxicity in vitro against human 
Jurkat-T acute lymphoblastic leukemia cells, and DU-145 human prostate cancer cells while 
being less toxic to normal T-lymphocytes. Notably 3 and, particularly 4, were very toxic to 
cisplatin-resistant Jurkat shBak cells (Bax/Bak-deficient Jurkat cells), indicating a cell death 
pathway that may be different from that of cisplatin. The interaction of these Pd(II) complexes 
with plasmid (pBR322) DNA was very weak (3) or non-existing at all (4), indicating an 
alternative biomolecular target for these cytotoxic compounds.
59
 
The more recent project in our research lab involved the synthesis of Au(III) and Pd(II) 
heterometallic complexes with IM ligands derived from ferrocenyl-phosphanes (Figure 10).
60
 
The trimetallic derivatives M2Fe (M = Au, Pd, 5 and 6) exhibited important cytotoxic effects in 
the low micromolar range in all the studied cells and being slightly less toxic to non-tumorigenic 
human embryonic kidney cell line (HEK-293T). The interaction of Pd(II) derivative 6 with 
plasmid (pBR322) DNA showed a strong interaction demonstrating significant retardation of the 
faster-running supercoiled form, while Au(III) complex 5 showed no interaction. However, 
Au(III) complex showed to be a good inhibitor of the zinc-finger protein PARP-1, while the 
Pd(II) complex was noticeably less potent. Our results support the idea of different reactivity of 
the complexes with the investigated biomolecules depending on the metal ion and not only on 
the ligand set.
60 
One of the outcomes of our studies with IM ligands was that cyclometallated 
monometallic gold(III) and palladium(II) compounds proved to be more stable than coordination 
derivatives in physiological media. It seems that the skeleton C,N- is a better alternative to 
stabilize mononuclear metal centers than the N,N- backbone when iminophosphorane ligands are 
used. However, stable mononuclear Pt(II)
58 
and trimetallic coordination Fe-Au(III)2 and Fe-
Pd(II)2
60
 coordination compounds which display important antitumoral effects were prepared.  
The successful results of studies with cyclometallated and coordination compounds 
conducted in our research group, led us to further explore the synthesis and biological activities 
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2.1. Ultimate goal of the work described in this Thesis 
 
 The ultimate goal of my research is to develop effective potential cancer 
chemotherapeutics based on metallic complexes with a mode of action different from that of 








 transition metal centers in 
physiological media and modifications of these ligands will afford compounds with improved 
antitumor properties and/or properties to better understand their mode of action. We envisioned 
these modifications in the following way: i) incorporation of water soluble phosphines in the 
skeleton to increase the hydrophilicity of the complexes; ii) incorporation of luminescent 
molecules in the ligand to ideally be able to track these complexes inside the cells by techniques 
like fluorescence microscopy; iii) incorporation of a second different metal in the ligand (like 
ferrocene) to prepare heterometallic complexes to improve their activity as anti-tumor agents by 
the interaction of  different metals with multiple biological targets or by the improved 






2.3. Specific Aims of this Thesis 
 
Aim 1: Synthesis and study of the stability in solution of compounds with iminophosphorane-
containing ligands which may behave as potential anticancer agents. 
a) Synthesis of water-soluble, ferrocene-based and luminescent iminophosphorane ligands 
to use them in the preparation of gold(III), platinum(II), palladium(II) and ruthenium(II) 
coordination and organometallic complexes.  
b) Study of the stability of the compounds in deuterated solvents or buffers by 31P{1H},1H 
NMR and UV-vis spectroscopy.  
 
Aim 2: Study of the mechanism of action of the new iminophosphorane compounds. 
Study of the interaction of these compounds with different bimolecular targets like DNA 
and HSA by different techniques (gel electrophoresis, circular dichroism, thermal 
denaturation experiments and fluorescence spectroscopy).  
 
 
Since this is an interdisciplinary project while my doctoral work has focused on the specific aims 
described above our group, along with the groups of our collaborators, has worked in the 
biological and mechanistic evaluation of these compounds in order: 
 
1) To study the antiproliferative properties of the new compounds in different human cancer cell 
lines and in non-tumorigenic human cell lines such as a human embryonic kidney cell line 
(HEK-293T) or a human renal proximal tubular cell line (RPTC). 
 
2) To investigate the cell death pathway (apoptosis, necrosis, necroptosis) of selected compounds 
and explore their mode of action by additional studies (inhibition of capthesin, involvement of 
caspases and/or p-53 in the cell death pathway). 
In the case of the luminescent compounds, to study (by fluorescence microscopy) their 





3) To study the in vivo activity in mice (including pharmacokinetic studies) of the most 
promising water-soluble ruthenium candidate discovered so far. 
 
 
I will include in this thesis complete data on the biological evaluation of these compounds as this 
is relevant to understand the outcomes and significance of my research but I will detail in every 
chapter the contributions of other scientists. My research has consisted on the rational design 
and the synthesis and complete characterization of the ligands and metallic compounds 
described in this thesis, the study of the stability in solution of the new metallic complexes and 
the study of the interactions of these compounds with biomolecular targets like DNA and Human 






SYNTHESIS OF COORDINATION AND ORGANOMETALLIC 
GOLD(III), PALLADIUM(II) AND PLATINUM(II) 
COMPOUNDS CONTAINING A LUMINESCENT 
IMINOPHOSPHORANE LIGAND. IN VITRO EVALUATION 




3.1. Potential of metal-based theranostics 
 
 As explained in the introduction, during the past two decades, a large number of metal-
based complexes with promising anticancer activities have been reported.
1
 In the last five years, 
a shift has taken place in the field, with more emphasis being placed on understanding how these 
metallodrugs work. Mechanistic approch may be of help to design improved metal-based drugs 
by supressing the side effects and clinical problems related to the use of existing platinum-
derived drugs such as cisplatin.
2-5 
One approach is to design new active metal-based compounds 
that can be tracked in vitro and in vivo in order to “visualize” the cellular location and fate of 
these complexes.  
Many transition-metal complexes display very interesting photophysical properties that 
make them suitable as therapeutics agents for targeting and detection of specific biomolecules.
6 
These type of compounds are considered to be potential metal-based theranostic, a term which is 
defined as the combination of therapy and diagnostic imagining into a single modality.
3,6
 The 
advantage of using this type of approach is that the therapeutic and detection abilities can be 
combined within a single metal complex, allowing the progress of any disease to be monitored 
without the requirement for an additional labeling or imaging agent.
6
   
Phosphorescent metal complexes have been widely applied for sensing, bio-imaging and 
organic light-emitting diode applications. They possess several advantageous features that make 
them suitable as sensing or imaging probes. Photophysical properties of metal complexes make 
them sensitive to changes in their environment. Moreover, they usually display significant Stokes 




emission light. In addition, the long phosphorescence lifetime of metal complexes allows their 
phosphorescence to be readily distinguished in the presence of endogenous fluorophores likely to 
be present in biological environments by the use of fluorescence.
6
 
 Within this context, we aimed to explore the anticancer properties of iminophosphorane 
d
8
 transition metal complexes incorporating a luminescent molecule, as well as to determine their 
intracellular distribution by using fluorescence microscopy.
3,7,8
  
 The following chapter reports on the synthesis, characterization and luminescence studies 
of new gold(III), palladium(II) and platinum(II) derivatives containing previously reported
9
 
iminophosphorane ligand derived from 8-aminoquinoline [Ph3P=N-C9H6N] (1). These metal-
complexes were evaluated for their antiproliferative properties in a human ovarian cancer cell 
line (A2780S), in human lung cancer cells (A-549) and in a non-tumorigenic human embryonic 
kidney cell line (HEK-293T). The compounds were also tested for their possible interactions 
with plasmid (pBR322) DNA used as a model nucleic acid, and for their reactivity with the 
transport protein human serum albumin (HSA). 
 
3.2. Synthesis and characterization 
 The iminophosphorane ligand [Ph3P=N-C9H6N] (1) can be prepared by a modification of 
a previously reported procedure.
8
 8-azidoquinoline was obtained by reaction of 8-
aminoquinoline with trifyl azide
9
 and subsequently reacted with triphenylphosphine (PPh3) in 
CH2Cl2 at room temperature for one hour, using the Staudinger method.
10
 Upon addition of 




), or to 
CH2Cl2 solutions/suspensions of PdCl2(COD) and PtCl2, coordination complexes of gold(III) (2, 








Scheme 1.  Preparation of the new luminescent metallic complexes 2-7. 
  














H} NMR, mass spectrometry, conductivity and elemental 
analysis. The crystal structures of the gold(III) (3) and the palladium(II) compound (4) were 
determined by an X-ray analysis (Figure 1). Selected bond lengths and angles for both 




 The geometry about the gold(III) and palladium(II)
 
centers is pseudo-square planar with 
the N(2)-M(1)-N(1) angle of 80.5(4)
o
 (3) and 80.5(2)
o
 (4) suggesting a rigid ‘bite’ angle of the 
chelating ligand. The Au and Pd centers are on an almost ideal plane with negligible deviations 
from the least-squares plane.  
 
Figure 1. Molecular structure of the cation in compound [Au((Ph3P=N-8-C9H6N)-κ-
N,N)Cl2]ClO4 3 and of the compound [Pd((Ph3P=N-8-C9H6N)-κ-N,N)Cl2] 4 with the atomic 
numbering scheme.  
 
The main distances M-N(1) or M-N(iminic) and M-N(2) found for the Pd complex 4 are 



















 The distances Au-
N(1), Au-M(2), Au-Cl(1) and Au-Cl(2) in 3 are similar to the ones obtained by X-ray 
















distances P=N are shorter than in compounds which incorporate a carbonyl group bonded to the 




Table 1. Selected bond lengths [Å] and angles [
o
] for complexes 3 and 4. 
3 4 
Au(1)-N(2) 1.998(8) Pd(1)-N(2) 2.034(5) 
Au(1)- N(1) 2.045(13) Pd(1)- N(1) 2.060(5) 
Au(1)-Cl(2) 2.254(3) Pd(1)-Cl(2) 2.2738(15) 
Au(1)-Cl(1) 2.278(5) Pd(1)-Cl(1) 2.2903(15) 
P(1)-N(1) 1.656(11) P(1)-N(1) 1.622(5) 
N(2)-Au(1)-N(1) 80.5(4) N(2)-Pd(1)-N(1) 80.5(2) 
N(2)-Au(1)-Cl(2) 172.7(3) N(2)-Pd(1)-Cl(2) 170.63(15) 
N(2)-Au(1)-Cl(1) 95.1(3) N(2)-Pd(1)-Cl(1) 93.62(15) 
N(1)-Au(1)-Cl(2) 95.4(3) N(1)-Pd(1)-Cl(2) 95.51(13) 
N(1)-Au(1)-Cl(2) 175.7(3) N(1)-Pd(1)-Cl(2) 173.73(14) 
Cl(2)-Au(1)-Cl(1) 88.88(15) Cl(2)-Pd(1)-Cl(1) 89.91(6) 
 
 





spectroscopy in deuterated solvents.  Most compounds are stable for weeks in CD3CN or CD2Cl2 
solution. The stability in DMSO-d6 solution was also evaluated for all of the compounds (see 
Appendix for more details). Gold(III) compounds 2 and 3 have half-lives of 4 (2) or 6 (3) hours, 
after which they decompose to phosphane oxide (Ph3P=O) and the coordination gold(III) 
compound based on the deprotonated uninegative bidentate 8-aminoquinoline fragment [Au(N-
8-C9H7N)-κ-N,N)Cl2]. The poor stability for some monometallic Au(III) iminophosphorane 
coordination complexes
14,16 
and their decomposition to biologically active gold(III) amino 
derivatives
14
 has been described before. The coordination Pd(II) compound 4 in DMSO-d6 
solution has a half-life of about 1.5 hours and over time 4 evolves to the endo cyclometalated 
species [Pd{κ
3
-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl] (6 in Scheme 1) by activation of the C-H of 




compound 5 evolves to a cyclometalated analogue of 6 to give species [Pt{κ
3
-C,N,N-
C6H4(PPh2=N-8-C9H6N}Cl] (7 in Scheme 2) by heating it in DMSO. 
The cyclometalated Pd(II) (6) and Pt(II) (7) species have been fully characterized by 




H} NMR), mass spectrometry, conductivity and 
elemental analysis (see the Experimental Section). These species can also be obtained as pure 
compounds in high yields (Scheme 1) by reaction of IM ligand 1 with Pd(AcO)2 in CH2Cl2 at 
room temperature, followed by treatment with LiCl in CH3OH (6) or by refluxing the 
coordination platinum(II) compound 5 in CH2Cl2 for 3 days (7). The cyclometalated species 6 
and 7 are stable in DMSO-d6 solution with half-lives of several weeks. The fact that 6 and 7 are 
orthometalated species is clearly inferred from the analysis of their NMR spectra. 6 and 7 display 




H} NMR signals with respect to the coordination compounds 4 and 






H} NMR spectra of 6 and 7 there are also new signals due to 
the presence of 4 protons (a-d) of the cyclometalated aryl ring and six well resolved peaks, for 
the carbons of this C6H4- fragment. Moreover, the 
2
JPt-P coupling constant of 426 Hz is visible 




H} NMR with 
195




H} NMR is a doublet at -2899.7 ppm. A JPt-P 
coupling constant is not observable for the coordination iminophosphorane compound 5. This 




 The iminophosphorane ligand in compounds 6 and 7 acts as a C,N,N- pincer ligand. 
Urriolabeitia et al. have reported on the selective C-H activation by palladium(II) complexes in 
iminophosphoranes based on type of IM ligand, solvents that were used and the temperature at 
which the cyclometalation reaction takes place giving either endo or exo derivatives.
17-20
 The 
semi-stabilized IM ligand [Ph3P=N-C9H6N] (1) coordinates to a palladium or platinum center (II) 
in compounds 4 and 5 affording cyclometalated endo derivatives with the IM acting as a C,N,N- 
pincer ligand in 6 and 7. The only example of a Pt(II) cyclometalated compound containing an 
iminophosphorane ligand reported so far is the endo [Pt(C6H4-2-PPh2=N-C(O)-2-NC5H4-κ-









3.3. Luminescence studies 
 
These studies were performed by Dr. Josefina Jiménez and Elena Gascón at the University of 
Zaragoza, Spain. 
 
 The luminescence studies of the metallic complexes 2-7 and of the previously described 
IM ligand 1
8
 whose luminescence had not been reported before were carried out. All the 
compounds are luminescent in DMSO solution (5 x 10
-4
 M) at room temperature.  
 The excitation and emission data as well as the lifetimes for excited states are 
summarized in Table 2. The lifetimes are all relatively long (7-12 s), which indicate the 
emission transitions are all forbidden and phosphorescent. Ligand 1, non-cyclometalated 
complexes 2-4 and cyclometalated palladium complex 6 all show similar optical behavior. The 
spectra show a broad band with the emission maximum at around 486-521 nm, upon excitation 
between 290-410 nm (see Appendix for more details). Consequently, an intraligand transition 
modified by the coordination to metal is probably responsible for the luminescence in all of these 
complexes 2-4 and 6. The luminescence profile and features (excitation and emission maxima) of 
the cyclometalated platinum complex 7 are different. For this compound, an emission band 
showing some evidence of vibrational structure is observed, whose maximum is red-shifted from 
521 nm in the free ligand 1 to 677 nm (see also Appendix). This spectral shift suggests a 
3
MLCT 
character in the excited state of 7.
21
 On the other hand, unlike what we observed for 1 and 
complexes 2-6, the absorption spectrum of 7 exhibits a lower-energy band in the 400-500 nm 
region (see Appendix) at substantially longer wavelength than the absorption of the free ligand. 
This new band leads to the observed emissions and is likely to arise from charge-transfer 
transitions involving the metal, as it has been described for other Pt(II) complexes. Thus, a triplet 
state of mixed ππ*/MLCT character is probably responsible for the phosphorescence in 7.
21-25  
Non-cyclometalated platinum complex 5 deserves special attention. A DMSO diluted 
solution of this pure compound is brightly emissive yellow under a common UV lamp (ex 365 
nm) at room temperature. However, the spectrum shows two emissions, whose intensities depend 
on the excitation wavelength and the time of the luminescence measurement (see Figures 20 and 
21 in Appendix). At 390 nm, it exhibits two emission bands, a broad one with the maximum at 




profile and features similar to those observed for the cyclometalated platinum complex 7, with a 
maximum at 677 nm. Excitation at a longer wavelength, 450 nm, only gives the emission band at 
677 nm. When the luminescence of this solution is measured immediately afterwards the 
spectrum only shows the emission band at 677 nm. Under a common UV lamp (ex 365 nm) we 
observed an orange-red emission for the irradiated area while the non-irradiated area remained 
yellow. This observation seems indicative of the transformation of coordination complex 5 into 







spectroscopy. The transformation is not clean, though, and the NMR spectra of the DMSO 
solution after irradiation show other signals besides those corresponding to 5 and 7, which have 
not been identified.  
 















2 and 3 are rare examples of non-cyclometalated gold(III) complexes with chlorido 
ligands which emit in a fluid solution at room temperature.
 
Two essential control parameters to 
obtain luminescent (square-planar) gold(III) complexes have been highlighted: the ligand field 
strength and the rigidity of chelating ligands.
26,27
 These parameters are also relevant for the 
preparation of luminescent platinum(II) complexes.
21
 The iminophosphorane ligands are strong 
-donors, and this is expected to lead to an increase in the ligand field strength, which, in turn, 
decreases the probability for the thermal population of non-emissive d-d states. Importantly, for 
Compound max, solution (298 K)
a 
 exc em [ (s)] 
1 296, 336, 370, 407 521[10] 
2 290, 350 sh, 371 sh, 400 513[11] 
3 294, 337, 370, 404 517 [10] 
4 298 sh, 342, 368 sh 496 [7] 
5 306, 343, 377 sh, 390 513 [12] 
6 294, 341 sh, 378, 402 486 [10] 




all complexes, the energy of the excitation and emission bands are potentially of suitable 
wavelengths for cellular distribution studies.
7  
The luminescence properties of the compounds in DMSO solution was also studied over 
time. As expected, the most stable cyclometalated palladium and platinum compounds in DMSO 
solution (6, 7) and ligand 1 did not change their luminescence significantly over time.
 
Figure 2 
shows the change of the luminescence properties of compound 6 in DSMO solution at room 











Figure 2. Study of the luminescence of compound 6 in DMSO solution 5 x 10
-4
 M at RT over 
time (24 hours). 
 
In the case of coordination Au(III) complexes, 2 and 3, and coordination Pd(II) complex, 
4, the study of the luminescence overtime affords results that are in agreement with the stability 
of these compounds in DMSO solution. As mentioned before, 2 and 3 decompose (with half-
lives of ca. 4 (2) and 6 (3) hours in DMSO-d6) to phosphane oxide (Ph3P=O) and the 
coordination Au(III) compound [Au(N-8-C9H7N)-κ-N,N)Cl2]. Compound 2 shows a shift of the 
emission band at 513 nm to lower wavelength (473 nm) in concomitance to the appearance of 
two new bands of lower intensity at 634 and 683 nm after 3.5 hours. 


























 The spectrum is identical 24 hours later and therefore it may correspond to that of 
decomposition product [Au(N-8-C9H7N)-κ-N,N)Cl2]. Compound 3 is slightly more stable and 
the change in intensity and position of the bands to give spectra identical to that of 2 over time 
occurs 8 hours later. Coordination Pd(II) complex 4 shows a shift of the emission band at 496 nm 
to lower wavelength (486 nm), which corresponds to that of the endo cyclometalated species 6 
decomposition product. 
 The study of the luminescence of compound 7 in a mixture DMSO:H2O (50:50) was 
carried out and a broad emission band at 669 nm was observed, which is similar to that obtained 
for 7 in DMSO (see Figure 25 in the Appendix). However, the spectrum was completely 
different after 6 h, showing two broad emission bands at 430 and 630 nm, which may correspond 
to decomposition products. NMR studies of solutions of mixtures of 7 in DMSO:H2O close to 
1:1 ratio showed decomposition to different products over time including most plausibly 
cyclometalated species 7 with a Cl displaced by DMSO and hydrolysed species. Importantly, the 
solutions containing these products are still luminescent after 24 hours and their excitation and 
emission bands are of suitable wavelengths for intramolecular cellular distributions studies.  
 These preliminary luminescence studies support the idea to select the most intense 
compounds 3 and 7 as candidates for further intramolecular cellular distribution studies by 
fluorescence microscopy. 
 
3.4. Antiproliferative studies 
 




 The antiproliferative properties of ligand 1 and metallic complexes 2-7 were assayed by 
monitoring their ability to inhibit cell growth using the MTT assay. The cytotoxic activity of the 
compounds was determined as described in the Experimental Section in the human ovarian 
cancer A2780 cell line, and in the human lung cancer cell line A549, in comparison to cisplatin. 
The results are summarized in Table 3. Ligand 1 and its PPh3-based decomposition product 
(Ph3P=O) are not cytotoxic in all tested cell lines. The coordination complexes 2 (Au(III)) and 5 




than cisplatin toward the A2780 cell line (low micromolar range). However, these compounds 
are poorly selective, being very cytotoxic also towards the non-tumorigenic HEK-293T cell line. 
The selectivity towards the A2780 cells is more pronounced for the coordination and 
cyclometalated Pd(II) compounds 4 and 6. Most compounds are poorly cytotoxic towards the 
human lung cancer cell line A459, with the exception of the cyclometalated monometallic Pt(II) 
compound 7 which is ca. 3-fold more cytotoxic than cisplatin. However 7 is quite toxic to HEK-
293T cell lines as well. 
 















MTT assay (see experimental). All compounds were dissolved in 1% of DMSO and diluted with 
water before addition to cell culture medium for a 72 h incubation period. Cisplatin was 
dissolved in H2O. 
b
Since the biological activity of cationic iminophosphorane gold compounds is 
due to the cation, 2 was used to evaluate the biological activity of compounds 2 and 3 with 
identical cations.  
 
 
Studies of intracellular distribution on A2780 cells were attempted with selected 
compounds (e.g. 3, and 7) using fluorescence microscopy, but unfortunately, and in spite of the 
different conditions tested (different compounds’ concentrations and incubation time with cells), 
it was impossible to observe any fluorescence. 
 
 A2780 A549 HEK-293T 
Ph3P=O > 100 > 100 > 100 
1 > 100 > 100 > 100 
2* 6.35 ± 0.69 25.1 ± 3.8 21.6 ± 5.1 
4 11.0 ± 1.5 62.5 ± 3.7 53.5 ± 10.4 
5 3.33 ± 0.14 19.5 ± 6.5 10.8 ± 0.8 
6 13.2 ± 2.1 86.5 ± 2.5 66.0 ± 5.5 
7 3.56 ± 0.70 4.60 ± 0.50 2.64 ± 0.87 




3.5. Interaction with plasmid (pBR322) DNA 
 
 The key role of DNA in cell replication makes this biomolecule one of the most 
interesting targets in cancer chemotherapy. It is known that most cytotoxic platinum drugs can 
form strong covalent bonds with the DNA bases.
28
 However, a variety of platinum compounds 
act as DNA intercalators upon coordination to the appropriate ancillary ligands, while most 
gold(III) compounds display reduced affinity for DNA.
29,30
 There are also reports of palladium 
derivatives interacting with DNA in covalent
31,32
 and non-covalent ways.
33,34
 Conversely, most 
gold-based compounds do not display strong interaction with DNA.
35,36
 Therefore, agarose gel 
electrophoresis studies were performed to unravel the effects of compounds 2-7 on plasmid 




Figure 3. Electrophoresis mobility shift assays for cisplatin and compounds 2-7 (see 
Experimental Section for details). DNA refers to untreated plasmid pBR322. A, B, C and D 




 Plasmid (pBR322) DNA has two main forms: OC (open circular or relaxed form, Form 
II) and CCC (covalently closed circular or supercoiled form, Form I). Generally, the larger the 
retardation of supercoiled DNA (CCC, Form I), the greater the DNA unwinding produced by the 
drug.
37,38
 Changes in electrophoretic mobility of both forms are usually taken as evidence of 
direct metal-DNA interactions, such as covalently binding the drug to DNA. Binding of cisplatin 
to plasmid DNA, for instance, results in a decrease in mobility of the CCC form and an increase 
in mobility if the OC form (lanes A-D for cisplatin, Figure 3).
 
Treatment of plasmid (pBR322) DNA with increasing amounts of compounds 3-7 do not 
affect the mobility of the faster-running supercoiled form (Form I or CCC) at ratios up to 1.0 
metal/DNAbp. In the case of the coordination compounds of gold(III) (3) and platinum(II) (5), at 
the highest ratio of 2.0 metal/DNAbp, there is retardation of the faster-running supercoiled form 
(CCC). It can be, however, concluded that these complexes have no (4, 6, 7) or weak interaction 
(3, 5) with plasmid (pBR322) DNA. 
On the other hand, the coordination gold(III) compound 2 modifies the electrophoretic 
mobility and the retardation of the faster-running supercoiled form (CCC) in the same way as 
described previously for other coordination gold(III) compounds containing iminophosphorane 
ligands.
11
 This is due to the poor or lack of stability of these complexes in DMSO/buffer 
solutions that causes a cleavage of the P=N from the IM ligand, subsequently decomposing the 
Au(III)-IM complex into Ph3P=O and cytotoxic square-planar gold(III) compounds,
11
 which are 
known to intercalate in DNA. Compound 3 is slightly more stable than 2 in solution and 
therefore this effect is less noticeable. However, oxidative damage of the DNA produced by the 
metal center cannot be ruled out. The rest of compounds which are more stable (coordination and 
cyclometalated compounds of palladium(II) and platinum(II) have no or a weak interaction with 
plasmid (pBR322) DNA. It has been established to be the case for some coordination and 
organometallic compounds of gold(III) and organometallic derivatives of palladium(II) 
containing iminophosphorane ligands.
11,14,16,39 
Moreover, coordination iminophosphorane 
complexes of palladium and platinum have displayed interactions with DNA stronger but of a 






3.6. Interaction with human serum albumin (HSA) 
 
 Human serum albumin (HSA) is the most abundant carrier protein in plasma, making 
about 60% of the total serum protein concentration. The main function of HSA include 
maintaining osmotic blood pressure, serving as a depot protein, and transporting diverse 
endogenous and exogenous ligands including fatty acids, bilirubin, drug molecules and metal 
ions.
40
 Furthermore, HSA is able to bind a variety of substrates including metal cations, 
hormones and most therapeutic drugs. It has been demonstrated that the distribution, the free 
concentration and the metabolism of various drugs can be significantly altered as a result of their 
binding to the protein.
41
 HSA possesses three fluorophores, these being tryptophan (Trp), 
tyrosine (Tyr) and phenylalanine (Phe) residues, with Trp214 being the major contributor to the 
intrinsic fluorescence of HSA. This Trp fluorescence is sensitive to the environment and binding 
of substrates, as well as changes in conformation that can result in quenching (either dynamic or 
static).  
 We recorded the fluorescence spectra of HSA in the presence of increasing amounts of 
compounds 2-7 and cisplatin in the range of 300-450 nm upon excitation of the tryptophan 
residue at 295 nm (Figure 4). The compounds caused a concentration dependent quenching of 
fluorescence without changing the emission maximum or shape of the peaks, as seen in Figure 4 
(A) for compound 3. Quenching measurements are a valuable source to reveal the accessibility 
of fluorophores to quenchers since a decrease in intensity at a specific wavelength is observed in 
emission spectra upon quencher addition. However, there are a number of quenching 
mechanisms that are available. By the addition of other molecules, excited fluorophores 
experience energy loss due to collision between molecules. In the case of collisional (dynamic) 
quenching, the quencher must diffuse to the fluorophores and contact the excited fluorophore 
physically, which returns to the ground state after the energy of the excitation previously 
absorbed is taken away by the quencher. When the quencher binds to a fluorescent molecule, 
quenching due to the ground-state complex formation between two molecules occurs. For that 
reason, static quenching is a valuable source of information about the binding between the 






The fluorescence data were analyzed by the Stern-Volmer equation. While a linear Stern-
Volmer plot is indicative of a single quenching mechanism, either dynamic or static, the positive 
deviation observed in the plots of F0/F versus [Q] of our compounds (Figure 4) suggests the 
presence of different binding sites in the protein.
42
 Of note, a similar behaviour was observed in 
the case of some coordination and organometallic iminophosphorane complexes of d
8
 metals for 
which it was also reported as concentration dependent fluorescence quenching.
14,16 
In this graph 
higher quenching by the iminophosphorane complexes was observed compared to that of 
cisplatin under the chosen conditions and without changing the emission maximum or shape of 
the peaks. 
 In the case of [MCl2(PTA=N-C(O)-2-NC5H4)] (M = Pd, Pt) isothermal titration 
calorimetry (ITC)
16
 showed two different binding interactions which explained the lack of 
linearity observed in the fluorescence quenching studies, as the Stern-Volmer method assumes 
all binding sites to be equivalent. We believe that a similar binding takes place for the 




Figure 4. (A) Fluorescence titration curve of HSA with compound 3. Arrow indicates the 
increase of quencher concentration. (B) Stern-Volmer plot for HSA fluorescence quenching 





In conclusion we have prepared a series of luminescent iminophosphorane complexes of 
gold(III), palladium(II) and platinum(II) derived from 8-aminoquinoline. The coordination 
palladium(II) and platinum(II) compounds can evolve further, under appropriate conditions, to 
give stable cyclometalated endo species [M{κ
3
-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl] (M = Pd, Pt) 
by C-H activation of the phenyl group of the PPh3 fragment. All the compounds exhibit 
important cytotoxic effects in the low micromolar range in a human ovarian cancer cell line 
(A2780S), and in particular the Pd(II) derivatives (monometallic coordination 4 and 
cyclopaladated 6) show promising selectivity being poorly toxic for the non-tumorigenic human 
embryonic kidney cell line (HEK-293T). 
Studies of the interactions of the compounds with plasmid (pBR322) DNA indicate that, 
unless they lose the IM skeleton in solution, they have none or little interaction with DNA 
supporting the idea of different mechanisms of action than cisplatin. The complexes display a 
concentration dependent fluorescence quenching of HSA which has been correlated to a faster 
binding of our compounds with HSA compared to cisplatin.  
Even though the luminescence properties of the compounds did not allow for the 
detection inside the cells via fluorescence microscopy, these results will allow us to design new 
IM complexes in order to achieve better stability in biological media and to increase the 
fluorescence detection limits. More particularly, the focus will be on the synthesis of 
cyclometalated IM derivatives containing luminescent phosphines.  
  
3.8. Experimental section 
 
Materials and methods 
 
All manipulations involving air-free syntheses were performed at an nitrogen vacuum manifold 
using standard Schlenk-line techniques under an argon atmosphere or in a glove-box MBraun 
MOD System. Solvents were purified by use of a PureSolv purification unit from Innovative 
Technology, Inc. The phosphine substrate PPh3 was purchased from Sigma-Aldrich, K[AuCl4], 




without further purification. The purity of the compounds, based on elemental analysis, is 
≥99.5%. NMR spectra were recorded in a Bruker AV400 (
1
H NMR at 400 MHz, 
13
C NMR at 
100.6 MHz, 
31
P NMR at 161.9 MHz, 
195
Pt NMR at 85.8 MHz). Chemical shifts (δ) are given in 




C resonances were measured 









H} was referenced to [PtCl6]
2-
. Infrared spectra (4000-250 cm
-1
) were recorded 
on a Nicolet 6700 FT-IR spectrophotometer from nujol mulls between polyethylene sheets. 
Elemental analyses were performed on a Perkin Elmer 2400 CHNS/O Analyzer, Series II. Mass 
spectra (ESI) were performed on an Agilent Analyzer and on a Bruker Analyzer. Conductivity 
was measured in an OAKTON PC 700 pH/conductivity meter in acetone solution. 
Electrophoresis experiments were carried out in a Bio-Rad Mini sub-cell GT horizontal 
electrophoresis system connected to a Bio-Rad Power Pac 300 power supply. Photographs of the 
gels were taken with an Alpha Innotech FluorChem 8900 camera. Fluorescence intensity 
measurements were carried out on a PTI QM-4/206 SE Spectrofluorometer (PTI, Birmingham, 
NJ) with right angle detection of fluorescence using a 1 cm path length quartz cuvette.  
 




An alternative method of synthesis was used: a solution of PPh3 (2.59 mmol) in CH2Cl2 was 
added dropwise to a solution of 8-Azidoquinoline
9
 (2.59 mmol) in CH2Cl2 at RT and allowed to 
react for 1 h. The solvent was reduced in vacuo to 2 mL and Et2O (10 mL) was added. A pale-
yellow solid precipitated and was filtered off and dried in vacuo. 1 was used without further 
purification. Yield: 0.857 g, 82%.  
Synthesis of 2 and 3 






To K[AuCl4] (0.076 g, 0.2 mmol) in dry MeCN (10 mL), AgClO4 (0.091 g, 0.44 mmol) for the 
obtention of 2 or AgPF6 (0.111 g, 0.44 mmol) for the obtention of 3 in dry CH3CN (5 mL) was 
added. The reaction mixture was stirred in the darkness for 30 min and subsequently filtered 




yellow solutions became purple instantly. After stirring for 30 min the reaction mixture was 
filtered through celite (to remove KClO4) and then the solvent was reduced in vacuo to ~2 mL. 
Upon addition of Et2O (10 mL), a purple solid was obtained, which was washed with CH3CN 
(<1 mL at a time) and Et2O and dried in vacuo.  
 
2: Yield: 0.1198 g, 73%. Anal. Calcd. for C27H21AuCl2F6N2P2 (817.28): C, 39.68; H, 2.59; N, 











H NMR (CD3CN): δ 6.66 (1H, d, J = 7.8 Hz, H7), 7.15 
(1H, t, J = 8.0 Hz, H6), 7.62 (1H, d, J = 8. 2 Hz, H5), 7.62-7.82 (9H, m, Hpara + Hmeta), 8.04 (1H, 
dd, J = 8.3, 5.7 Hz, H3), 8.13 (6H, dd, J = 12.6, 7.6 Hz, Hortho), 8.85 (1H, d, J = 8.3 Hz, H4), 9.44 




H} NMR (CD3CN): δ 121.6 (s, C9H6N), 122.6 (s, C9H6N), 122.9 
(d, J = 5.0 Hz, C7), 123.6 (s, C5), 123.9 (s, C3), 128.8 (s, C6), 128.9 (d, J = 13.3 Hz, Cmeta), 131.4 
(s, Cipso), 134.2 (d, J = 10.6 Hz, Cortho), 135.1 (d, J = 3.0 Hz, Cpara), 144.4 (s, C4), 146.1 (s, 
CN=P), 148.4 (s, C2). IR (cm
-1
):  370 (Au-Cl), 838 (v br, PF6
-
), 1266 (P=N). Conductivity 
(acetone):  = 110 µS/cm.  
 
3: Yield: 0.109 g, 69%. Anal. Calcd. for C27H21AuCl3N2O4P (771.77): C, 42.02; H, 2.74; N, 







(CD3CN): δ 39.6 (s). 
1
H NMR (CD3CN): δ 6.48 (1H, d, J = 7.7 Hz, H7), 7.06 (1H, t, J = 8.0 Hz, 
H6), 7.49 (1H, d, J = 8.1 Hz, H5), 7.62-7.82 (9H, m, Hpara + Hmeta), 7.93 (1H, dd, J = 8.0, 5.6 Hz, 





H} NMR (CD3CN): δ 121.5 (s, C9H6N), 122.4 (s, C9H6N), 122.6 (s, C7), 124.1 (s, C5), 
124.2 (s, C3), 128.4 (s, C6), 130.2 (d, J = 13.3 Hz, Cmeta), 131.5 (s, Cipso), 134.1 (d, J = 10.5 Hz, 
Cortho), 135.1 (d, J = 2.8 Hz, Cpara), 144.0 (s, C4), 145.8 (s, CN=P), 149.0 (s, C2). IR (cm
-1
):  368 
(Au-Cl), 1083 (v, br) and 622 (ClO4
-
), 1267 (P=N). Conductivity (acetone):  = 128 µS/cm. 
  
Synthesis of 4  
[Pd((Ph3P=N-8-C9H6N)-κ-N,N)Cl2] 
 
[PdCl2(COD)] (0.041 g, 0.15 mmol) and 1 (0.042 g, 0.15 mmol) were dissolved in dry and 




precipitate had formed. The solvent was then reduced to a minimum in vacuo and upon addition 
of Et2O a pale orange solid was obtained which was washed twice with CHCl3 and dried in 
vacuo. Solution of 1 (0.081 g, 0.2 mmol) in CH2Cl2 was dropwise added to the a solution of 
PdCl2(COD) (0.2 mmol) in CH2Cl2 while stirring at RT and allowed to react for 30 min. The 
product was then concentrated under vacuum and precipitated with diethyl ether, producing a 
light orange solid. 
 
Yield: 0.098 g, 84%. Anal. Calcd. for C27H21Cl2N2PPd (581.77): C, 55.74; H, 3.64; N, 4.82. 









(CDCl3): δ 30.0 (s). 
1
H NMR (CDCl3): δ 6.27 (1H, d, J = 7.8 Hz, H7), 6.88 (1H, t, J = 7.9 Hz, 
H6), 7.13 (1H, d, J = 8.0 Hz, H5), 7.47 (1H, dd, J = 8.3, 5.2 Hz, H3), 7.58-7.65 (9H, m, Hpara + 




H} NMR (CDCl3): δ 118.6 (s, C7), 118.7 (s, C5), 121.8 (s, C3),  125.2 (s, C9H6N), 126.2 (s, 
C9H6N), 127.2 (s, C6), 129.0 (d, J = 12.9 Hz, Cmeta), 130.0 (s, Cipso), 133.2 (d, J = 3.0 Hz, Cpara), 
133.8 (d, J = 9.8 Hz, Cortho), 138.2 (s, C4), 149.7 (s, CN=P), 150.2 (s, C2). IR (cm
-1
):  342 (Pd-
Cl), 1268  (P=N). Conductivity (acetone):  = 3.4 µS/cm. 
 
Synthesis of 5 
[Pt(Ph3P=N-8-C9H6N)-κ-N,N)Cl2] 
 
A solution of 1 (0.1616 g, 0.4 mmol) in 20 mL of CH2Cl2 was added to a suspension of PtCl2 
(0.1064 g, 0.4 mmol) in 15 mL and refluxed for 3 h. Upon completion a brown side-product was 
filtered off and the resulting yellow solution was concentrated under vacuum. Upon addition of 
diethyl ether, a bright yellow solid was obtained.  
 
Yield: 0.1662 g, 62%. Anal. Calcd. for C27H21Cl2N2PPt (670.43): C, 48.37; H, 3.16; N, 4.18. 
Found: C, 48.18; H, 3.14; N, 4.15. MS(ESI+) [m/z]: 635.1 [M - Cl]
+









H} NMR (CDCl3): δ -1930.3 (s). 
1
H NMR (CDCl3): δ 6.23 (1H, d, J  = 7.9 Hz, 
H7), 6.83 (1H, t, J  = 7.9 Hz, H6), 7.11 (1H, d, J  =8.0 Hz, H5), 7.46 (1H, t, J  = 8.3 Hz, H3), 
7.57-7.67 (9H, m, Hpara + Hmeta), 8.14 (6H, dd, J = 8.0, 8.2 Hz, Hortho), 8.30 (1H, d, J  =8.1 Hz, 








C5), 122.1 (s, C3), 125.0 (s, C9H6N), 126.0 (s, C9H6N), 127.0 (s, C6), 129.0 (d, J = 12.6 Hz, 
Cmeta), 130.2 (s, Cipso), 133.2 (d, J = 2.9 Hz, Cpara), 133.8 (d, J = 9.9 Hz, Cortho), 137.3 (s, C4), 
148.6 (s, C2), 151.0 (s, CN=P). IR (cm
-1
):  341 (Pt-Cl), 1266 (P=N). Conductivity (acetone):  
= 1.2 µS/cm. 
 





A solution of 1 (0.121 g, 0.3 mmol) in 20 mL of CH2Cl2 was added to Pd(OAc)2 (0.067 g, 0.3 
mmol) in 10 mL CH2Cl2. The mixture was allowed react overnight (15 h) while stirring at RT. 
Excess LiCl (0.020 g, 0.47 mmol) in CH3OH was then added and the mixture was left to react 
for 30 min. Concentration under vacuum and precipitation with diethyl ether afforded an orange 
solid. 
 
Yield: 0.133 g, 81%. Anal. Calcd. for C27H20ClN2PPd (545.31): C, 59.47; H, 3.70; N, 5.14. 





(CDCl3): δ 43.4 (s). 
1
H NMR (CDCl3): δ 6.73 (1H, dd, J = 6.6, 1.7 Hz, H7), 6.90 (1H, ddd, J = 
11.3, 7.7, 1.4 Hz, Hd), 7.05 (1H, ddd, J = 12.8, 7.4, 1.1 Hz, Hc), 7.14-7.20 (2H, m, H5 + H6), 7.26 
(1H, t, J = 7.7 Hz, Hb), 7.45 (1H, dd, J = 8.3, 4.8 Hz, H3), 7.53-7.61 (4H, m, Hmeta), 7.65-7.61 
(2H, m, Hpara), 7.91-7.99 (4H, m, Hortho), 8.17 (1H, dd, J = 8.3, 1.5 Hz, H4), 8.24 (1H, dd, J = 7.9, 




H} NMR (CDCl3): δ 115.7 (d, J = 7.9 Hz, 
C7), 117.2 (s, C5 + C6), 121.9 (s, C3), 124.6 (d, J = 15.6 Hz, Cd), 125.5 (s, C9H6N), 126.4 (s, 
C9H6N), 127.4 (s, C5 + C6), 128.8 (d, J = 4.7 Hz, Cc), 129.4 (d, J = 11.9 Hz, Cmeta), 130.7 (s, 
Cipso), 131.3 (d, J = 3.1 Hz, Cb), 133.1 (d, J = 10.4 Hz, Cortho), 133.6 (d, J = 2.8 Hz, Cpara), 137.7 
(s, C4), 138. 6 (d, J = 14.7 Hz, Ca), 143.5 (d, J = 144.7 Hz, Ce, C-P), 147.2 (s, CN=P), 148.4 (s, 
C2), 154.5 (d, J = 19.1 Hz, Cf, C-Pd). IR (cm
-1
):  307 (Pd-Cl),  1285 (P=N). Conductivity 













The coordination platinum(II) complex 5 (0.167 g, 0.25 mmol) was dissolved in CH2Cl2 and the 
resulting solution refluxed for 3 days. After cooling at RT, the solution was concentrated under 
vacuum and 20 mL of diethyl ether were added. A yellow solid precipitated (7) which was 
filtered off, dried in vacuo and used without further purification.  
 
Yield: 0.1353 g, 87%. Anal. Calcd. for C27H20ClN2PPt  H2O (651.08): C, 49.74; H, 3.40; N, 







(CDCl3): δ 44.7 (s, 
2




H} NMR (CDCl3): δ -2899.69 (d, 
2
JP-Pt = 419 Hz). 
1
H 
NMR (CDCl3): δ 6.74 (1H, t, J = 4.3 Hz, H7), 6.93 (1H, dd, J = 11.7, 7.6 Hz, Hd), 7.06 (1H, dd, J 
= 13.4, 6.9 Hz, Hc), 7.14-7.20 (2H, m, H5 + H6), 7.31 (1H, dd, J = 7.6 Hz, Hb), 7.51 (1H, dd, J = 
8.3, 4.8 Hz, H3), 7.55-7.60 (4H, m, Hmeta), 7.69 (2H, t, J = 7.2 Hz, Hpara), 7.95 (4H, dd, J = 12.3, 




H} NMR (CDCl3): 
δ 116.1 (s, C7), 117.8 (s, C5 + C6), 122.1 (s, C3), 124.0 (d, J = 15.6 Hz, Cc), 125.2 (s, C9H6N), 
126.0 (s, C9H6N), 127.5 (s, C5 + C6), 129.1 (d, J = 4.7 Hz, Cd), 129.5 (d, J = 12.2 Hz, Cmeta), 
131.1 (d, J = 3.2 Hz, Cb), 131.3 (s, Cipso), 133.2 (d, J = 10.5 Hz, Cortho), 133.7 (d, J = 2.8 Hz, 
Cpara), 137.1 (d, J = 13.8Hz, Ca), 137.6 (s, C4), 142.7 (d, J = 138.4 Hz, Ce, C-P), 147.4 (s, CN=P), 
147.7 (s, C2), signal corresponding to C-Pt (Cf) not observable. IR (cm
-1
):  319 (Pt-Cl), 1286 




Absorption spectra in solution were recorded with a Unicam UV-4 spectrophotometer. Steady-
state photoluminescence spectra were recorded with a Jobin-Yvon Horiba Fluorolog FL-3-11 
spectrofluorimeter using band pathways of 3 nm for both excitation and emission. 
Phosphorescence lifetimes were recorded with a Fluoromax phosphorimeter accessory 
containing a UV xenon flash tube at a flash rate between 0.05 and 25 Hz. The lifetime data were 





Cell culture and inhibition of cell growth 
 
The human lung cancer cell line A549 and the human ovarian cancer cell line A2780 and the 
human (obtained from the European Centre of Cell Cultures ECACC, Salisbury, UK) were 
cultured in DMEM (Dulbecco’s Modified Eagle Medium) and RPMI, respectively, containing 
GlutaMaxI supplemented with 10% FBS and 1% penicillin/streptomycin (all from Invitrogen), at 
37°C in a humidified atmosphere of 95% of air and 5% CO2 (Heraeus, Germany). Non-tumoral 
human embryonic kidney cells HEK293 were kindly provided by Dr. Maria Pia Rigobello 
(CNRS, Padova, Italy), and were cultivated in DMEM medium, added with GlutaMaxI 
(containing 10% FBS and 1% penicillin/streptomycin (all from Invitrogen) and incubated at 
37°C and 5% CO2. For evaluation of growth inhibition, cells were seeded in 96-well plates 
(Costar, Integra Biosciences, Cambridge, MA) and grown for 24 h in complete medium. 
Solutions of the compounds were prepared by diluting a freshly prepared stock solution (in 
DMSO) of the corresponding compound in aqueous media. Afterwards, the intermediate 
dilutions of the compounds were added to the wells (100 L) to obtain a final concentration 
ranging from 0 to 150 M, and the cells were incubated for 72 h. DMSO at comparable 
concentrations did not show any effects on cell cytotoxicity. Following 72 h drug exposure, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to the cells at a 
final concentration of 0.25 mg ml
-1
 incubated for 2 h, then the culture medium was removed and 
the violet formazan (artificial chromogenic precipitate of the reduction of tetrazolium salts by 
dehydrogenases and reductases) dissolved in DMSO. The optical density of each well (96-well 
plates) was quantified three times in tetraplicates at 540 nm using a multiwell plate reader, and 
the percentage of surviving cells was calculated from the ratio of absorbance of treated to 
untreated cells. The IC50 value was calculated as the concentration reducing the proliferation of 









Interaction of of compounds 2-7 and cisplatin with plasmid (pBR322) DNA by 
Electrophoresis 
(Shift Mobility Assay) 
 
10 µL aliquots of pBR322 plasmid DNA (20 µg/mL) in buffer (5 mM Tris/HCl, 50 mM NaClO4, 
pH = 7.39) were incubated with molar ratios between 0.25 and 2.0 of the compounds at 37 
o
C for 
20 h in the darkness. Samples of free DNA and cisplatin-DNA adduct were prepared also as 
controls. After the incubation period, 2 µL of loading dye were added to the samples and of these 
mixtures, only 7 µL were finally loaded into the gel. The samples were separated by 
electrophoresis in 1%(w/v) agarose gel for 1.5 h at 84 V in Tris-acetate/EDTA buffer (TAE). 
Afterwards, the gel was dyed for 30 min with a solution of GelRed Nucleic Acid stain.  
 
Interaction of metal complexes with HSA by Fluorescence Spectroscopy 
 
The excitation wavelength was adjusted at 295 nm, and the emission spectra were recorded at 
room temperature in the range of 300 to 450 nm. The fluorescence intensities of the new 
compounds, the buffer and the DMSO are negligible under these conditions, and so is the effect 
of additions of pure DMSO to the fluorescence of HSA. An 8 mM solution of each compound in 
DMSO was prepared and ten aliquots of 2.5 µL were added successively to a solution of HSA 
(10 µM) in phosphate buffer (pH = 7.39), the fluorescence being measured after each addition. 
The data was analyzed using the classical Stern-Volmer equation  
  







Table with the crystal data and structure refinement for complexes 3 and 4, luminescence 
profiles and studies of the luminescence overtime in solution for ligand 1 and compounds 2-




H} NMR spectroscopy. 
 
3.9.1. Crystallographic Data for Compounds 3 and 4. 
 
Single crystals of 3a and 3d (see details below) were mounted on a glass fiber in a random 
orientation. Data collection was performed at room temperature on a Kappa CCD diffractometer 
using graphite monochromated Mo-Ka radiation (l=0.71073 Å). Space group assignments were 
based on systematic absences, E statistics and successful refinement of the structures. The 
structures were solved by direct methods with the aid of successive difference Fourier maps and 
were refined using the SHELXTL 6.1 software package. All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were assigned to ideal positions and refined using a riding 
model. Details of the crystallographic data are given in Table S1 (below). These data can be 
obtained free of charge from The Cambridge Crystallographic Data Center via 
www.ccdc.cam.ac.uk/data_request/cif. (CCDC 977990 for compound 3, and 977991 for 
compound 4). 
 
3: Crystals of 3 (purple prisms with approximate dimensions 0.25 x 0.23 x 0.23mm) were 
obtained from a solution of 3 in CH3CN by slow diffusion of Et2O at RT. 4: Crystals of 4 (orange 
prisms with approximate dimensions 0.25 x 0.24 x 0.22mm) were obtained from a solution of 4 









Table 4. Crystal Data and Structure Refinement for Complexes 3 and 4. 
 
Compound 3 4 
formula C27H20Cl2N2PAu. CH3COCH3. ClO4
-
 C27H21Cl2N2PPd.3CHCl3 
fw 828.81 939.83 
T [K] 293(2) 293(2) 
 (MoKα)[Å] 0.71073 0.71073 
crystal system Triclinic Orthorombic 
space group P-1 P2(1)2(1)2(1) 
a [Å] 7.894(5) 19.497(4) 
b [Å] 15.290(5) 10.517(2) 
c [Å] 25.892(5) 18.232(4) 
α [
o
] 90.028(5) 90 
β [
o
] 90.039(5) 90 
γ [
o
] 90.581(5) 90 
V [Å]
3
 3125(2) 3738.5(13) 
Z 4 4 
Dcalcd (g cm
-3
) 1.762 1.670 
µ (mm
-1
) 5.057 1.351 
GOF 1.053 1.060 
R1[I>2σ] 0.0512 0.0483 












3.9.2. Luminescence Studies for Ligand 1 and compounds 2-7. 

























































Figure 5. Absorption spectra of ligand 1 and gold compounds 2 and 3 in DMSO solution (5 x 10-
4
 M) at RT. 
































































Figure 6. Absorption spectra of ligand 1 and palladium compounds 4 and 6 in DMSO solution (5 
x 10
-4




































































Figure 7. Absorption spectra of ligand 1 and platinum compounds 5 and 7 in DMSO solution (5 
x 10
-4
 M) at RT. 


























Figure 8.  Excitation (blue) and emission (red) spectra of compound 1 in DMSO solution (5 x 
10
-4


























Figure 9. Luminescence of compound 1 in DMSO solution (5 x 10-4 M) at RT over time (24 h). 
 


























Figure 10. Excitation (blue) and emission (red) spectra of compound 2 in DMSO solution (5 x 
10
-4






























Figure 11. Luminescence of compound 2 in DMSO solution (5 x 10-4 M) at RT over time (24 h). 
 

























Figure 12. Excitation (blue) and emission (red) spectra of compound 3 in DMSO solution (5 x 
10
-4


































Figure 13. Luminescence of compound 3 in DMSO solution (5 x 10-4 M) at RT over time (24 h). 
 



























Figure 14. Excitation (blue) and emission (red) spectra of compound 4 in DMSO solution (5 x 
10
-4



























Figure 15. Luminescence of compound 4 in DMSO solution (5 x 10
-4
 M) at RT over time (24 h). 
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Figure 16. Excitation (blue and green) and emission (red) spectra of compound 5 in DMSO 
solution (5 x 10
-4





























Figure 17. Excitation (blue) and emission (red) spectra of compound 5 in DMSO solution (5 x 
10
-4
 M) at RT immediately after the first measurement of luminescence. 
 

























Figure 18. Excitation (blue) and emission (red) spectra of compound 6 in DMSO solution (5 x 
10
-4






























Figure 19. Luminescence of compound 6 in DMSO solution (5 x 10
-4
 M) at RT over time (24 h). 
 


























Figure 20. Excitation (blue) and emission (red) spectra of compound 7 in DMSO solution (5 x 
10
-4
































Figure 21. Luminescence of compound 7 in DMSO solution (5 x 10
-4
 M) at RT over time (24 h). 



















Figure 22. Excitation (blue) and emission (red) spectra of compound 7 in DMSO:H2O (50:50) 
solution (5 x 10
-4






























Figure 23. Luminescence of compound 7 in DMSO:H2O (50:50) solution (5 x 10
-4
 M) at RT 
over time (24h). 
 









H} NMR spectra for compounds 4 and 7. 
 
Compound Time (DMSO-d6) 
4 h 1 d 2 d 4 d 1 w 2 w Half life (50%) 
2 53% 13%  0%   4 h 
3 73% 31%  0%   6 h 
4 4% 0%     1.5 h 
5 41% 9%  9% 9%  2 h 
6 >99% >99% >99% >99% >99% >99% weeks 
7 >99% >99% >99% >99% >99% >99% weeks 
 
















Figure 24. Conversion of coordination palladium compound [Pd((Ph3P=N-8-C9H6N)-κ-N,N)Cl2] 
4 (δ  = 30.0 ppm) into cyclometalated [Pd{κ
3
-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl] 6 (δ = 44.6 
ppm) in DMSO-d6 solution over time. Small peak at δ  = 29.4 ppm corresponds to Ph3P=O. 
 
Figure 25. Study of the stability of cycloplatinated compound [Pt{κ
3
-C,N,N-C6H4(PPh2=N-8-
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SYNTHESIS OF CYCLOMETALLATED IMINOPHOSPHORANE 
GOLD(III) AND PLATINUM(II) COMPLEXES. IN VITRO 




4.1. Cyclometallated gold(III) and platinum(II) compounds as potential anticancer agents 
 
From the various strategies and approaches that have been employed in the search of 
more effective and selective potential anticancer metallodrugs,
1
 organometallic compounds have 
emerged as attractive candidates.
2
 It has been reported that organometallic platinum compounds 
perform better than non-organometallic derivatives.
3 
Overall, organometallic compounds are 
more stable in physiological environments and more lipophilic than coordination metal 
complexes, which allows for the design of anticancer metallodrugs with improved properties.
2
 In 
the last five years, several reviews on the anticancer activity of organometallic compounds of 






 organometallic compounds have been 
studied as potential anticancer agents. A number of complexes containing the [Pt(COD)] 
fragment and different ligands, such as alkyls, alkynyls, an nucleosides have been recently 
described.
19-21
 Platinum COD alkynyl compounds showed high toxicity against HT-29 colon 
carcinoma and MCF-7 breast adenocarcinoma cell lines
22,23
 while [PtMe(R-COD)L] 
compounds
24
 with different ligands (halides, alkyl, aryl, alkynyl) revealed higher toxicity to 
HeLa cells in comparison to that of cisplatin.
 
In the case of gold(III), it is well known that pincer 
ligands containing carbon- and nitrogen-ligands stabilize the metal center against reduction to 
gold(I) and gold(0) species in physiological media.
25 
Some cyclometallated gold(III) 
complexes
26-28 
based on C-N-N and C-N-C pincer complexes have displayed notable anticancer 




the σ(M-C) bond in these complexes, potentially increases the stability allowing the 
organometallic fragment to reach the cell unaltered. Additionally, for platinum-based compounds 
the presence of aromatic groups in the cyclometallated ligand might favor intercalative binding 
to DNA (π-π stacking), while the labile positions in the coordination sphere of the metal may 
favor covalent coordination to DNA (similar to that for cisplatin). Very recently, a luminescent 
DNA intercalator cyclometallated platinum(II) complex, [Pt(C^N^N)(C-NtBu)]ClO4 
(HC^N^N=6-phenyl-2,2’-bipyridyl) with a potent inhibitory effect in human cancer cells in vitro 
and in a xenograft model in mice has been described.
29
 The stabilization of the topoisomerase I–
DNA complex with resulting DNA damage by the cyclometallated compound is suggested to 
contribute to its anticancer activity.  
 
 
Chart 1. Possible cyclometallation positions in organometallic iminophosphorane derivatives. 
 
Iminophosphorane ligands can be cyclometallated at different positions generating stable 
organometallic compounds containing pincer C,N- and C,N,N- ligands.
30-32
 Urriolabeitia and co-
workers described cyclometallation processes for palladium(II) compounds for which exo or 
endo products could be obtained depending on the ligand, the solvent and the temperature 
employed. Endo derivatives are those generated by C-H activation of an aryl group (H in ortho to 




Chart 1). Exo derivatives are those generated by C-H activation on an aryl group contained in the 
imino or amido fragment of the IM ligand. Additionally, organometallic exo compounds can be 
prepared by exchange of a bromine or chlorine atom by a metal in the imino or amido fragment 
of the iminophosphorane. By modification of synthetic conditions and choice of appropriate 
ligands we can potentially prepare exo or endo cyclometallated complexes. Most endo 
derivatives involve the use of semi-stabilized IM ligands (Chart 1). This synthetic route limits 
the use of phosphines to those containing at least one aryl group. This becomes important if we 
want to use alternative phosphines in order to improve the hydrophilicity of the final product or 
to tune electronic/steric properties. On the other hand, the preparation of exo derivatives allows 
for the use of a variety of different phosphines. The best substrates for this purpose are stabilized 
iminophosphoranes containing CO or -CH2- between the aryl group to be metallated in the ortho 
position and the N=PR3 fragment
31
 (Chart 1). 
 
 
Chart 2. Endo gold(III) and exo palladium(II) complexes previously prepared in our group.
33,34 
 
As mentioned in the introduction, our group  prepared endo cyclometallated compounds 
of gold(III) with the IM ligand Ph3P=NPh.
33,35
 In the previous chapter we also described 
cyclometallation processes happening at high or room temperature in polar solvents with the 




the iminophosphorane moiety behaved as a C,N,N- pincer ligand.
31
 In order to obtain 
organometallic compounds of palladium(II) in water, we synthesized an iminophosphorane 
ligand (PTA=N-C(O)-2BrC6H4 (C,N-IM)) containing PTA. Exo palladium(II) complexes were 
obtained by oxidative addition of a palladium(0) derivative on the C-Br bond (Chart 2).
34
 All our 
studies with iminophosphorane metal compounds indicated that in most cases the 
cyclometallated compounds were more stable in physiological media than coordination N,N- 
compounds, and that they displayed relevant anticancer properties (especially cationic 
compounds).
33,35
  Within this frame work, we aimed to prepare exo cyclometallated IM 
compounds of gold(III) and platinum(II) in a systematic way in order to expand the range of 
phosphines incorporated into the final molecule to tune the hydrophilicity and/or electronic/steric 
properties of the resulting complexes.  
This chapter reports on the synthesis of novel exo cyclometallated C,N-IM compounds of 
gold(III) and platinum(II) containing the water-soluble phosphine PTA (1,3,5-Triaza-7-
phosphaadamantane) and the synthesis of endo C,N-IM compounds of platinum(II) derivatives 
never described before. These metal-complexes along with previously described exo derivative 
[Au(2-C6H4C(O)N=PPh3)Cl2] (1)
36
 and cisplatin have been evaluated against a number of human 
cancer cell lines in vitro. We studied the interaction of these complexes with plasmid (pBR322) 
DNA and HSA and the interaction of the platinum(II) compounds with Calf Thymus DNA by 
circular dichroism. Initial cell death mechanistic insights of the most active compounds in cancer 
cells are also described in this chapter. Additionally, the permeability of selected platinum(II) 
compounds was evaluated by two different assays: in vitro caco-2 monolayers and rat perfusion 
assay, in order to make comparisons with cisplatin and drugs or compounds that can be orally 
administered.  
 
4.2. Synthesis and characterization 
 
The synthesis of the exo cyclometallated gold(III) and platinum(II) compounds was based 
on the preparation of [Hg(Ph3P=N-CO-2-C6H4)Cl] by Nicholson et al.
36 
The C-H activation at 
the N-CO-Ph fragments takes place at a manganese center and by transmetallation of the 
resulting cyclometallated iminophosphorane manganese compounds to HgCl2, the 
organomercury derivatives with PPh3, [Hg(Ph3P=N-CO-2-C6H4)Cl],
36






 (whose synthesis and characterization will be 




Scheme 1. Previously described synthesis of organomercury compounds containing the semi-




 which will be described 
in Chapter V of this Thesis. 
 




)  with 
NMe4[AuCl4] or [PtCl2(COD)] afforded previously described compound [Au(2-
C6H4C(O)N=PPh3)Cl2] (1)
36
 and new cyclometallated exo iminophosphorane complexes of 
gold(III) and platinum(II) of the type  [Au(2-C6H4C(O)N=PTA)Cl2] (2) and [Pt(2-




Scheme 2. Synthesis of gold(III) and platinum (II) cyclometallated exo iminophosphorane 






The reaction of [Hg(PPh3=N-CO-2-C6H4)Cl] with [PtCl2(COD)] did not afford a pure 
cycloplatinated compound. Different synthetic conditions were tried and in most cases abundant 
Pt(0) decomposition took place while unreacted [Hg(PPh3=N-CO-2-C6H4)Cl] and Ph3P=O were 
the observed products along with free COD. Longer refluxing times in polar solvents afforded 
small amounts (4-10%) of a possible cyclometallated product along with [Hg(PPh3=N-CO-2-
C6H4)Cl] and Ph3P=O. 
New compounds 2 and 3 are obtained as air-stable yellow and white solids, respectively. 
Compound 2 is neutral whereas the Pt(II) derivative 3 is cationic (2:1 ions) as confirmed by 
conductivity measurements (see Experimental Section). Compound 3 is only soluble in solvents 
such as DMSO or DMF. We found that the COD ligand in 3 is immediately exchanged by 
DMSO molecules in DMSO-d6 solution at room temperature and that the new IM-cyloplatinated 
species did not change in DMSO-d6 over time (see Appendix, Figure 18). This was surprising 
since a COD ligand is not easily replaceable and usually requires thermal activation. The 
structures of these compounds have been proposed on the basis of elemental analysis, NMR and 
IR spectroscopy and MS spectrometry. Both compounds are soluble in mixtures 1:99 










The structure of 2 has been determined by an X-ray analysis and it is very similar to that 
of previously reported
36
 compound [Au(2-C6H4C(O)N=PPh3)Cl2] (1)
36
 with very close distances 
and angles. The molecular structure of 2 is depicted in Figure 1 while selected structural 
parameters are collected in Table 1. The analysis confirms the square-planar arrangement around 
the gold(III) center with a bite angle of  81.68(8)
o
. Like in other C,N-IM cycloaurated 
complexes
32,33,36,39 
the Au-Cl(1) bond trans to the carbon is longer (2.3834(5) Å) than the Au-
Cl(2) trans to the nitrogen (2.2798(5) Å) due to the higher trans influence of the C donor atom. 
As observed in compound 1, upon coordination to the gold there is an increase in both the P-N 
and N–C bond lengths when compared to the uncoordinated ligand
40
 (P-N: 1.626(3) Å in ligand, 
1.6658 (18) Å in 2; N–C:1.353(5) Å in ligand, 1.401(3) Å in 2). This effect is also observed in 
the IR spectra of compound 2 for which band corresponding to the P-N bond appears at a lower 
frequency than that for the free ligand (1,289 cm
-1
 versus 1,374 cm
-1
). As described in the 
structure of compound 1, a decrease of the C=O bond length was observed (from 1.245(5) Å in 
the ligand to 1.213(3) Å in the cycloaurated complex).   
 
Table 1. Selected Structural Parameters of complex 2 obtained from X-ray single crystal 
diffraction studies.
 
Bond lengths in [Å] and angles in []. 
 
Au(1)-Cl(1) 2.3834(5) N(1)-Au(1)-Cl(2) 173.33(5) 
Au(1)-Cl(2) 2.2798(5) N(1)-Au(1)-Cl(1) 97.32(5) 
Au(1)-C(1) 2.020(2) Cl(2)-Au(1)-Cl(1) 88.62(2) 
Au(1)-N(1) 2.0497(18) P(1)-N(1)-Au(1) 126.07(10) 
P(1)-N(1) 1.6658(18) P(1)-N(1)-C(7) 119.25(15) 
N(1)-C(7) 1.404(3) N(1)-C(7)-C(6) 112.16(19) 
C(7)-O(1) 1.213(3) N(1)-C(7)-O(1) 123.72(19) 
C(7)-C(6) 1.478(3) C(7)-N(1)-Au(1) 114.68(14) 
C(6)-C(1) 1.385(3) C(7)-C(6)-C(1) 118.0(2) 
  C(6)-C(1)-Au(1) 113.24(16) 
C(1)-Au(1)-N(1) 81.68(8) N(1)-P(1)-C(10) 113.99(10) 
C(1)-Au(1)-Cl(2) 92.44(6) N(1)-P(1)-C(8) 116.45(10) 
C(1)-Au(1)-Cl(1) 178.28(6) N(1)-P(1)-C(13) 117.81(10) 
80 
 










 had been described by our research group at 
Brooklyn College.
33,35 
We had never synthesized Pt(II) endo compounds with the IM Ph-N=PPh3 
ligand or evaluated their biological activity. The reaction of [Hg{C6H4(PPh2=N(C6H5)-2}Cl]
32,39
 
with [PtCl2(COD)]  was carried out and a cationic species (4) was obtained. Compound 4 (as for 
the exo compound 3) has a mercury chloride containing anion (in this case [Hg2Cl6]
2-
). In order 
to avoid the use of organomercury compounds and the presence of mercury in the resulting 
compound, a “greener” synthetic approach
41
 based of the transmetallation with an 
organogold(I)phosphine compound [Au{C6H4(PPh2=N(C6H5))-2}(PPh3)] described previously
32
 
was employed (Scheme 3).  
 
Scheme 3. Synthesis of the new platinum(II) cyclometallated endo iminophosphorane complexes 
4 and 5. 
 





 The reaction described here with 
[PtCl2(COD)] proceeds much faster and in much milder conditions than that for the synthesis of 
4 (25 min at RT in CH2Cl2 instead of 5 days in refluxing acetone). Compound 5 is obtained in 
moderate yield (58%). In order to avoid the formation of a neutral platinum(II) dimer with 




NH4PF6 was added. In this way, we obtained compound 5, an analogue of cationic compound 4 
with a mercury-free anion (PF6
-
). The structures of these compounds have been confirmed by 
elemental analysis, NMR (including 
195
Pt NMR) and IR spectroscopy, and MS spectrometry 
studies. In this case the compounds do not exchange the COD ligand for DMSO molecules at RT 
in DMSO-d6 solution as in the case of compound 3 which may have some implications for the 
biological activity of the compounds. Compounds 4 and 5 are also soluble in mixtures 1:99 
DMSO:H2O solutions at micromolar concentrations which are relevant for biological studies. A 
mercury-free analogue of compound 3 could not be obtained since the preparation of the 
appropriate Au(I) transmetallation agent from the organomanganese compound (Scheme 1) was 




Figure 2. Molecular structure of the cation in compound 4. The anion [Hg2Cl6]
2-
 is omitted for 
clarity. 
 
The number of cycloplatinated iminophosphorane compounds described previously is 







 in which the iminophosphorane 




either an exo (3) or endo (4, 5) position acting as a C,N-pincer ligand. The other two 
coordination positions for the Pt(II) center are occupied by the COD ligand. The molecular 
structure for compound 4 was determined by X-ray crystollagraphy confirming the proposed 
structure. The molecular structure of the cation in 4 is depicted in Figure 2 while selected 
structural parameters are collected in Table 2. A complete drawing of the crystal structure of 4 
including the [Hg2Cl6]
2-
 anion and crystallization molecules along with a more complete Table of 
distances and angles are provided in the Appendix, section 4.8.1, Tables 7-9. 
The coordination geometry around the platinum atom is slightly distorted from square-
planarity, with the C(1)-Pt(1)-N(1) angle of 85.31(9)
o
 suggesting a rigid ‘bite’ angle. The X(1)-
Pt(1)-N(1) also deviates (94.14(9)
o
). The distance Pt-N(1) 2.039(2) Å is shorter than that for 
other C,N- cyclometallated Pt(II) derivatives such as dmba (dimethylbenzylamine) compounds 
(ca. 2.1230-2.1340 Å).
e.g. 17,44,45
 The distances Pt-N(1) and Pt-C(1) both of 2.039(2) Å are almost 
identical to those found for Au-N(1) and Au-C(1) (both 2.035(4) Å) in a cyclometallated 
compound with the same IM ligand such as [Au{C6H4(PPh2=N(C6H5))-2}(PPh3)].
32
 The 
distances Pt-X(1) and Pt-X(2) to the centroids of the COD ligand are 2.169(3) and 2.039(3) Å, 
respectively, which reflects the higher trans-influence of C versus N (longer Pt-X(1) distance). 
 
 
Table 2. Selected Structural Parameters of the cation in complex 4 obtained from X-ray single 
crystal diffraction studies. Bond lengths in [Å] and angles in [º]. 
Pt(1)-C(1) 2.039(2) N(1)-Pt(1)-C(1) 85.31(9) 
Pt(1)-N(1) 2.039(2) C(1)-Pt(1)-X(1) 178.95(9) 
Pt(1)-X(1) 2.169(3) C(1)-Pt(1)-X(2) 94.79(10) 
Pt(1)-X(2) 2.039(2) N(1)-Pt(1)-X(1) 94.14(9) 
P(1)-N(1) 1.622(2) N(1)-Pt(1)-X(2) 179.01(9) 
P(1)-C(2) 1.773(2) X(1)-Pt(1)-X(2) 85.78(10) 
P(1)-C(7) 1.797(3) C(19)-N(1)-Pt(1) 125.82(16) 
P(1)-C(13) 1.797(3) C(19)-N(1)-P(1) 116.21(16) 
N(1)-C(19) 1.444(3) C(19)-N(1)-P(1) 116.21(16) 











H NMR spectroscopy. All the complexes are stable for months in DMSO-d6 
solution (see spectra and stability table in the Appendix, sections 4.8.2 and 4.8.3). As mentioned 
before, compound 3 exchanges the COD ligand by DMSO immediately when dissolved in 
DMSO-d6 (free COD is clearly visible along with coordinated DMSO). In the case of 
compounds 4 and 5, this exchange is extremely slow and after one week the percentage of free 
uncoordinated COD observed is around 6%. Compounds 4 and 5 are stable in DMSO and 
mixtures 1:99 DMSO:PBS for 24 hours as established by UV-Vis spectroscopy. The UV-Vis 
band shifts from 262 nm in DMSO to 225 nm in 1:99 DMSO:PBS for compound 4, and from 
264 nm in DMSO to 225 nm in 1:99 DMSO:PBS for compound 5. The UV-Vis band observed 
for the free iminophosphrane ligand Ph3P=NPh in DMSO appears at 257 nm, while in 
DMSO:PBS there are two visible bands, a major band at 230 nm and a minor band at 265 nm. 
This might explain the shift observed for compounds 4 and 5 in the UV-VIS spectra in 
DMSO:PBS solution when compared to DMSO solution (see Addpendix). 
 
4.3. Biological activity in vitro 
 
These studies were performed by Dr. Isabel Marzo, Oscar Gonzalo and Alfonso Serrano del 
Valle at the University of Zaragoza, Spain. The studies on non-carcinogenic RPTC cell lines 
were performed by PhD student Benelita T. Elie in our laboratory. 
 
4.3.1. Antiproliferative studies in vitro 
 
 The antiproliferative properties of the gold(III) and platinum(II) complexes 1-5 and 
ligand COD were assessed by monitoring their ability to inhibit cell growth using the MTT assay 
(see Experimental Section). The cytotoxicity activity of the compounds was determined in 
several human cancer cell lines: leukemia Jurkat-T, lung A549, prostate DU-145, pancreas 
MiaPaca2, and triple negative breast MDA-MB-231, in comparison to cisplatin. The results are 
summarized in Table 3. The COD ligand is poorly cytotoxic in all tested cell lines (IC50 >125 






Cyclometallated neutral gold(III) compound showed similar cytotoxicity to cisplatin 
while compound 2 was less cytotoxic for all the studied cell lines with the exception of the 
leukemia Jurkat cell line. We have found previously that the replacement of PPh3 by PTA in IM-
cyclometallated complexes decreases the cytotoxicity.
37
 The IC50 value for Jurkat for compound 





Cationic gold(III) complexes containing IM ligands are more 
cytotoxic than neutral derivatives.
33,35
 The cationic cyclometallated platinum compounds 
described here 3 and especially 4 and 5 were considerably more cytotoxic than cisplatin in all the 
cell lines studied. 4 and 5 (same cation) display almost identical IC50 values with the exception 
of A549 and MDA-MB-231 for which compound 4 containing the Hg2Cl6
2-
 anion is twice as 
active than 5. The data indicates that cytotoxicity for these compounds comes mainly from the 
cationic platinum fragment.  
 
Table 3. IC50 (µM) of metal complexes 1-5, ligand COD and cisplatin in human cell lines.
a
 All 
compounds were dissolved in 1% of DMSO and diluted with water before addition to cell culture 
medium for a 24 h incubation period. Cisplatin was dissolved in H2O. 




1 3.4 ± 0.5 85.3 ± 5.9 40 ± 8.1 81.8 ± 2.6 101.8 ± 16 14.6 ± 1.4 
2 9.5 ± 0.07 >125 > 125 > 125 > 125 > 125 
3 2.13 ± 0.24 20.8 ± 1.7 22.5 ± 4.2 7.53 ± 5.0 14.6 ± 3.7 4.0 ± 0.42 
4 0.43 ± 0.06 0.85 ± 0.29 0.93 ± 0.43 0.79 ± 0.09 0.39 ± 0.05 1.25 ± 0.25 
5 0.53 ± 0.13 2.01 ± 0.89 0.81 ± 0.07 1.03 ± 0.06 0.84 ± 0.29 0.94 ± 0.07 
COD > 125 > 125 > 125 > 125 > 125 > 125 
Cisplatin 10.8 ± 1.2 114.2 ± 9.1 112.5 ± 33 76.5 ± 7.4 131.2 ± 18 69.0 ± 6.7 
a 
Data are expressed as mean ± SD (n =4). 
 
 In order to assess the compounds’ selectivity for cancerous cells with respect to normal 




human embryonic kidney cells HEK293T. In most cases the cytotoxicity is comparable for the 
cancerous and HEK293T cells. All compounds are more toxic to leukemia than to HEK293T cell 
lines (2 to 12 times) and compound 4 is more toxic to all the cell lines than to the HEK293T cell 
lines. The toxicity of mercury-free compound 5 to HEK293T is comparable to that in the human 
cancer cell lines. As HEK293T cell lines (immortalized cells) can display a higher sensitivity to 
chemicals we measured the effect of compound 5 on human renal proximal tubular cells (RPTC). 
Renal proximal tubular cells in primary culture have been described as an in vitro model to study 
nephrotoxicity.
37
 The IC50 value (XTT assay 24 hours see SI for details) for 5 in this cell line was 
2.77±0.83 µM making 5 more sensitive to cancerous cell lines than to RPTCs. In addition, we 
will describe in chapter V an IM ruthenium compound  [(η
6
-p-cymene)Ru{(Ph3P=N-CO-2-N-
C5H4)-κ-N,O}Cl]Cl which displayed similar IC50 values in vitro for all the human cancer cell 
lines described above and HEK293T but which was very effective in vivo on MDA-MB-231 




4.3.2. Mechanism of cell death for compound 5 
 
The mechanism of cell death induced by mercury-free cytotoxic cycloplatinated 
compound 5 was analyzed in two cell lines of different origin: A549 lung carcinoma and Jurkat 
T-cell leukemia. Phosphatidyl serine exposure, plasma membrane damage and nuclear 
morphology were assessed in both cell lines after treatment with 5. Caspase implication in the 
toxicity of 5 was studied using the general caspase inhibitor z-VAD-fmk. In A549 cells we found 
that z-VAD-fmk protected cells from 5 at doses up to 0.5 µM (Figure 3) inhibiting both 
phosphatidylserine exposure (annexin V binding) and plasma membrane permeabilization (7-
ADD uptake). As expected, phosphatidylserine exposure was more dependent on caspase 
activity. At higher concentrations 7-AAD staining, but not annexin V binding, increased, 








Figure 3. Role of caspases on cell death induced by compound 5 in A595 cells. Cells were 
cultured for 24 h in the presence of 5 at the indicated concentrations, alone (solid lines) or 
combined with the general caspase inhibitor z-VAD-fmk (dashed lines). Subsequent, 
phosphatidylserine exposure (triangles) and cell membrane permeabilization (squares) were 
analyzed by flow cytometry after staining with annexin V-DY634 and 7-AAD respectively. 
Results are mean+/-SD of two independent experiments with duplicates. 
 
 
The apparent decrease in the percentage of annexinV positive cells could reflect cell 
disintegration caused by necrosis. Consistently, z-VAD-fmk did not inhibit cell death at 1 µM 
(Figure 3).  When an early event of apoptosis, loss of mitochondrial transmembrane potential, 
was analyzed we also observed that caspase inhibition by z-VAD-fmk only partially reduced 
∆Ψm loss caused by 5 (Figure 4), further suggesting that compound 5 can induce caspase-







Figure 4. Caspase implication in mitochondrial effects of compound 5 in A549 cells. Cells were 
cultured for 24 h in the presence of compound 5 at the indicated concentrations, alone (solid line) 
or combined with the general caspase inhibitor z-VAD-fmk (dashed line). Then, transmembrane 
mitochondrial potential was analyzed by flow cytometry after staining with the probe DiOC6(3). 
Results are mean+/-SD of two independent experiments with duplicates. 
 
Jurkat cells were more sensitive to 5 than A549 cells, with an IC50 of 0.6 µM, even 
though this cell line does not express functional p53, discarding an essential role of this protein 
in the activity of compound 5. In these cells the percentage of 7-AAD (Figure 5) and that of 
Annexin V-positive (data not shown) cells were the same in every assay. High sensitivity of 
Jurkat cells was confirmed in short-term experiments as we observed that 5 at 0.5 µM induced 
cell death in almost 100% of cells even at 6 h. Caspase inhibition by z-VAD-fmk completely 
avoided cell death at 6 h.  However, longer treatment with 5 induced both caspase-dependent and 









Figure 5. Implication of caspases in cell death induced by compound 5 in Jurkat cells. Cells 
were treated with compound 5 for 6 or 24 h in the presence or in the absence of the general 
caspase inhibitor z-VAD-fmk. Membrane integrity was analyzed by flow cytometry after 
staining with 7-AAD, respectively, as indicated in the Experimental Section. Results are 
mean±SD of two independent experiments. 
 
Mitochondrial damage was also analyzed in Jurkat cells (Figure 6). At 24 h treatment 
with 5 caused a decrease in ∆Ψm in 80% of cells, compared to 32% in cells treated with 5 in the 
presence of the general caspase inhibitor z-VAD-fmk. In order to determine whether 
mitochondrial damage caused by 5 was irreversible and committed cells to death, cells were 
washed and re-suspended in fresh medium. After a further 24 h incubation in fresh medium ∆Ψm 
collapse was observed in nearly 100% of cells (Figure 6). These results indicate that caspase 
inhibition only delays cell death in Jurkat cells and 5 induces cell damage leading to cell death 
independently of caspase activation. Thus, these experiments confirm that alternative caspase-







Figure 6. Jurkat cells were treated with 5 or 5+z-VAD for 24 h and then harvested, washed and 
seeded in fresh medium. After further 24 h in fresh medium mitochondrial transmembrane 
potential (∆Ψm) was analyzed as indicated in the Experimental Section. Results are mean+/-SD 
of three independent experiments. 
 On the other hand analysis of nuclear morphology indicated that 5 induced typical 
apoptotic features (chromatin condensation and fragmentation) that were prevented by z-VAD-
fmk in both cell lines (Figure 7). However, some nuclei of cells treated with 5 + zVAD displayed 
an altered morphology when compared to controls. This morphology could be caused by 
necroptosis
48
 or AIF-mediated cell death.
49 
 
Figure 7. Compound 5 induces apoptosis in Jurkat (upper panels) and A549 cells (bottom 
panels). Cells were cultured for 24 h in the presence of compound 5 (0.5 µM), alone or combined 
with the general caspase inhibitor z-VAD-fmk or left untreated (Control). Nuclei were stained 





Finally, the implication of mitochondria in the toxicity of compound 5 was analyzed.  
Jurkat-shBak cells, obtained by RNAi of Bak
49
 were employed. Since Jurkat cells do not express 
Bax, Jurkat-shBak cell line constitutes a model of human leukemia cells deficient in the intrinsic 
(mitochondrial) pathway of apoptosis. A cell line transfected with a non-specific shRNA was 
used as a control (Jurkat pLVTHM). As shown in Figure 8, Jurkat-shBak cells were less 
sensitive to 5 than control cells. However, high concentrations of 5 induced Bax/Bak 
independent cell death in Jurkat-shBak cells, suggesting that this compound could be useful in 
the treatment of tumors with alterations in the intrinsic pathway of apoptosis. 
 
 
Figure 8. Jurkat-pLVTHM (control) and Jurkat-shBak cells were treated with compound 5 for 
24 h. Mitochondrial transmembrane potential was analyzed as indicated in the Experimental 
Section. Results are mean±SD of three independent experiments. 
 
 
To summarize, from these initial mechanistic studies it seems clear that the cell death 
type for compound 5 is mainly through caspase-dependent apoptosis but that it triggers caspase-
independent cell death when apoptosis is blocked pointing out to a mode of action different from 







4.3.3. Lipophilicity and permeability assays 
 
These studies were performed by Víctor Mangas-Sanjuán, Dr. Marta González-Alvarez, Dr. 
Isabel González-Alvarez and Prof. Marival Bermejo at the University Miguel Hernández, Spain. 
 
The lipophilicity of the most active cycloplatinated 4 and 5 was determined by 
calculation the partition coefficients (see Table 4 and Experimental Section) between n-octanol 
and phosphate buffer (pH 7.00).  Partition coefficients have been used to predict the permeability 
of drugs since there is a good correlation between intestinal permeability and physicochemical 
parameters such as lipophilicity. 
 
Table 4. Partition Coefficients (ratio n-octanol: phosphate buffer) of Compounds 4 and 5 and 
reference Metoprolol. 
Compound P logP 
Metoprolol 0.20 ± 0.02 -0.68 
4 0.54 ± 0.03 -0.26 
5 1.05 ± 0.05 0.02 
 
Metoprolol was chosen as the reference compound for permeability since 95% of the 
drug is known to be absorbed from the gastrointestinal tract. Thus, drugs that exhibit partition 
coefficients and human intestinal permeability values greater than or equal to the corresponding 
value for metoprolol are considered high-permeability drugs. Drugs with estimated partition 
coefficients and human intestinal permeability values less than the corresponding value for 
metoprolol are classified as low-permeability drugs. This type of correlation is a suitable source 
of information on the passive and also possible carrier mediated absorption mechanism. From 






Figure 9. Permeability values obtained from apical to basal (Pab) and from basal to apical (Pba) 
of Cisplatin (at different concentrations), cycloplatinated 4, 5 and permeability reference 
compounds (Metoprolol, Cimetidine and Lucifer Yellow) at 20 µM in Caco-2 cells. Data 
correspond to the averaged values for three independent experiments. 
 
 Subsequently, the permeability of cisplatin as commercialized parent compound, 
cycloplatinated 4 and 5 as test compounds and Metoprolol, Cimetidine and Atenolol/Lucifer 
Yellow as reference compounds of high, intermediate and low permeability respectively, were 
determined using an in vitro cell model based on the measurement of the permeability of the 
compounds through Caco-2 monolayers
50,51 
and an in situ method by performing a rat perfusion 
assay.
52,53 
Results from the in vitro cell assay are shown in Figure 9 and data collected in Table 5 
while the results in the rat model are depicted in Figure 10 and data collected in Table 6. 
Pab is the value corresponding to the permeability from apical to basolateral chamber that 
simulates the permeability in the physiological sense from intestine to plasma. The Pba value 
corresponds to the permeability form basolateral to apical chamber. This Pba value would be the 
hypothetical value for the permeability “from plasma to intestine”. Despite Pba value has not 
physiological sense, this parameter and the ratio Pab/Pba can help to elucidate the mechanism of 







Table 5. Permeability values obtained by the Caco-2 cell monolayers assay. Metoprolol, 
Cimetidine and Lucifer Yellow were used as model compounds of high, medium and low oral 
permeability. Data correspond to the averaged values for three independent experiments. 
 

































Cell transport assays reveal that cisplatin is a compound with very low permeability. This 
permeability value (5.44·10
-07
cm/s) indicates that cisplatin is not a drug suitable for oral route 
administration if the objective is to obtain therapeutic plasma values. However, organoplatinum 
compounds 4 and 5 show higher permeability values than cisplatin. In fact, the permeability 
value of compound 4 is ten-fold higher than that of cisplatin at the same concentration and the 
permeability of compound 5 is fifty-fold higher. The permeability of compound 4 is higher than 
Lucifer Yellow and Cimetidine but lower than Metoprolol. 4 can be considered a compound of 
medium oral permeability. However, the permeability of compound 5 is higher than that of 
compound 4 and even higher than Metoprolol (in accordance with the lipophilicity data) 
indicating that it can be considered a highly permeable compound. The high permeability of 






Figure 10. Absorption rate coefficients in rats. 
 
Results from the in situ rat model assays confirm those obtained by the in vitro cell 
experiments. The permeability of compound 4 is higher than that of Atenolol, slightly higher that 
the permeability of Cimetidine but lower than that of Metoprolol. Compound 4 can be 
considered a compound of intermediate permeability. Compound 5 exhibits higher permeability 
than compound 4 and slightly higher than Metoprolol indicating that 5 is a highly permeable 
compound. Both compounds 4 and 5 display a much better absorption profile than cisplatin. 
 
Table 6. Absorption rate coefficients, Ka, and permeability values obtained from in situ rat 
assays. Metoprolol, Cimetidine and Atenolol were used as model compounds of high, medium 
and low oral permeability. Data correspond to values of six independent experiments. 
Compound Ka(h
1












 2.00 ±  0.11 4.72·10
-05





 2.12 ±  0.22 5.50·10
-05





 2.30 ±  0.15 5.40·10
-05





 1.68 ±  0.12 3.97·10
-05





 0.22 ±  0.02 5.19·10
-06











In addition, the relationship between caco-2 cells permeability and oral fraction absorbed 
in the experimental system (represented in Figure 11) had been validated and previously used for 
fraction absorbed predictions.
54
 The permeabilities of cisplatin and derivatives 4 and 5 were 
included in this correlation. The oral fraction absorbed predicted is more than 60% for compound 
4 and almost 100% for compound 5 demonstrating its improved absorbability properties with 
respect to cisplatin. In the absence of solubility or dissolution limitations the absorption of these 
compounds would be almost complete, thus with the adequate formulation strategy they 




Figure 11. Correlation between oral fractions absorbed vs permeability values obtained from 
Caco-2 cell monolayers transport assay in apical to basal direction (Pab). Gray diamonds 
correspond to the internally validated correlation (IVC).
54
 Triangles correspond to permeability 
reference compounds (metoprolol/caffeine for high permeability, Cimetidine for intermediate 
permeability and Lucifer Yellow for low permeability). Light grey squares correspond on tested 






4.4. Interactions with DNA 
 
Since DNA replication is the key event for cell division, it is among critically important 
targets in cancer chemotherapy. Most cytotoxic platinum drugs form strong covalent bonds with 
DNA bases.
55
 However, a variety of platinum compounds act as DNA intercalators upon 
coordination to the appropriate ancillary ligands.
56
 It has been reported that most gold(III) 
compounds display reduced affinity for DNA
33
 although there are a number of Au(III) porphyrin 
complexes
5,25,57 
and cyclometallated species with C-N-C pincer ligands
5,25,58 
that act as DNA 
intercalators and, in some cases as DNA topoisomerase inhibitors. We investigated the 
interaction of the gold(III) and platinum(II) complexes with plasmid (pB322) DNA and with Calf 
Thymus DNA and directly compared to that of cisplatin.  
 
4.4.1. Interaction of complexes 1-5 with plasmid (pBR322) DNA 
 
To gain insight into the nature of the compound-DNA interactions, gel electrophoresis 
studies were performed with gold(III) (1 and 2) and platinum(II) (3-5) complexes on plasmid 
(pBR322) DNA (Figure 12). Plasmid (pBR322) presents two main forms, OC (open circular or 
relaxed) and CCC (covalently closed circle or supercoiled), which display different 
electrophoretic mobility. Changes in the electrophoretic mobility of any of the forms upon 
incubation of the plasmid DNA with a compound are usually interpreted as evidence of drug-
DNA interaction. Generally, a drug that induces unwinding of the CCC form will produce a 
retardation of the electrophoretic mobility, while coiling of the OC form will result in increased 
mobility. Figure 12 shows the effect of cisplatin and compounds 1-5 on plasmid (pBR322) DNA 
after incubation at 37ºC for 20 h in Tris/HCl buffer at different drug/DNA ratios. As previously 
reported, cisplatin is able to both increase and decrease the mobility of the OC and the CCC 
forms, respectively.
59
 Treatment with increasing amounts of compounds 1, 2, 4 and 5 do not 
cause any shift for either form, consistent with no unwinding or other changes in topology under 
the chosen conditions. Treatment with increasing amounts of 3 retards the mobility of the faster-
running supercoiled form (Form I) especially at higher molar ratios. In order to understand the 
interaction of 3 with DNA, platinum compounds 3-5 were incubated with Calf Thymus DNA and 






Figure 12. Electrophoresis mobility shift assays for cisplatin and compounds 1-5 (see 
Experimental Section for details). DNA refers to untreated plasmid pBR322. A, B, C and D 
correspond to metal/DNAbp ratios of 0.25, 0.5, 1.0 and 2.0 respectively. 
 
4.4.2. Interaction with Calf Thymus DNA 
 
More detailed DNA conformational changes can be detected by means of Circular 
Dichroism (CD) spectroscopy. CD spectral technique is very sensitive to diagnose alteration of 
the secondary structure of DNA that results from DNA-drug interactions. A typical CD spectrum 
of Calf Thymus DNA shows a positive band with a maximum at 273 nm due to base stacking, 
and negative band with a minimum at 242 nm due to helipticity, characteristic of the B 
conformation of DNA.
60 
Therefore, changes in the CD signals can be assigned to corresponding 
changes in DNA secondary structures. In addition, it is known that simple groove binding or 
electrostatic interaction of small molecules causes little or no alteration to any of the CD bands 
when compared to major perturbation induced by covalent binding or intercalation. The most 
dramatic changes in the CD spectrum of CT DNA can be observed with compound 3 (Figure 
13A). Upon addition of increasing amounts of the complex, the intensity of the positive band 
diminishes and a new negative band at 287 nm and a positive band at 251 nm appears. This type 
of modification in CD spectrum of CT DNA is characteristic of conformational changes in DNA 
from B, usual right-handed form of DNA, to Z, left-handed form of DNA.
61 
The formation of 
left-handed helix of Z-form DNA structure is similar to the transition seen in purely electrostatic 










 anion in compound 3 seems to lead to the conformational change from B form to Z 
form. 
Cycloplatinated endo compound 4 leads to minor changes of the B-type CD spectrum 
(Figure 13B), with slight decrease of the intensities of the positive bands and with no 
modification in the negative region. This points out that the DNA binding of complex 4 induces 
conformational changes including conversion from a more B-like to a more C-like structure 
within the DNA molecule.
64
 This conformational change is indicative of a non-intercalative 
mode of binding of the complex and offers support for either groove binding or electrostatic in 
nature
65,66
 and it might be due to the lower concentration of Hg
2+
 released by compound 4, 
[Hg2Cl6]
2-
 (compared to that released by compound 3, with a [Hg4Cl10]
2-
 anion) although the 
influence of the more lipophilic Pt(II) cation could not be completely ruled out. 
 
 
Figure 13. CD spectra of CT DNA (195 µM) and CT DNA incubated with 0.1, 0.25, 0.5 and 1.0 
equivalents of compounds 3 (A), 4 (B), 5 (C) and cisplatin (D) for 20 h at 37ºC. 
99 
 
Finally, as shown in Figure 13C, compound 5 leads to no modification of the DNA bands 
with respect to untreated CT DNA, suggesting that the interaction of compound 5 with CT DNA 
is almost non-existent. This is in good agreement with our findings described above about the 
influence of the mercury anion in compounds 3 and 4 in their interaction with CT DNA since the 
anion in compound 5 is PF6
-
. 
In conclusion, the experiments of DNA-drug interactions have shown that compound 3 
induces the formation of left-handed helix of Z-form DNA through strong electrostatic 
interactions and compound 4 appears to be either groove binding or electrostatic in nature. This 
is supported by two main facts: 1) retardation of the plasmid (pBR322) DNA electrophoretic 
mobility is observed only for compound 3; and 2) results obtained by CD spectroscopy. 
Importantly, the mercury-free cationic organoplatinum compound 5 does not seem to interact 
with DNA indicating that as for other transition-metal IM complexes,
33-35,37,43,46,47  
its antitumor 
properties are due to non-DNA related mechanisms/factors. 
 
4.5. Interaction with HSA  
  
  As mentioned in Chapter III, human serum albumin (HSA) is the most abundant carrier 
protein in plasma and is able to bind a variety of substrates including metal cations, hormones 
and most therapeutic drugs. It has been demonstrated that the distribution, the free concentration 
and the metabolism of various drugs can be significantly altered as a result of their binding to 
this protein.
67
 HSA possesses three fluorophores, namely tryptophan (Trp), tyrosine (Tyr) and 
phenylalanine (Phe) residues, with Trp214 being the major contributor to the intrinsic 
fluorescence of HSA. This Trp fluorescence is sensitive to the environment and binding of 
substrates, as well as changes in conformation that can result in quenching (either dynamic or 
static).  
  Thus, the fluorescence spectra of HSA in the presence of increasing amounts of the 
compounds 1-5 and cisplatin were recorded in the 300-450 nm range upon excitation of the 
tryptophan residue at 295 nm. The compounds caused a concentration dependent quenching of 
fluorescence without changing the emission maximum or the shape of the peak, as seen on 
Figure 14A for compound 3. All these data indicate an interaction of the compounds with HSA. 




Stern-Volmer plot is indicative of a single quenching mechanism, either dynamic or static, the 
positive deviation observed in the plots of F0/F versus [Q] of compounds 2-4 (Figure 14C) 
suggests the presence of different binding sites in the protein with different binding affinities.
68
 
Of note, a similar behavior was observed in the case of coordination iminophosphorane 
complexes of d
8
 metals for which we also reported a concentration dependent fluorescence 
quenching.
34,37,43,46,47 
On the other hand, the Stern-Volmer plot for complexes 1 and 5 shows a 
linear relationship (Figure 14D), suggesting the existence of a single quenching mechanism, 
most likely dynamic, and a single binding affinity. The Stern-Volmer constants for complexes 1 






, respectively.  
  In general, higher quenching by the iminophosphorane complexes was observed 
compared to that of cisplatin under the chosen conditions, most likely due to the faster binding of 
our compounds with HSA, as compared to cisplatin. 
 
 
Figure 14. (A) Fluorescence titration curve of HSA for compound 3. Arrow indicates the 
increase of quencher concentration. Stern-Volmer plot for HSA fluorescence quenching 





We have shown in this chapter a systematic way to synthesize novel exo cyclometallated 
C,N-IM compounds of gold(III) and platinum(II) containing the water-soluble phosphine PTA. 
This synthetic method could be expanded to incorporate different phosphines in the IM ligand to 
tune the hydrophilicity and/or electronic/steric properties of the resulting metal complexes. I also 
prepared an endo C,N-IM compound of platinum(II) for comparison purposes. These complexes 
resulted stable in solution of DMSO-d6 and in DMSO:PBS buffer (1:99) overtime as 
demonstrated by NMR and UV-vis spectroscopic studies. The compounds, along with exo 
derivative [Au(2-C6H4C(O)N=PPh3)Cl2], were evaluated against a number of human cancer cell 
lines in vitro. The platinum compounds 3 and particularly, 4 and 5 were significantly more 
cytotoxic than cisplatin in all the cell lines studied; indicating that cytotoxicity of 4 and 5 comes 
mainly from the cationic fragment. The interaction of complexes 3-5 with plasmid (pBR322) and 
calf thymus DNA by circular dichroism demonstrated different modes of action. Compound 3 
induces the formation of left-handed helix of Z-form DNA through strong electrostatic 
interactions, while compound 4 appears to be either grove binding or electrostatic in nature. In 
addition, higher quenching of has fluorescence was observed compared to that of cisplatin under 
the chosen conditions, most likely due to the faster reactivity of the complexes with HSA, as 
compared to cisplatin. 
All the above metioned results have helped us to identify a mercury-free lipophilic 
cationic cycloplatinated iminophosphorane compound (5) as a good candidate for subsequent 
advanced precilinical studies. This compound is not only active against a number of cisplatin 
resistant cell lines, but also less toxic on human renal proximal tubular cell lines. Initial 
mechanistic studies carried out by our collaborators in Spain indicate that the cell death type for 
compound 5 is mainly through caspase-dependent apoptosis but that it triggers caspase-
independent cell death when apoptosis is blocked. These facts along with the lack of interaction 
observed for 5 with plasmid (pBR322) and CT DNA points to a mode of action different from 
that of cisplatin. Permeability studies of 5 by two different assays: in vitro caco-2 monolayers 
and a rat perfusion model, have revealed its high permeability profile (comparable to that of 
metoprolol or caffeine) and an estimated oral fraction absorbed of 100% which potentially makes 




that cyclometallated iminophosphorane compounds containing d
8
 metals (especially cationic 
species) are more stable in physiological media and display relevant anticancer properties. 
 
4.7. Experimental section 
 
Materials and methods 
 
All manipulations involving air-free syntheses were performed using standard Schlenk-line 
techniques under a nitrogen atmosphere or in a glove-box MBraun MOD System. Solvents were 
purified by use of a PureSolv purification unit from Innovative Technology, Inc. The phosphine 
substrate PTA and PPh3 were purchased from Sigma-Aldrich, [Mn2(CO)10] and [PtCl2(COD)] 
were purchased from Strem chemicals, Na/Hg were purchased from Fisher Scientific and used 







and IM ligands Ph3P=N-CO-2-N-C5H4,
38
 were prepared by 
reported methods. The purity of the compounds, based on elemental analysis, is ≥99.5%. NMR 
spectra were recorded in a Bruker AV400 (
1
H NMR at 400 MHz, 
13
C NMR at 100.6 MHz, 
31
P 
NMR at 161.9 MHz, 
195
Pt NMR at 85.7 Hz). Chemical shifts (δ) are given in ppm using CDCl3 
or DMSO-d6 as solvent, unless otherwise stated. Elemental analyses were performed on a Perkin 
Elmer 2400 CHNS/O Analyzer, Series II. Mass spectra HR-ESI (high-resolution electrospray 
ionization) or MALDI (matrix-assisted laser desorption/ionization) were performed on an 
Agilent Analyzer or a Bruker Analyzer. Conductivity was measured in an OAKTON 
pH/conductivity meter in acetone solution (10
−3
 M). X-ray collection was performed at room 
temperature on using graphite-monochromated and 0.5 mm-MonoCap-collimated Mo-K 
radiation (λ = 0.71073 Å) with the ω scan method. DNA thermal denaturation experiments were 
performed with a Cary 100 Bio UV-visible spectrophotometer. Circular Dichroism spectra were 
recorded using a Chirascan CD Spectrometer equipped with a thermostated cuvette holder. 
Electrophoresis experiments were carried out in a Bio-Rad Mini sub-cell GT horizontal 
electrophoresis system connected to a Bio-Rad Power Pac 300 power supply. Photographs of the 
gels were taken with an Alpha Innotech FluorChem 8900 camera. Fluorescence intensity 
measurements were carried out on a PTI QM-4/206 SE Spectrofluorometer (PTI, Birmingham, 




Synthesis of 2 
[Au(2-C6H4C(O)N=PTA)Cl2] 
 
[Hg(2-C6H4C(O)N=PTA)Cl] (0.15 g, 0.3 mmol), [NMe4][AuCl4] (0.12 g, 0.2 mmol) and 
[NMe4]Cl (0.035 g, 0.32 mmol) were stirred at RT in CH2Cl2 (15 mL) for 1 day in a foil-covered 
flask. The solvent was removed under reduced pressure. The fraction containing compound 2 
was then extracted from the solid residue with CHCl3 (3 x 10 mL) and the resulting yellow 
solution filtered through a column of celite. The volume was reduced (< 3 mL) and upon 
addition of Et2O (20 mL) a pale yellow solid was precipitated. This solid was finally isolated by 
filtration and dried in vacuo.  
 
Yield: 0.15 g (93%). Anal. Calc. for C13H16N4OPCl2Au (543.14): C, 28.75; H, 2.97; N, 10.32. 
Found: C, 28.32; H, 3.07; N, 9.93%. ESI-MS: m/z: 507.04 (100%, [M-Cl]
+





H} NMR (CDCl3): δ -7.66 (s), (DMSO-d6): -2.68 (s); 
1
H NMR (CDCl3): δ 4.54 (6H, AB 
system, NCH2N), 5.10 (6H, d, 
2
JPH = 9.1 Hz, PCH2N), 7.34 (1H, d, 
3
JHH = 7.0 Hz, 6-C6H4), 7.38 
(dd, 
3
JHH = 7.8, 
3
JHH =  7.8 Hz, 4-C6H4), 7.42 (dd, 
3
JHH = 7.2, 
3
JHH = 7.1 Hz, 5-C6H4), 8.04 (d, 
3




H} δ 55.78 (d, 
1
JPC = 36.8 Hz, PCH2N), 72.37 (d, 
3
JPC = 10.8 Hz, 
NCH2N), 128.64 (s, 2-C6H4), 129.73 (s, 3-C6H4), 130.74 (s, 5-C6H4), 134.42 (s, 4-C6H4), 143.16 
(s, Au-C) ppm. Signals corresponding to NC=O and C1 not observable. IR (cm
-1
):  352 (Au-Cl), 
1299 (N=P) 1654 (C=O). Conductivity: 37.66 μS/cm (acetone) (neutral). 
 
Synthesis of 3 
[Pt(2-C6H4C(O)N=PTA)(COD)]2Hg4Cl10 
 
[Hg(2-C6H4C(O)N=PTA)Cl]  (0.225 g, 0.44 mmol) and [PtCl2(COD)] (0.165 g, 0.44 mmol) 
were refluxed in CH3CN (20 mL) for 2 h giving rise to white solid that was filtrated off and 
washed with Et2O (3 x 10 mL), benzene (2 x 5 mL) and hexane (2 x 10 mL). After drying in 
vacuo, complex 3 was isolated as a white powder.  
 
Yield: 0.097 g (40%). Anal. Calc. for C42H56Cl10Hg4N8O2P2Pt2 (2313.94): C, 21.80; H, 2.44; N, 
4.84. Found: C, 21.72; H, 2.58; N, 4.72. ESI-MS: m/z: 470.1 ([M-COD- Hg4Cl10]
+


















H} NMR (DMSO-d6): δ -
3652.87 (s). 
1
H (DMSO-d6): δ 2.30 (8H, s, COD), 4.39 (6H, s, NCH2N), 4.91 (6H, d, 
2
JPH = 10.3 
Hz, PCH2N), 5.51 (4H, s, COD), 7.07 (1H, m, 4-C6H4), 7.16 (1H, m, 5-C6H4), 7.29 (1H, d, 
3
JHH 
= 7.3 Hz, 6-C6H4), 8.15 (1H, d, 
3




H}( DMSO-d6): 27.98 (s, COD), 
54.27 (d, 
1
JPC = 39.2 Hz, PCH2N),), 71.30 (d, 
3
JPC = 10.2 Hz, NCH2N), 124.6 (s, 4-C6H4),  128.1 
(s, 6-C6H4), 128.9 (s, COD), 131.9 (s, 5-C6H4), 132.7 (s, 3-C6H4), 135.0 (s, 1-C6H4), 138.0 (d, 
2
JCPt = 10.2 Hz, 2-PtC), 182.1 (d, 
2
JPC = 5.18 Hz, C=O)  ppm. IR (cm
-1
):  1300 (N=P), 1643 
(C=O). Conductivity: 129 μS/cm (DMF) (1:2 electrolyte). 
 





[Hg{C6H4(PPh2=N(C6H5)}Cl] (0.18 g, 0.3 mmol) and [PtCl2(COD)] (0.11 g, 0.3 mmol) were 
refluxed in acetone (30 mL) for 5 d. The solvent was removed under reduced pressure. The final 
product was extracted with CH2Cl2 and the resulting solution filtered through a column of celite 
giving a light yellow solution. The solution was concentrated (< 3 mL) and upon addition of 
Et2O (20 mL), the final product was precipitated as a white solid, isolated by filtration and dried 
in vacuo. 
 
Yield: 0.20 g (72%). Anal. Calc. for C64H62N2P2C6lPt2Hg2 · CH2Cl2 (1961.24): C, 38.84; H, 











H} NMR (CDCl3): δ 
-3622.47 (d, 
2
JPPt = 404 Hz). 
1
H NMR (CDCl3): δ 2.66 (8H, m, COD), 5.12-5.30 (4H, m, COD), 
6.88 (2H, m, 2-,6-NAr), 7.12 (1H, m, 4-NAr), 7.21 (2H, m, 3-,5-NAr), 7.35 (1H, m, 4-C6H4), 




H} CDCl3): δ  28.24 (s, COD), 
31.23 (s. COD), 89.30 (s, COD), 116.12 (s, COD), 124.3 (d, 
1
JPC = 91.6 Hz, Ci), 127.1 (d, 
5
JPC = 
2.7 Hz, 4-NAr), 127.8 (d, 
3
JPC  = 13.9 Hz, 4-C6H4), 129.5 (d, 
3
JPC  = 2.9, Hz, m-C6H5), 129.7 (s, 
3-,5-NAr), 130.1 (d, J = 4.8 Hz, 2-,6-NAr), 132.7 (d, 
2
JPC = 14.3 Hz, 3-C6H4), 133.3 (m, o-,p-
C6H5), 134.3 (d, 
4
JPC = 2.3 Hz, 5-C6H4), 147.8 (s, Pt-C). IR (cm
-1
):  529 (Pt-N), 1310 (N=P). 









[Au{C6H4(PPh2=N(C6H5))-2}(PPh3)] (0.28 g, 0.3 mmol) and PtCl2(COD) (0.11 g, 0.3 mmol) 
were stirred in CH2Cl2 (20 mL) for 25 min at RT, follow by addition of NH4PF6 (0.049g, 0.3 
mmol). The resulting solution was stirred for an additional 1 h. The solution was concentrated 
(<3 mL) and dry Et2O (20 mL) was added giving rise to gray precipitate which was stirred for 10 
min. The precipitated gray solid was isolated by filtration and washed with water (4 x 2 mL) and 
a cold mixture (1:8) of CH2Cl2/Et2O (4 x 5 mL) yielding a white solid that was dried in vacuo. 
 
Yield: 0.14 g (58%). Anal. Calc. for C32H31F6NP2Pt (800.63): C, 48.01; H, 3.90; N, 1.75. Found: 
C, 47.74; H, 4.11; N, 1.74%.  ESI-MS: m/z: 655.18 (100%), [M]
+














H NMR (CDCl3): δ 2.64 (8H, m, COD), 5.20 (4H, m, COD), 6.88 (2H, m, 2-,6-
NAr), 7.09 (1H, m, 4-NAr), 7.20 (2H, m, 3-,5-NAr), 7.23 (1H, m,  3-C6H4), 7.33 (1H, m, 4-




H} (CDCl3): δ  28.05 (s, 
COD), 31.02 (s. COD), 89.22 (s, COD), 116.49 (s, COD), 124.3 (s, Cipso), 125.2 (s, Cipso), 127.0 
(d, 
5
JPC = 2.9 Hz, 4-NAr), 127.6 (d, 
5
JPC = 13.9 Hz, 4-C6H4), 129.5 (d, 
3
JPC  = 2.5, Hz, m-C6H5), 
129.6 (s, 3-,5-NAr), 130.1 (d, 
3
JPC = 4.9 Hz, 2-,6-NAr), 132.6 (d, 
2
JPC = 13.8 Hz, 3-C6H4), 133.3 
(m, o-,p-C6H5), 134.2 (d, 
4
JPC  = 2.9 Hz, 5-C6H4), 147.8 (s, Pt-C). IR (cm
-1
):  566 (Pt-N), 838 
(br, PF6
-
), 1298 (N=P). Conductivity: 106.5 μS/cm (acetone) (1:1 electrolyte). 
 
X-Ray crystallography 
A gold block-like crystal with the size of 0.10  0.18  0.18 mm
3
 was selected for geometry and 
intensity data collection with a Bruker SMART APEXII CCD area detector on a D8 goniometer 
at 100 K. The temperature during the data collection was controlled with an Oxford Cryosystems 
Series 700+ instrument. Preliminary lattice parameters and orientation matrices were obtained 
from three sets of frames. Data were collected using graphite-monochromated and 0.5 mm-
MonoCap-collimated Mo-K radiation (λ = 0.71073 Å) with the ω and φ scan method. Data were 




refinement. Multi-scan absorption corrections were applied by using the SCALE program for the 





Non-hydrogen atoms were refined with anisotropic displacement parameters, and hydrogen 
atoms were placed in idealized positions (C-H = 0.95-0.99 Å) and included as riding with 
Uiso(H) = 1.2 or 1.5 Ueq(non-H). 
Cell culture, inhibition of cell growth and cell death analysis 
(MTT toxicity assays) 
For toxicity assays cells (5 x104 for Jurkat cells and 104 for adherent cell lines) were seeded in 
flat-bottom 96-well plates (100 µl/well) in complete medium. Adherent cells were allowed to 
attach for 24 h prior to addition of cisplatin or tested compounds. Compounds were added at 
different concentrations in triplicate. Cells were incubated with cisplatin or compounds for 24 h  
and then cell proliferation was determined by a modification of the MTT-reduction method.
  
Briefly, 10 µl/well of MTT (5 mg/ml in PBS) was added and plates were incubated for 1-3 h at 
37 ºC. Finally, formazan crystal was dissolved by adding 100 µl/well 
i
PrOH (0.05 M HCl) and 
gently shaking. The optical density was measured at 570 nm using a 96-well multiscanner 
autoreader (ELISA).  
Cell death analysis 
Apoptosis/necrosis hallmarks of cells treated with compound 5 were analyzed by measuring 
mitochondrial membrane potential, plasma membrane integrity and exposure of 
phosphatidylserine. Cells were treated with different concentrations and at different incubation 
times as indicated in figure legends. In some experiments the general caspase inhibitor z-VAD-
fmk was added at 50 µM 1 h before compounds. For mitochondrial membrane potential 
determination cells (2.5x10
5
 in 200 µl) after treatment with 5 were incubated at 37ºC for 15 
minutes in medium containing 5nM DiOC6(3) (Molecular Probes). Phosphatidylserine exposure 
was quantified by labeling cells with AnnexinV-DY634 (Invitrogen) after treatment with 5. 
AnnexinV was added at a concentration of 0.5 µg/ml in Annexin Binding Buffer (ABB) and 
cells were incubated at room temperature for 15 min. Plasma membrane integrity was evaluated 
by staining with 7-Amino-Actinomycin D (7-AAD, Inmunostep). At the end of the treatment 




cases, cells were diluted to 1 ml with ABB or PBS (Phosphate Buffered Saline) to be analyzed 
by flow cytometry (FACScan, BD Bioscience, Spain).  
Permeability determinations 
(Cell culture and transport assays) 
Caco-2 cells were grown in Dubelcco’s Modified Eagle’s Media containing L-glutamine, fetal 
bovine serum and penicillin-streptomycin. To obtain cells monolayers 250000 cells/cm
2
 were 
seeded on each well with polycarbonate membrane with 4.2 cm
2 
area. Plates were incubated at 
standard conditions of 37ºC temperature, 90% humidity and 5% CO2 until confluence. After 19-
21 days the integrity of the each cell monolayer was evaluated by measuring the trans-epithelial 
electrical resistance (TEER). Values ranging 500-750 Ωcm
2
 were considered appropriated. 
Transport studies were performed using an orbital environmental shaker at constant temperature 
(37ºC) and agitation rate (50 rpm). Hank’s balanced salt solution (HBSS) supplemented with 
HEPES was used to fill the receiver chamber and to prepare the drug solution placed in the donor 
chamber. Four samples of 200 µL each one were taken from the receiver chamber side at 
predefined times (15, 30, 60 and 90 minutes) and the same volumen were replaced with fresh 
buffer. Moreover, two samples of the donor side were taken at the beginning and the end of the 
experiment. Moreover, the amount of compound in cell membranes and inside the cells was 
determined at the end of experiments in order to check the mass balance and the percentage of 
compound retained in the cell compartment was always less than 5%. 
Transport studies were performed in both directions, from apical-to-basal (A-to-B) and from 
basal-to-apical (B-to-A) sides. The volume of donor compartment was 2 mL in A-to-B direction 
and 3 mL in B-to-A direction. 
Analysis of the samples 
Samples were analyzed by HPLC using a 5 μm, 4 x 200 mm Novapack C18 column. Samples of 
Cisplatin and compound 4 were analyzed with UV detection (λ=240 nm) and the mobile phase 
was 95:5, acetonitrile: water, with a flow rate of 1mL/min, and the injected sample volume was 
50 μL. Samples of compound 5 were analyzed similarly but using a UV detector at λ=215 nm 















































  (1)     
where Creceiver, t is concentration of compound in the receiver chamber at t time, Qtotal is the total 
amount of drug in both chambers, Vreceiver and Vdonor are the volumes corresponding to receiver 
and donor compartment respectively in each chamber, Creceiver, t-1 is concentration of compound 
in receiver chamber at previous time, f is the sample dilution factor due to replaced volume, S is 
the surface area of the monolayer, Δt is the time interval and P is the permeability coefficient. 
This equation takes into account the continuous change of the donor and receiver concentrations, 
i.e. non-sink conditions. However, when the transport rate is low, there are not significantly 
changes between the donor and the receiver concentrations with time.  In this conditions sink 





P    (2) 
where dQ/dt is the apparent appearance rate of drug in the receiver side calculated using linear 
regression of amounts in the receiver chamber versus time, S is the surface area of the monolayer 
and C is the drug concentration in the donor chamber. 




Studies were performed by triplicate and the data were presented as mean ± SD. Student’s t-test 
were performed with SPSS 16.0 (SPSS Inc.) in order to determine statistically significant 





In situ absorption experiments 
The absorption experiments were performed using an in situ loop technique described by 
Doluisio.
52
 The study was approved by the Scientific Committee of the Faculty of Pharmacy and 
followed the guidelines described in the EC Directive 86/609, the Council of the Europe 
Convention ETS 123 and Spanish national laws governing the use of animals in research (Real 
Decreto 223/1988, BOE 67, 18-3-98: 8509-8511). Male Wistar rats weighing 280-320 g were 
used after 8 h of fasting. Previously to surgical procedure, animals were anesthetized with 
Diazepam (Valium, Roche) (1,67 mg/kg), Ketamine (Ketolar; parke-Davis) (50mg/kg) and 
Atropine (atropine sulfate; Braun) (1mg/kg). The body temperature was maintained during the 
procedure by heating with a lamp.  Therefore, a midline abdominal incision were performed and 
a loop was isolated from duodenal and ileal region of each rat. The proximal ligatures of the 
duodenal and ileal regions were placed approximately 1 cm from the pylorus and 2 cm above the 
ileocecal junction. The bile duct was tight up in all experiments. 50 mL of cleaning solution 
(Solution A (pH 7,4): 9,2 g NaCl, 0.34 g KCL, 0.19 g CaCl2*H2O and 0.76 g NaH2PO4*2 H2O 
per liter) were used to flushed out the content of the loop and then 20 mL volume of solution B 
(NaCl g, NaH2PO4*2H2O 1/15M 3.9 mL, Na2HPO4 1/15M 6.1 mL and water up to 1L) were 
perfused to condition the intestinal mucosa prior to the experiments. A catheter was tight up at 
both intestinal ends and connected to a glass syringe by the use of a stopcock type valve. Under 
this set up, the intestinal segment is an isolated compartment and the drug solution can be 
perfused. The drug solutions were prepared freshly day at 20 µM using solution B as solvent and 
perfused into the loop and then the entire intestine was restored into the abdominal cavity. 
Samples of the perfusate were carried out every 5 minutes for 30 minutes.  
Permeability Calculations 
The apparent first order absorption rate coefficients (kapp) were obtained by non-linear fitting of 
a monoexponential equation to the luminal concentrations versus time.  
C = C0 · e
−kapp·t
         (3) 
where the C is the drug concentration remaining in the lumen, kapp is the apparent absorption 
rate constant, and C0 corresponds to a calculated fraction of the initial perfusion concentration. 




solution, the adsorption to the membrane, and the loading process in the enterocyte. So, the 
intercept, C0, is lower than the perfusion concentration. The quasi-steady-state is achieved in the 
membrane when this process is finished. Under these conditions, the disappearance of the 
compound from the lumen can be considered as a first order process during the sampling time 
interval.  For these reasons, only the concentrations obtained after 5 min were used for regression 
analysis. In order to obtain good prediction data water reabsorption correction of was introduced 
for the concentrations calculations. 
The intestinal permeability values were calculated taking into account the relationship between 
ka and Peff:  
  ( · ) / 2eff aP k R  (4) 
where R is the radius of the intestinal segment, calculated as area/volume ratio. The effective 
intestinal permeabilities (Peff) of the tested compounds (means of at least of three animals) were 
used as indexes of the absorption effectiveness.  
Interaction of compounds 1-5 and cisplatin with plasmid (pBR322) DNA by 
Electrophoresis 
(Mobility Shift Assay) 
 
10 µL aliquots of pBR322 plasmid DNA (20 µg/mL) in buffer (5 mM Tris/HCl, 50 mM NaClO4, 
pH = 7.39) were incubated with different concentrations of the compounds 1-5 (in the range 0.25 
and 2.0 metal complex:DNAbp) at 37 
o
C for 20 h in the dark. Samples of free DNA and 
cisplatin-DNA were prepared as controls. After the incubation period, the samples were loaded 
onto the 1 % agarose gel. The samples were separated by electrophoresis for 1.5 h at 84 V in 
Tris-acetate/EDTA buffer (TAE). Afterwards, the gel was stained for 30 min with a solution of 
GelRed Nucleic Acid stain.  
 
Interaction of compounds 3-5 and cisplatin with Calf Thymus DNA by Circular Dichroism 
Stock solutions (5 mM) of each complex were freshly prepared in water prior to use. The right 
volume of those solutions was added to 3 ml samples of an also freshly prepared solution of CT 




ratios of 0.1, 0.25, 0.5 and 1.0 drug/DNA. The samples were incubated at 37 ºC for a period of 
20 h. All CD spectra of DNA and of the DNA-drug adducts were recorded at 25 ºC over a range 
220-330 nm and finally corrected with a blank and noise reduction. The final data is expressed in 
molar ellipticity (millidegrees). 
Interaction of compounds 1-5 and cisplatin with HSA by Fluorescence Spectroscopy 
A solution of each compound (8 mM) in DMSO was prepared and ten aliquots of 2.5 µL were 
added successively to a solution of HSA (10 µM) in phosphate buffer (pH = 7.4) to achieve final 
metal complex concentrations in the range 10-100 µM. The excitation wavelength was set to 295 
nm, and the emission spectra of HSA samples were recorded at room temperature in the range of 
300 to 450 nm. The fluorescence intensities of all the metal compounds, the buffer and the 
DMSO are negligible under these conditions. The fluorescence was measured 240 s after each 
addition of compound solution. The data were analyzed using the classical Stern-Volmer 
equation F0/F = 1 + KSV[Q]. 
 
Cell culture and XTT assay for RPTC cells 
 
The human Renal Proximal Tubule Cells (RPTC) a non-tumoral human kidney epithelial 
cell line (obtained from Lifeline Cell Technology, Frederick, Maryland, USA) were cultured in 
Lifeline's RenaLife Medium containing RenaLife LifeFactors with 2.4 mM L-Glutamine, 5 
Î¼g/mL  rh insulin, 1.0 Î¼M epinephrine, 10 nM  triiodothyronine, 0.1 Î¼g/mL hydrocortisone 
hemisuccinate, 10 ng/mL rh EGF, 0.5% FBS and 5 Î¼g/m transferrin PS (all from Lifeline Cell 
Technology), at 37°C in a humidified atmosphere of 95% of air and 5% CO2 (Brooklyn College, 
CUNY, US).  For evaluation of cell viability, cells were seeded at a concentration of 5×10^3 
cells/well in 90 µl Lifeline's RenaLife complete medium into tissue culture grade 96-well flat 
bottom microplates (Thermo Scientific BioLite Microwell Plate, Fisher Scientific, Waltham, 
Massachusetts, USA) and grown for 24 h. Solutions of the compounds were prepared by diluting 
a freshly prepared stock solution (in H2O) of the corresponding compound in Lifeline's RenaLife 
complete medium. Afterwards, the intermediate dilutions of the compounds were added to the 
wells (10 µL) to obtain a final concentration ranging from 0.1 to 200 µM, and the cells were 
incubated for 24 h. Following 24 h drug exposure, 50 µL of 2,3-Bis-(2-Methoxy-4-Nitro-5-




USA) labeling mixture per well was added to the cells at a final concentration of 0.3 mg/ml and 
incubated for 4 h at 37°C in a humidified atmosphere of 95% of air and 5% CO2. The optical 
density of each well (96-well plates) was quantified using EnVision Multilabel Plate Readers 
(Perkin Elmer, Waltham Massachusetts, USA) at 450 nm wavelength to measure 
absorbance. The percentage of surviving cells was calculated from the ratio of absorbance of 
treated to untreated cells. The IC50 value was calculated as the concentration reducing the 
proliferation of the cells by 50% and is presented as a mean (± SE) of at least two independent 








Crystallographic data for compounds 2 and 4 including complete drawing of the structure and 











H} NMR spectra for compounds 1-5 in 
DMSO-d6; stability of compounds 4 and 5 in DMSO:PBS (1:99) determined by Uv-Vis. 
 
4.8.1. Crystallographic Data for Compounds 2 and 4. 
Table 7. Crystal data for compounds 2 and 4. 
Compound 2 4 
Formula C13H16N4OPCl2Au C66H66Cl10Hg2N2P2Pt2 
Formula weight 543.13 2095.01 
T [K] 100(2) 100(2) 
 (Mo-K) [Å] 
0.71073 0.71073 
Crystal system Orthorhombic Triclinic 
Space group P b c a P   

1  
a [Å] 12.8453(8) 11.1159(5) 
b [Å] 11.0611(7) 11.8606(5) 
c [Å] 22.6045(14) 14.8021(6) 
 [
o
] 90 92.5060(10) 
 [
o
] 90 99.7520(10) 
 [
o
] 90 115.8280(10) 
V [Å
3
] 3211.7(3) 1715.94(13) 
Z 8 1 
Dcalcd (g cm
-3
) 2.247 2.027 
 (mm
-1
) 9.599 9.000 
GOF 1.057 1.048 
R1 [I > 2(I)] 0.0142 0.0186 








Table 8. Selected Structural Parameters of complex 2 obtained from X-ray single crystal 
diffraction studies (see drawing above). Bond lengths are given in [Å] and angles in [º]. 
Au(1)-Cl(1) 2.3834(5) N(1)-Au(1)-Cl(2) 173.33(5) 
Au(1)-Cl(2) 2.2798(5) N(1)-Au(1)-Cl(1) 97.32(5) 
Au(1)-C(1)                     2.020(2) Cl(2)-Au(1)-Cl(1)             88.62(2) 
Au(1)-N(1)                     2.0497(18) P(1)-N(1)-Au(1) 126.07(10) 
P(1)-N(1) 1.6658(18) P(1)-N(1)-C(7) 119.25(15) 
N(1)-C(7) 1.404(3) N(1)-C(7)-C(6) 112.16(19) 
C(7)-O(1)                      1.213(3) N(1)-C(7)-O(1) 123.72(19) 
C(7)-C(6) 1.478(3) C(7)-N(1)-Au(1)              114.68(14) 
C(6)-C(1)                     1.385(3) C(7)-C(6)-C(1)               118.0(2) 
  C(6)-C(1)-Au(1) 113.24(16) 
C(1)-Au(1)-N(1)               81.68(8) N(1)-P(1)-C(10)              113.99(10) 
C(1)-Au(1)-Cl(2)              92.44(6) N(1)-P(1)-C(8)               116.45(10) 








Table 9. Selected Structural Parameters of complex 4 (see drawing incorporating the anion 
above) obtained from X-ray single crystal diffraction studies. Bond lengths are given in [Å] and 
angles in [º]. 
Pt(1)-C(1) 2.039(2) N(1)-Pt(1)-C(1) 85.31(9) 
Pt(1)-N(1) 2.039(2) N(1)-Pt(1)-C(25) 95.99(9) 
Pt(1)-C(30) 2.150(2) N(1)-Pt(1)-C(26)   91.92(8) 
Pt(1)-C(29) 2.160(2) N(1)-Pt(1)-C(29) 162.15(9) 
Pt(1)-C(26) 2.268(2) N(1)-Pt(1)-C(30) 160.07(9) 
Pt(1)-C(25) 2.287(2) C(1)-Pt(1)-C(25) 163.39(9) 
P(1)-N(1) 1.622(2) C(1)-Pt(1)-C(26) 161.34(9) 
P(1)-C(2) 1.773(2) C(1)-Pt(1)-C(29) 96.26(10) 
P(1)-C(7) 1.797(3) C(1)-Pt(1)-C(30) 92.76(10) 
P(1)-C(13) 1.797(3) P(1)-N(1)-Pt(1) 117.55(11) 
N(1)-C(19) 1.444(3) C(19)-N(1)-Pt(1) 125.82(16) 
C(1)-C(2)   1.409(3) C(19)-N(1)-P(1) 116.21(16) 
Hg(1)-Cl(1) 2.6117(7) Cl(1)-Hg(1)-Cl(2) 107.66(2) 
Hg(1)-Cl(2) 2.3808(7) Cl(2)-Hg(1)-Cl(3) 135.47(3) 
Hg(1)-Cl(3) 2.3865(7) Cl(3)-Hg(1)-Cl(1) 105.68(2) 
Hg(1)-Cl(1)#1 2.6665(7) Cl(2)-Hg(1)-Cl(1)#1 106.38(2) 
Cl(1)-Hg(1)#1 2.6666(7) Cl(3)-Hg(1)-Cl(1)#1 102.92(3) 
  Cl(1)-Hg(1)-Cl(1)#1 88.90(2) 










Compound Time (DMSO-d6) 
1 d 4 d 1  w 3 w 1 m 2 m 3 ms 4 m Half life (50%) 
1  >99%  90%  55% 36%  2 months 
2    >99%  90% 50%  3 months 
3       >99%  months 
4   >99% 90%    84% months 
5 >99%  96% 94%    77% months 
 






















Figure 16. 31P{1H} NMR spectrum of compound 2 in DMSO-d6 ( -2.66 (s) ppm) overtime. 
 






Figure 18. 1H NMR spectrum of compound 3 in DMSO-d6 overtime. 
 






Figure 20. 1H NMR spectrum of compound 4 in DMSO-d6 overtime. 
 








H NMR spectrum of compound 5 in DMSO-d6 overtime. 
4.8.4. UV-Vis spectra of compounds 4 and 5 in CH2Cl2 and in DMSO, and in 1% DMSO-
PBS solution overtime. 
 





Figure 24. UV-visible spectrum of compound 4 (50.0 µM) in DMSO recorded overtime. 
 
Figure 25. UV-visible spectrum of compound 4 (15.0 µM) in 1:99 DMSO/PBS-1X (pH 7.4) 





Figure 26. UV-visible spectrum of compound 5 (10.0 µM) in dichloromethane. 
 






Figure 28. UV-visible spectrum of compound 5 (50.0 µM) in 1:99 DMSO/PBS-1X (pH 7.4) 
recorded overtime, incubation at RT. 
 





Figure 30. UV-visible spectrum of iminophosphorane ligand Ph3P=NPh (50.0 µM) in 1:99 
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RUTHENIUM(II) COMPOUNDS WITH N,N- CHELATING AND 
C,N- (CYCLOMETALLATED) IMINOPHOSPHORANE LIGANDS. 




5.1. Ruthenium(II and III) as potential anticancer agents 
 
As mentioned in chapter I, ruthenium compounds have emerged as promising candidates 
for metal based cancer chemotherapeutics.
1-5
 Like platinum-based drugs, ruthenium compounds 
can exchange N- and O-donor molecules with the added advantage of the possibility of forming 
octahedral complexes (of interest in reactions with DNA). As described in Chapter I, three 
ruthenium(III) coordination complexes have successfully completed phase I clinical trials and 
entered phase II (NAMI-A,
4,6
 KP1019 and KP1339
4,7,8 
).  
More recently, ruthenium (II)-arene complexes (with a piano-stool structure) have also 
been described as promising candidates.
4,9-18
 The two most relevant examples, which have 
undergone advanced preclinical studies are RM175, described by Sadler et al. and RAPTA-T 
reported by Dyson et al. (Figure 1).
 
RAPTA-T, containing the hydrophilic and monodentante 
PTA phosphine ligand, showed to reduce the growth of lung metastases in mice bearing 
mammary carcinoma and was able to inhibit highly invasive breast cancer. RM175 demonstrated 
to be active in vivo against triple-negative breast cancer cell lines.13,19 Pfeffer-Gaiddon and co-
workers reported on C,N-cyclometallated compounds (such as RDC11 in Figure 1) that inhibited 
the growth of human cancer xenografts in mice more efficiently than cisplatin.
4,10,20-23
 Notably, it 
did not cause severe side effects in liver, kidneys, neuronal sensory system or blood cells 





Figure 1. Selected ruthenium(III) and (II) compounds with important antitumor and/or 
antimetastatic properties.
4-22,35-37 and refs. therein
 
 
Very recently, Dyson et al. showed that RAPTA-C reduces the growth of primary tumors 
in preclinical models for ovarian and colorectal carcinomas through an antiangiogenic 
mechanism, most likely through binding to the histone protein core in chromatin rather than to 
the DNA.
24,25 
Another recent report by the same group described Ru(II)-arene complex with a 
perfluoroalkyl-modified ligand (A, in Figure 1) that displayed antiproliferative activity against 
four cancer cell lines in vitro and with no toxic effect to non-tumoral cells. Furthermore, in vivo 
studies of A in a xenografted ovarian carcinoma (A2780) grown on the chicken chorioallantoic 
membrane model (CAM) led to a 90% reduction in tumor growth, displaying a stronger 
antivascular effect than RAPTA-C.
24
 
Dyson et al. also reported on the evaluation of a similar Ru(II)-arene complex, with a 
long fluorous chain (B, in Figure 1), which exhibited a synergistic tumor growth reduction in 




shown that combining chemotherapy with regional mild hyperthermia, applying heat locally to 
rise the tumor temperature between 40-42ºC, can sensitize tumor tissue to anticancer agents 
resulting in improved local control, treatment efficacy and overall survival prolongation.
26
  
 The recent strategy to bind a drug of well-known therapeutic value (such as curcumin, 
ketoconazole, clotrimazole, hydroxyflavones, hydroxyquinolinones, letrozole, indolobenzazepins 
or aspirin) to ruthenium centers has rendered a number of complexes with improved properties 
with respect to the parent organic drugs for cancer.
e.g.27-34
 In this context, ruthenium compounds 
resembling staurosporine (like DW1/2 in Figure 1) developed by Meggers and co-workers are 
relevant examples of potential chemotherapeutics targeting protein kinases.
4,10,35-37 
Hartinger et al. explored new routes to develop metallodrugs by coordinating 
pharmacophores to metal fragments with established anticancer properties. In their study, oxicam 
backbone that is found in the nonsteroidal anti-inflammatory drugs, was incorporated into an 
organometallic Ru(II)-arene compound. The most lipophilic compound in this study (C in Figure 
1) displayed the most cytotoxicity against human colon carcinoma (HCT116) cell lines in vitro. 
Even though the IC50 of the compound was not significantly low, this and other compounds in 
this study could be further explored to fully understand their mode of action. In comparison, 
other ruthenium compounds complexes, such as NAMI-A and RAPTA derivatives, were 
noncytotoxic in vitro but exhibited high activity against metastases in vivo.
38
 
In a recent study done by Süss-Fink and co-workers, dinuclear p-cymene ruthenium 
complex was synthesized and evaluated in vitro for its anticancer activity in series of cancer cell 
lines (diruthenium-1 in Figure 1). Diruthenium-1 was found to be highly cytotoxic towards 
ovarian cancer (A2780) cell lines in vitro, in low nanomolar range (30 nM). The complex was 
further studied in vivo in tumor-bearing mice at a dose of 0.6 mg/kg and showed to significantly 




Nowadays, there are examples of multinuclear ruthenium compounds,
40,41
 ruthenium 
derivatives which can be activated by light,
42
 that are thermoresponsive,
43
 that can be obtained 
by a combinatorial approach,
44 
 as well as ruthenium compounds that can be delivered to tumor 






 or transport 
proteins.
50
 However, there is still a need to find the ultimate target(s) for these ruthenium 




in order to develop more powerful and selective chemotherapeutics.
4
 In addition, more in vivo 
data is needed to make more reliable predictions of structure-biological activity correlations.
17,19 
Within this context, we aimed to explore the potential of IM complexes containing metals 
other than d
8
 transition metals (Au(III), Pd(II) and Pt(II)) as anticancer agents and we focused on 
ruthenium(II) compounds. The following chapter reports on the preparation, characterization and 
stability studies of organometallic ruthenium(II) compounds containing different 
iminophosphorane ligands. Preliminary biochemical and biochemical studies (in vitro effects on 
human cancer cells, type of cell death and permeability studies on selected compounds) were 
performed by our collaborators. I studied the interactions of the compounds with plasmid 
(pBP322) DNA and of selected compounds on Calf Thymus DNA by different techniques 
(melting point, CD circular dichroism). Finally the effects of a water-soluble compound with the 
best pharmacological profiles on human cancer xenografts in mice (performed by a PhD student 
from our laboratory) will be reported and discussed to put the results into context and discuss the 
potential of these ruthenium compounds as cancer chemotherapeutics. 
 
5.2. Synthesis and characterization of ruthenium(II) organometallic complexes containing 
iminophosphorane ligands 
 
The synthesis of ruthenium(II) piano-stool complexes containing iminophosphorane 
ligands has been described by Urriolabeitia and co-workers.
51
 We have employed here p-cymene 
as the arene group coordinated to the ruthenium centers. Thus, compounds 1-4 can be easily 







 (Scheme 1). 4 is an example of a new heterometallic ruthenium 
complex containing a ferrocene fragment. 
Ruthenium(II) complexes with cyclometallated IM (pincer C,N-) ligands have been 
prepared by transmetallation with organomercury derivatives.
51
 However the nature of the IM 
ligand played a crucial role and compounds with semi-stabilized IM ligands containing carbonyl 







Scheme 1. Preparation of cationic ruthenium(II) compounds containing IM ligands. 
 
 
In addition, we also aimed to prepare cycloruthenated compounds in which the aryl group 
of the imino fragment is coordinated to the metal center (exo derivatives) as opposed to an aryl 
group of the phosphine fragment (endo derivatives) in order to be able to incorporate different 
phosphines into the final molecule to tune electronic/steric properties of the resulting complexes. 
As described in Chapter IV, cyclometalated iminophosphorane exo derivatives can be prepared 
by reaction of the appropriate metal compound with the organomercury derivative Hg(Ph3P=N-
CO-2-C6H4)Cl.
58
 As mentioned in the previous chapter, C-H activation at the N-CO-Ph 




cyclometalated iminophosphorane manganese compounds to HgCl2, the organomercury 
derivatives with PPh3 [Hg(Ph3P=N-CO-2-C6H4)Cl]
58
 or water soluble phosphine  PTA 
[Hg(PTA=N-CO-2-C6H4)Cl] (7) are obtained in high yields. Transmetallation reactions of 
[Hg(Ph3P=N-CO-2-C6H4)Cl]
58
  and 7 with [(η
6
-p-cymene)Ru(μ-Cl)Cl]2 afford new 
cyclometallated compounds [(η
6
-p-cymene)Ru(IM-k-C,N)Cl] (IM = Ph3P=N-CO-2-C6H4 8; 
PTA=N-CO-2-C6H4 9) in high yields (Scheme 2). 
 
 
Scheme 2. Preparation of the new cycloruthenated compounds 8 and 9 containing IM ligands. 
 
All the compounds are obtained as air stable solids in moderate to high yields. Their 
structures have been proposed on the basis of microanalytical, spectroscopic (IR and NMR), 
conductivity and MS spectrometry data. Some of the compounds are slightly hygroscopic. As 
previously proposed by Urriolabeitia and co-workers,
51
 the IM ligand in compounds 1 and 2 is 
bonded as a chelate giving a fac-Cl,N,O arrangement while in compounds 3 and 4 the 
arrangement is fac-Cl,N,N. This can be clearly inferred from the IR data. There is a strong 
absorption at 1531 cm
-1
 due to νCO stretch for 1 and 2 shifted to lower frequencies with respect 
to that of the free ligand at 1598 cm
-1
. For 3 and 4 the signal that can be assigned to νPN stretch 
is shifted to lower frequency than that of the free ligands (see Experimental Section). As 







NMR signals for 1 and 2 resemble that of the free ligand whereas for 3 and 4 the signals are 
strongly shifted to low field with respect to the free ligands, indicating iminic N-bonding. In 
addition, the ortho protons of the quinoline (H2) and pyridine (H6) in the 
1
H NMR spectra for 3 
and pyridine (H6) for 4 are shifted downfield supporting the idea of N-coordination. Compound 4 






spectrum in the area of the p-cymene and Cp rings) and its variable temperature NMR spectra are 
collected in the Appendix. 





-C6H6)Ru(k-N,O-Ph3P=N-CO-2-N-C5H4)]PF6 with very similar 
distances and angles. The molecular structure for the cation of 1 is depicted in Figure 2. Selected 
bond lengths and angles for compound 1 are collected in Table 1.  
 
 
Figure 2. Molecular structure of the cation of compound 1. 
 
Table 1. Selected Structural Parameters of complex 1 obtained from X-ray single crystal 
diffraction studies (see drawing above). Bond lengths are given in [Å] and angles in [º]. 
 
Ru(1)-O(1)  2.110(3) Ru(1)-Cl(1) 2.3775(14) 
Ru(1)-N(1) 2.095(4) O(1)-C(16) 1.266(6) 
Ru(1)-C(10) 2.153(5) C(1)-N(2) 1.337(7) 
Ru(1)-C(6) 2.154(5) C(1)-C(2) 1.385(8) 
Ru(1)-C(7) 2.171(5) N(2)-P(1) 1.619(5) 
Ru(1)-C(9) 2.187(5) N(1)-Ru(1)-O(1) 76.68(14) 
Ru(1)-C(11) 2.191(5) O(1)-Ru(1)-Cl(1) 83.61(10) 
Ru(1)-C(8) 2.204(5) N(1)-Ru(1)-Cl(1) 83.13(12) 
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The analysis confirms the piano-stool structure around the ruthenium center as well as the 
coordination of the IM ligand through the N and O atoms. Ru-C distances are on average slightly 





 as expected. 
Compounds 8 and 9 are cycloruthenated neutral species with the IM ligand in an exo 
disposition [(η
6
-p-cymene)Ru(IM-k-C,N)] (IM = Ph3P=N-CO-2-C6H4 8; PTA=N-CO-2-C6H4 9). 
Their 
1
H NMR spectra show signals due to η
6








H} NMR spectra are strongly shifted downfield with respect of those for the free ligand as 
reported before for endo cycloruthenated species.
51
 
The cationic compounds with chloride as counterion (2, 3, and 4) are highly soluble in 
water (70 to 100 mg/mL). The cycloruthenated derivative 9 with a water-soluble phosphine PTA 
(9) is much less soluble in water (1 mg/mL 9). 1, and cyclorutenated 8 and 9 are soluble in 
micromolar concentrations in 1:99 DMSO:H2O mixtures. All the complexes but 9 are stable for 
weeks in DMSO-d6 solution (see spectra and stability table in the Appendix). The stability of the 






H NMR spectroscopy in D2O. The 
spectrum in D2O for compound [(η
6
-p-cymene)Ru{Cp-P(Ph2)=N-CH2-2-NC5H4}Fe(Cp)}]Cl (4) 





spectrum in D2O for 3  (δ= 37.73 ppm) shows an additional signal (δ= 38.34 ppm) that may be 





integration of these signals is ca. 45:55 and the spectrum does not change much over time (days). 





 is also visible in D2O (δ = 26.65 ppm) along with 








 and grows overtime. The 
1
H NMR spectrum of 2 in D2O 
after 5 days shows (in addition to those of compound 2) signals due to new species containing 
η
6





H} NMR spectrum shows most of the six peaks due to this C6H4P unit. The doublet that 
can be assigned to the C=O peak for these new cyclometalated species appears at 176.06 ppm 




coordinated to the ruthenium center (like in the case of the free ligand which displays a doublet 
at 175.34). The MS spectra of 2 in H2O overtime shows a peak at m/z = 617 with a pattern fitting 





cyclometalation processes at room temperature in DMSO of arylgroups from PPh3 in IM 
coordination complexes of Pd and Pt with the Ph3P=N-8-C9H6N IM ligand have been reported 
before.
55
 The half-life for 2 (14.5 mM) in D2O is 2.5 days (although the process slows down for 
more concentrated samples). The cyclometalation process for 2 proceeds faster in a 100 mM 
NaCl solution in D2O (half-life ca. 10 hours for a concentration of 2 of 14.5 mM) and by 
increasing the temperature (60% after 1 hour at 80
o
C). However, as it will be explained in 
section 5.3, the biological activity of compound 2 is very fast (in 8 hours it induces 80% of 
apoptosis on Jurkat cells) and thus we believe that the biological activity observed comes mainly 
from coordination compound 2 or its hydrolysis product. 
 
5.3. Biological activity in vitro 
 
These studies were performed by Dr. Isabel Marzo, Oscar Gonzalo and Daniel Ramírez de 
Mingo at the University of Zaragoza, Spain. The studies on non-carcinogenic RPTC cell lines 
were performed by PhD student Benelita T. Elie in our laboratory. 
 
5.3.1. Antiproliferation studies in vitro 
 
  The antiproliferative properties of the new ruthenium complexes 1-4, 8 and 9 and of the 
starting material [(η
6
-p-cymene)Ru(μ-Cl)Cl]2 were assayed by monitoring their ability to inhibit 
cell growth using the MTT assay (see Experimental Section). Cytotoxic activity of the 
compounds was determined in several human cancer cell lines: leukemia Jurkat-T, lung A549, 
prostate DU-145, pancreas MiaPaca2, and triple negative breast MDA-MB-231, in comparison 
to cisplatin. The results are summarized in Table 2. The starting material [(η
6
-p-cymene)Ru(μ-
Cl)Cl]2 is poorly cytotoxic in all tested cell lines (IC50 >125 µM). The IM ligands coordinated to 








ligand 8 were considerably more cytotoxic than cisplatin in all the cell lines studied. Compounds 
1 and 2 (same cation) display almost identical IC50 values but 2 is soluble in H2O. The ruthenium 
compound based on an iminophosphorane ligand containing a ferrocenyl phosphine Fe-Ru 4 was 
less cytotoxic than cisplatin. The bimetallic compounds Fe-Au and Fe-Pd also showed higher 
IC50 values when compared to trimetallic derivatives or compounds with different IM ligands. 
The cycloruthenated compound containing a water soluble IM ligand (IM-PTA) was more 
cytotoxic than cisplatin for the pancreas MiaPaca2, and triple negative breast MDA-MB-231 cell 
lines.  
 




, and cisplatin in 
human cell lines.
b
 All compounds were dissolved in 1% of DMSO and diluted with water before 





-p-cymene)Ru(μ-Cl)Cl]2 >125 µM in all cell lines. 
b
Data are expressed as mean ± 
SD (n =4). 
 
 In order to assess the compounds’ selectivity for cancerous cells with respect to normal 
cell lines, they were also screened for their antiproliferative effects on the non-tumorigenic 
human embryonic kidney cells HEK293T. In most cases the cytotoxicity is comparable for the 
cancerous and HEK293T cells. All compounds are more toxic to leukemia than to HEK293T cell 
lines (2 to 8 times) and compounds 1, 2, and 9 are more toxic to the prostate DU-145 cancer cell 
line than to HEK cell lines. In addition, 9 is more toxic to the pancreas MiaPaca2 cancer cell line 
 Jurkat A549 DU-145 MiaPaca2 MDA-MB-
231 
HEK-293T 
1 1.1 ± 0.14 9.9 ± 1.9 1.89 ± 0.64 2.4 ± 0.18 4.91± 2.7 2.8 ± 0.2 
2 0.78 ± 0.08 9.5 ± 2.1 1.55 ± 0.21 2.9 ± 0.8 2.61 ± 1.2 2.8 ± 0.2 
3 0.9 ± 0.32 43.3 ± 8.0 6.6 ± 0.85 7.0 ± 0.4 16.2 ± 0.9 2.2 ± 1.1 
4 9.3 ± 0.07 >125 148 ± 33 > 125 > 125 114.5 ± 14.8 
8 2.39 ± 0.27 29.9 ± 5.8 14.2 ± 4.2 8.2 ± 0.98 7.1 ± 0.11 4.1 ± 0.06 
9 17.7 ± 7.5 >125 125.5 ± 28 54.5 ± 16 75.4 ± 9.8 141.9 ± 13.1 




and to the breast cancer MDA-MB-231 cell line than to HEK293T although the IC50 for those 
cell lines are higher than other compounds in the table.  
  Importantly as HEK cell lines are immortalized cells that can display a higher sensitivity 
to chemicals, we measured the effect of compound 2 on human renal proximal tubular cells 
(RPTC). Renal proximal tubular cells in primary culture have been described as an in vitro 
model to study nephrotoxicity.
59
 The IC50 value (XTT assay 24 hours see Experimental Section) 
for 2 in this cell line was 13.84±1.46 µM (the value obtained for cisplatin as control was 
46.42±2.46 µM similar to a values previously reported
60
 for 24h in rabbit RPTC). Thus, 2 is 
more toxic to all the cancer cell lines studied than to the “healthy” human renal cell line and 
markedly more toxic to the leukemia Jurkat-T (17.7-fold), prostate DU145 (9-fold), triple 
negative breast cancer MDA-MB-231 (5.3-fold), and pancreas MiaPaca (4.7-fold) cancer cell 
lines. 
  2 with an IC50 of 2.64 µM is 30 times more cytotoxic in MDA-MB-231 breast cancer cell 
lines than compound RM175 (Figure 1) with an IC50 of 62 µM under the same conditions (MTT, 
24 h incubation). The toxicity of RM175 in HBL100 human epithelial cell lines (IC50= 54 µM) 




5.3.2. Mechanism of cell death 
 
  The mechanism of cell death induced by 2 and 3 was explored in Jurkat cells. Nuclei 
morphology after 24 h incubation with 1 µM solution of 2 or 3 was analysed by Hoechst 
staining.  Typical apoptotic features, chromatin condensation and fragmentation, were detected 
as shown in Figure 3. 
 
 




  Other apoptotic parameters such as phosphatidylserine exposure and mitochondrial 
membrane potential dissipation were analyzed, using fluorescent probes as indicated in the 
Experimental Section. Dose-response experiments (Figure 4, right panel) confirmed that 2 is 
more cytotoxic than 3, as also indicated by MTT assays. Time-course experiments indicated that 
2 induced apoptosis in around 80% of cells after 8 h treatment (Figure 4, left panel). Trypan blue 
staining confirmed that cell death was through apoptosis, with very low secondary necrotic cells 
at 6 h (data not shown). Phosphatidylserine exposure and loss of transmembrane mitochondrial 
potential occurred in the same percentage of cells, although at longer incubation periods, there 
was an apparent decrease in the percentage of AnnexinV positive cells that was in fact due to cell 





 cells gradually increasing during the 24 h period of the experiments (Figure 4, left panel). 
 
 
Figure 4. Dose-response quantification of PS exposure (A) and time-course analysis of PS 
exposure and ∆Ψm loss (B) caused by 2 and 3 in Jurkat cells. 
 
Proteins of the Bcl-2 family are key regulators of apoptosis and the levels of some 
members are modified in early phases of the process. Thus, we analyzed the effect of 2 in the 
levels of two antiapoptotic proteins of the Bcl-2 family (Bcl-XL and Mcl-1) and three 
proapoptotic members (Bim, Puma and Noxa) in Jurkat cells (Appendix Figure 43). Jurkat cells 
express very low levels of the other antiapoptotic member (Bcl-2). The main changes observed 




Puma (isoform b) and Bim (isoform beta). Also a slight decrease in the levels of the 
antiapoptotic members Bcl-XL and Mcl-1 was observed in cells treated with 2. The proapoptotic 
proteins are damage sensors that induce the activation of Bax and Bak and mitochondrial 
permeabilization to release cytochrome c, the key event in the intrinsic pathway of apoptosis.
61
 
  Taken together these results point to a classical apoptosis mechanism of cell death. This 
was confirmed by the finding that the cytotoxicity of both compounds was caspase-dependent 
(Figure 5). The general caspase inhibitor z-VAD-fmk completely abrogated PS exposure but it 
only partially reduced ∆Ψm loss (from 80% to 30% for 2 and from 40% to 20% for 3).  
 
 
Figure 5. Effect of the general caspase inhibitor z-VAD-fmk in apoptotic features induced by 2 
and 3. 
 
   ∆Ψm disruption was not completely inhibited by z-VAD-fmk we hypothesize that 2 and 
3 could activate caspase-independent pathways acting on mitochondria. In order to determine 
whether caspase inhibition prevented or just delayed cell death, we performed experiments in 
which cells were treated with 2 or 3 for 24 h in the presence of z-VAD-fmk and then washed and 
further cultured in fresh medium for 24 h. PS exposure was analysed after the first 24 h in the 
presence of compound+z-VAD-fmk and 24 h after washing. Only around 20% of cells were 
AnnexinV
+




cells treated with 2 alone were apoptotic at the end of the experiments. Thus, these results 
indicate that in the case of compound 2, caspase inhibition prevented death commitment in a 
very high percentage of cells since only 22% were Annexin V+ 24 hours after washing. 
However, in the case of 3, the percentage of AnnexinV+ cells 24 h after washing (32%) equalled 
that of cell treated with 3 alone for 24 h (28%), suggesting that in this case caspase inhibition did 
not prevent irreversible cell damage leading to cell death. These results suggest that 2 and 3 
could be acting through different mechanisms, with 3 causing caspase-independent 
premitochondrial damage. These differences in the mechanism of 2 and 3 could explain why 3 is 
less selective than 2 for tumor cell lines (Table 2). 
 
 
Figure 6. Analysis of long-term protection by z-VAD-fmk. 
 
Ruthenium compounds have been reported to induce p53-dependent and –independent 
cytotoxicity.
12,23
 In order to determine whether the cytotoxicity of the compounds here is p53-
dependent we analyzed the levels of p53 in A549 cells, bearing wt-p53, after a short term 
treatment with 2. As shown in Figure 7, treatment with 2 did not induce the stabilization of p53, 
and even at 3 and 6 h we observed a slight decline in p53 levels, probably due to cell death and 




compounds that induce short-term p53 accumulation.
12,23
 However, although p53 protein is 
induced by RM175 in HCT116 (colon carcinoma)
12
 or RDC-9 in A172 (glioblastoma) and 
HCT116,
23 
genetic inhibition of p53 does not avoid the cytotoxicity of these compounds, clearly 
indicating that other p53-independent mechanisms can be activated by ruthenium compounds. 
Moreover, Gaiddon et al. have shown that a p53
-/-
 cell line (TK6) exhibits the same sensitivity to 
RDC-9 than its p53
+/+
 parental cell line (NH32).
23
 Furthermore, compounds 1-3 showed high 
toxicity against p53 mutated cell lines (Jurkat, MiaPaca2, DU-145 and MDA-MB-231) as shown 
in Table 2. Since the activity of cisplatin has been reported to be p53-dependent, new 
organometallic compounds that activate p53-independent pathways could be useful in the 




Figure 7. p53 protein levels after short-term incubation of A549 cells with 2. B-Actin levels 











5.4. Reactivity with biomolecules 
 
5.4.1. Interaction with DNA 
 
  As described in chapters III and IV, since DNA replication is a key event for cell 
division, it is among critically important targets in cancer chemotherapy. Most cytotoxic 
platinum drugs form strong covalent bonds with DNA bases.
62
 However, a variety of platinum 
compounds act as DNA intercalators upon coordination to the appropriate ancillary ligands.
63
 
The more thoroughly studied ruthenium antitumor agents (Figure 1) have displayed differences 
with respect to their interactions with DNA depending on their structure.
4
 Thus, while NAMI-A 
is known to have fewer and weaker interactions with DNA than cisplatin,
4
 indazolium 
bisindazoletetrachlororuthenate (KP1019) undergoes interactions similar to cisplatin but with a 
lower intensity in terms of DNA-DNA and DNA-protein crosslinks.
64
 Organometallic piano-
stool ruthenium(II) compounds based on biphenyl rings RM175 interact strongly with DNA 
binding to guanines and by intercalation.
65,66
 Organometallic ruthenium(II) RAPTA derivatives, 
characterized by the presence of water-soluble PTA phosphine, exhibit pH-dependent DNA 
damage: at the pH typical of hypoxic tumor cells DNA was damaged, whereas at the pH 
characteristic of healthy cells little or no damage was detected.
67,68
 Cycloruthenated compounds 
based on pincer C,N ligands (RDC family) displayed a much weaker interaction with plasmid 
(pBR322) DNA when compared to cisplatin.
69,70
 Complexes of the type [Ru(Cp)(2,2-
bipy)(PR3)][CF3SO3]
 
have shown no observable interaction with DNA.
71
  
  In this context, we evaluated the effect of DNA interactions that could, to some extent, 
contribute to the observed cytotoxicity of compounds 1-4, 8 and 9, and the apoptotic behaviour 
of compounds 2 and 3. We followed the interaction with Calf Thymus DNA (CT DNA) by 
circular dichroism (CD), and with plasmid (pBR322) DNA by electrophoresis in agarose gel. 
The CD spectral technique is very sensitive to diagnose alterations on the secondary structure of 
DNA that result from DNA-drug interactions. A typical CD spectrum of CT DNA shows a 
positive band with a maximum at 275 nm due to base stacking, and a negative band with a 
minimum at 248 nm due to helipticity, characteristic of the B conformation.
72
 Therefore, changes 
in the CD signals can be assigned to corresponding changes in DNA secondary structure. In 




cause little or no alteration in any of the CD bands when compared to major perturbations 
induced by covalent binding or intercalation. 
  CD spectra of CT DNA incubated with compounds 1-4 (see Appendix, Figure 44) at 
37ºC and pH = 7.30 in Tris/HCl buffer up to molar ratio drug/DNA = 0.5 show no modification 
of the DNA bands with respect to untreated CT DNA, indicating that drug-DNA interactions, if 
existing, do not induce any observable perturbation on the DNA secondary structure under our 
experimental conditions 
  Higher ratios were also tested, although loss of CD signal was observed due to 
precipitation of the DNA induced by 1-4, most likely because of phosphate charge neutralization 
by the cationic compounds, which suggests the existence of an electrostatic attraction. DNA 
condensation or precipitation by neutralization of backbone charges has been previously 
described for other ionic ruthenium drugs
73
 and confirmed by us for compounds 2 and 3 through 
ICP-MS analysis of metal content in the DNA precipitate. In this experiment 500 µM 
concentration DNA solutions were treated with 2 equivalents of ruthenium compounds 2 and 3 
for 20 hours at 37ºC to promote DNA precipitation. The samples were then centrifuged and the 
resulting pellets were analyzed for DNA and metal concentration (see Experimental Section for 
more details). Our results show ruthenium content values of 2.60 ± 0.26 mg Ru/mg DNA for 
compound 2 and 2.43 ± 0.18 mg Ru/mg DNA for compound 3. This high Ru content in DNA 
precipitate, especially when compared to similar Ru compounds interacting with DNA through 
covalent interactions
29
 suggests that the key factor promoting the precipitation of DNA is the 
presence of the cationic ruthenium compound. 
  Attempts to obtain additional evidence of drug-CT DNA interactions were made by 
performing thermal denaturation experiments, but resulted in cyclometallation of compounds 1, 
2 and hydrolysis of 3 at temperatures above 60ºC, as previously discussed, preventing us from 
obtaining reliable information through this technique. 
  In order to gain further insights on the nature of the compound-DNA interactions, gel 
electrophoresis studies were also performed with the ruthenium(II) complexes 1-4, 8 and 9 on 







Figure 8.  Electrophoresis mobility shift assays for cisplatin, [Ru(η
6
-p-cymene)Cl]2  and 
compounds 1-4 and 8, 9. DNA refers to untreated plasmid pBR322. A, B, C and D correspond to 
metal/DNAbp ratios of 0.25, 0.5, 1.0 and 2.0 respectively. 
 
  For these experiments, cisplatin, all uncoordinated ligands and the starting dimeric 
organometallic ruthenium(II) complex [Ru(η
6
-p-cymene)Cl]2 were also measured as controls. 
Plasmid pBR322 presents two main forms, OC (open circular or relaxed) and CCC (covalently 
closed circular or supercoiled), which display different electrophoretic mobility. Changes in the 
electrophoretic mobility of any of the forms upon incubation of the plasmid with a compound are 
usually interpreted as evidence of interaction. Generally, a drug that induces unwinding of the 
CCC form will produce a retardation of the electrophoretic mobility, while coiling of the OC 
form will result in increased mobility. Figure 8 shows the effect of cisplatin and compounds 1-4, 
8 and 9 on DNA pBR322 after incubation at 37ºC for 20 h in Tris/HCl buffer up to drug/DNA 
ratio 2.0. As previously reported, cisplatin is able to both increase and decrease the mobility of 
the OC and the CCC forms, respectively.
74




and 2 induce retardation of the mobility of the CCC form of plasmid DNA, while the rest of the 
compounds, the neutral ligands, and the Ru starting dimer do not seem to induce any alteration 
on the mobility of the plasmid.  
  The results of CD, ICP-MS and gel electrophoresis taken together suggest that 
compounds 1-4 undergo only electrostatic interactions with DNA. This conclusion is supported 
by three main facts: 1) results obtained by CD spectroscopy do not show evidence of CT DNA 
modifications of secondary structure, suggesting that drug-DNA interactions, if any, are of weak 
nature, but neither covalent nor intercalation; 2) precipitation of CT DNA is observed in CD 
experiments at high ratios drug/DNA, and it is further confirmed by ICP-MS analysis of metal 
content in DNA precipitates, suggesting backbone charge neutralization, and 3) retardation of the 
plasmid DNA electrophoretic mobility is observed also at high drug/DNA ratios for compounds 
1 and 2, but only when plasmid DNA is incubated with the cationic metal compounds and not 
with the neutral ligands or neutral ruthenium starting material under the same conditions, which 
could also be consistent with charge neutralization or DNA precipitation. Loss of migration in 
electrophoresis experiments has been previously reported as a consequence of DNA precipitation 
for other cationic ruthenium compounds.
73
 The electrophoretic mobility results also suggest that 
the electrostatic interaction between DNA and compounds 1 and 2 is of larger magnitude than 
that experienced by 3 and 4, since no mobility retardation is observed for the latter compounds 
up to drug/DNA ratio of 2.0. Further evidence of this could be found in the fact that lower 
amount of Ru content in DNA is detected for compound 3 when compared to compound 2, 
according to ICP-MS results. 
  Thus, we hypothesize that the anti-tumor properties observed for compounds 1-4, 8 and 9 
are due to non-DNA related mechanisms/factors, as previously observed for other 
iminophosphorane complexes described before
52-55,75,76
 and some other ruthenium 
compounds.











5.4.2. Lack of inhibition of capthesin B 
 
This assay was performed at Reaction Biology Corporation. 
 
 Cathepsin B (cat B) is an abundant and ubiquitously expressed cysteine peptidase of the 
papain family, which has turned out to be a prognostic marker for several types of cancers.
77
 
Cathepsin B seems to be involved (along with other cathepsins) in metastasis, angiogenesis, and 
tumor progression.
78
 It has been proposed that cat B may be a possible therapeutic target for the 
control of tumor progression.
79
 RAPTA Ru compounds which inhibit cat B with IC50 in the low 
micromolar range can reduce the mass and number of metastases in vivo.
80
 We therefore, studied 
the inhibition of Cat B by compound 2 (see Experimental Section for details). Compound 2 does 
not inhibit the enzymatic activity of cat B at concentrations up to 100 µM indicating that this 
protease may not be a target for this type of arene-ruthenium(II) derivatives. 
5.4.3. Interaction with HSA 
 
Due to the abundance in plasma and relevance to drug binding
81
 of human serum albumin 
(HSA) we studied the interactions of the new ruthenium(II) IM complexes with this protein. The 
fluorescence spectra of HSA in the presence of increasing amounts of the compounds 1-5, 8, 9 
and cisplatin were recorded in the 300-450 nm range upon excitation of the tryptophan residue at 
295 nm. The compounds caused a concentration dependent quenching of fluorescence without 
changing the emission maximum or the shape of the peak. All these data indicate an interaction 
of the compounds with HSA. The fluorescence data was analyzed by the Stern-Volmer equation. 
While a linear Stern-Volmer plot is indicative of a single quenching mechanism, either dynamic 
or static, the positive deviation observed in the plots of F0/F versus [Q] of compounds 1-4 
(Figure 9) suggests the presence of different binding sites in the protein with different binding 
affinities.
82
 Similar behavior was observed in the case of coordination iminophosphorane 
complexes of d
8
 metals for which concentration dependent fluorescence quenching was 
reported.
52-55 
On the other hand, the Stern-Volmer plot for complexes 8 and 9 shows a linear 
relationship, suggesting the existence of a single quenching mechanism, most likely dynamic, 












Figure 9. (A) Fluorescence titration curve of HSA with compound 4. Arrow indicates the 
increase of quencher concentration. (B) Stern-Volmer plot for HSA fluorescence quenching 
observed with compounds 1-4, 8, 9 and cisplatin. 
 
In general, higher quenching by the iminophosphorane complexes was observed 
compared to that of cisplatin under the chosen conditions, most likely due to the faster binding of 
our compounds with HSA, as compared to cisplatin. 
153 
 
5.5. Effects on tumor growth in vivo with compound 2 
 
These studies were designed and performed by Benelita T. Elie, and Dr. Maria Contel, at the 
laboratory of Dr. Joe W. Ramos (University of Hawaii Cancer Center, Honolulu). 
 
5.5.1. Evaluation of the lethal and maximum tolerated doses 
 
The lethal and maximum tolerated doses of compound 2 were evaluated in C57/Black6 
mice (see Experimental Section for details). The lethal dose was determined to be 30 mg/kg/day. 
No biological samples were collected from those mice. The MTD was determined to be 10 
mg/kg/day, at which the mice showed no visible signs of distress over the 7 days course of 
treatment.   
Mice lost weight during the trial in a dose dependent manner where mice treated with 5 
mg/kg/day, 10 mg/kg/day, or 20 mg/kg/day lost 15%, 19% or 37% body weight respectively, 
while vehicle treated mice gained 3% body weight over the 7 days of treatment. Mice treated 
with 20 mg/kg/day were euthanized on day 6 of the trial as they had lost too much body weight 
and looked in distress.  
24 hours after the last dose all the mice used in the MTD study were euthanized and 
blood plasma, liver, spleen and kidneys were collected and used for histological analysis. 
Necropsy and histology indicate that mice treated at 20 mg/kg/day had discolored livers and 
atrophied spleens; at 10 mg/kg/day much less atrophy and minor discoloration was observed, 
while in mice treated at 5 mg/kg/day there was no detectable liver discoloration and no 
observable change in spleen size.   
Therefore, 5 mg/kg/every other day were chosen as the dose of to conduct the subsequent 
in vivo trial with compound 2. 
 
5.5.2. Effects of 2 in MDA-MB-231 mouse xenografts 
 
12 female NOD.CB17-Prkdc SCID/J (non-obese diabetic–severe combined 
immunodeficiency) were selected for the in vivo trial. The mice were inoculated with MDA-MB-




(about 5–6 mm diameter).  Each six MDA-MB-231-transplanted animals received compound 2 
(5 mg/kg/every other day) or vehicle (0.9% NaCl) intraperitoneally (i.p.). To palliate the weight 
loss observed in the MTD study all the mice used in this trial were fed a 46% fat-adjusted diet 
(Harlan Teklad, Madison, WI), plus HydroGel™(Harlan Teklad, Madison, WI) and received 
subcutaneous injection of 100µl Normal Saline on the off-treatment day. 
In the group treated with 2 (see Table 3 and Figure 10) we observed a significant 
decrease in tumor size (shrinkage) of 56% from the starting volume between day 1 and day 28 of 
treatment (after a total of 14 doses), while in the control vehicle treated group we observed 200% 
increase in tumor volume between day 1 and day 28 of treatment. One 2-treated mouse was 
removed from the trial because it was not feeding itself and showed other signs of distress, none 
of which were observed in the other mice on trial. No significant weight loss in mice treated with 
5 mg/kg/every other day was observed. Mice treated with 2 gained an average weight of 2.88%, 
while untreated mice gained an average of 18.67% weight (all groups were fed a 46% fat-
adjusted diet). 
 
Figure 10. % of reduction of tumor burden in a cohort of 12 female NOD.CB17-Prkdc scid/J 
mice inoculated subcutaneously with 5x10
6
 MDA-MB-231 cells. The treatment started when 
tumors were palpable (5-6 mm diameter). 6 mice were treated with compound 2 (pink bars), 6 
were treated with the vehicle 100 µl Normal Saline (0.9% NaCl) (black bars). 2 was 









































Table 3. Effects of 2 on the tumor growth of MDA-MB-231 mammary carcinoma in 
NOD.CB17-Prkdc scid/J mice. 
 
Treatment Group Primary Tumor (mm
3
) 
Controls 473.47 ± 45.44 
Compound 2 (5 mg/kg/e.o.d
a
  x 14) 59.58 ± 8.66 
a




The results clearly indicate that compound 2 is extremely efficient in vivo since it not 
only inhibits tumor growth but also results in the decrease in the size of the tumors by 56%. It is 
interesting to compare these results with those obtained with other arene-ruthenium (II) 
derivatives. Compound RM175 was reported to have a final primary tumor growth inhibition of 
30% at a dose of 7.5 mg/kg/day in an in vivo trial for breast cancer in mice
13
 while the 
compounds RAPTA-C reduced the growth of lung metastases in CBA mice bearing the MCa 
mammary carcinoma in the absence of a corresponding action at the site of primary tumor 
growth.
15,16
 More recently, a ruthenium-arene complex with a perfluoroalkyl-containing amine 
ligand demonstrated a 90% reduction in the tumor growth in a xenografted ovarian carcinoma 
tumor (A2780) grown in a chorioallantoic membrane (CAM) assay of chicken embryo.
18
 As 
stated above compound 2 is able to decrease tumor size. 
 
5.5.3. Pharmacokinetic study 
 
These studies were performed by Dr. Swayam Prabha and Tanmoy Sadhukha at the University of 
Minnesota. 
 
The pharmacokinetic profile of compound 2 in the NOD.CB17-Prkdc scid/J mice used 
for the in vivo study described above (Figure 11) is summarized in Table 4. Ruthenium content 
was determined using Inductively Coupled Plasma - Mass Spectrometry (ICP-MS). Compound 2 




within 2 h of dosing. The drug was eliminated slowly from the blood compartment with an 








During determination of total area under the concentration – time curve (AUC total) only 
7% of the AUC was extrapolated from the last time point suggesting a high confidence in the 
AUC, Vapp and apparent clearance (CLapp) determination. Blood concentration, at 6 hours after 
the last dose of compound 2, was 4.2 ± 1.3 µg/ml, which is higher (P < 0.1) than the Cmax after 
the first dose. This suggests an accumulation of compound 2 after each dose. While it is hard to 







) due to the different structures, oxidation states (see 
Figure 1) and the amounts employed in these studies (for example 70 mg total of 2 in 14 doses of 
5 mg/kg/every other day versus a total of 400 mg or 200 mg  for RAPTA-C) there are some 
differences that can be pointed out. The Vd (volume of distribution) of 2 when compared to that 
of more structurally related arene-ruthenium(II) RAPTA-C derivative is smaller which may be 
due to a higher water solubility of 2 or the possibility that it binds strongly to plasma-proteins. 
Indeed, we have seen in a qualitative way that compound 2 binds faster to HSA than cisplatin 
(section 5.4.3).  
Table 4. Pharmacokinetic parameters of compound 2 after first injection in NOD.CB17-Prkdc 
SCID/J mice. 
Pharmacokinetic parameters Values 
Kabs 1.39 h 
-1
 
Ke 0.055 h 
-1
 
t1/2 e 12.67 h 
t1/2 abs 0.50 h 
tmax 2.00 h 
Cmax 2.62 µg/ ml 
AUCtotal 54.47 µg.h/ml 
Vapp 33.57 ml 






Figure 11. Concentration of Compound 2 in plasma at various intervals after the first dose. 
At the end of the study, ruthenium content in liver, kidney and tumor was determined 
(Figure 12). The level of compound 2 is liver and kidney was less than 5 µg/g tissue weight 
while the tumor concentration was about 40 µg/g. The high level in tumor suggests enhanced 
tumor accumulation of compound 2 which may explain the high efficacy observed for this 
compound in the in vivo studies. The preferential accumulation of some ruthenium complexes in 





Figure 12. Compound 2 ruthenium content in tissues at the end of efficacy study. Data 






I have sucessfuly synthesized a series of organometallic ruthenium(II) complexes 
containing iminophosphorane ligands. The compounds, along with starting material [(η
6
-p-
cymene)Ru(μ-Cl)Cl]2, were evaluated against a number of human cancer cell lines in vitro and 
most compounds were more cytotoxic to all the cell lines then cisplatin. Only the cationic 
compounds (1 and 2) show interaction with plasmid (pBR322) DNA but it seems weak and 
electrostatic in nature. Precipitation of Calf Thymus DNA observed in CD experiments at high 
ratios drug/DNA, and further confirmed by ICP-MS analysis of metal content in DNA 
precipitates, suggesting backbone charge neutralization. Furthermore, higher quenching of HSA 
was observed compared to that of cisplatin under the chosen conditions, most likely due to the 
faster reactivity of the complexes with HSA, as compared to cisplatin. 
From all the iminophosphorane compounds that I prepared, highly water-soluble 
ruthenium-arene-iminophosphorane compound (2) was chosen as the best candidate to continue 
with advanced pre-clinical studies. This compound is active against a number of cisplatin 
resistant cell lines while been less toxic on human renal proximal tubular cell lines. Initial 
mechanistic studies indicated that the cell death type for compound 2 is mainly through 
canonical or caspase-dependent apoptosis. In addition, cell death seems to be independent of 
p53. The interaction of 2 with DNA is weak and electrostatic in nature. All these facts indicate 
that 2 has a mode of action different from that of cisplatin which may explain its activity in 
cancer cell lines quite resistant to cisplatin such as MDA-MB-231, A549 amd DU-145. 
Compound 2 does not inhibit protease cathepsin B in concentrations of 100 µM or lower. The 
efficacy of 2 in vivo has been demostrated on xenografted breast carcinoma MDA-MB-231-
tumors grown on NOD.CB17-Prkdc scid/J mice. An impressive tumor reduction (shrinkage) of 
56% was observed after 28 days treatment (14 doses of 5 mg/kg every other day) with low 
systemic toxicity. Pharmacokinetic studies showed a quick absorption of 2 in plasma with an 
elimination half-life of 12.67 hours (similar to that reported for other ruthenium derivatives). 
Importantly, 2 accumulated preferentially in the breast tumor tissues when compared to kidney 
and liver, which may explain its high efficacy in vivo. The simple, cheap and accessible synthesis 
of compound 2 (by simple coordination of an IM ligand to a well-known organometallic 




activity in vitro and in vivo makes it therefore a good candidate for further evaluation as a 
potential chemotherapeutic agent.   
 
5.7. Experimental section 
 
Materials and methods 
All manipulations involving air-free syntheses were performed using standard Schlenk-line 
techniques under a nitrogen atmosphere or a glove-box MBraun MOD System. Solvents were 



















 were prepared by reported methods. The purity of the compounds, 
based on elemental analysis, is ≥99.5%. In the case that the compound crystallizes with solvent 
the 
1
H NMR (CDCl3) spectrum is available in the Appendix. Elemental analyses were performed 
by Atlantic Microlab Inc. NMR spectra were recorded in a Bruker AV400 (
1
H NMR at 400MHz, 
13
C NMR at 100.6 MHz, 
31
P NMR at 161.9 MHz). Chemical shifts (δ) are given in ppm using 




C chemical shifts were 




H} was externally referenced 
to H3PO4 (85%). Infrared spectra (4000-250 cm
-1
) were recorded on a Nicolet 6700 FT-IR 
spectrophotometer from nujol mulls between polyethylene sheets. Mass spectra (electrospray 
ionization, ESI) were performed on an Agilent Analyzer, a Bruker Analyzer, or a Waters Q-Tof 
Ultima analyzer. Conductivity was measured in an OAKTON pH/conductivity meter in CH3CN 
solutions (10
-3
M). X-ray collection was performed at room temperature on a Kappa CCD 
diffractometer using graphite monochromated Mo-Kα radiation (λ=0.71073 Å).  Electrophoresis 
experiments were carried out in a Bio-Rad Mini sub-cell GT horizontal electrophoresis system 
connected to a Bio-Rad Power Pac 300 power supply. Photographs of the gels were taken with 
an Alpha Innotech FluorChem 8900 camera. Fluorescence intensity measurements were carried 
out on a PTI QM-4/206 SE Spectrofluorometer (PTI, Birmingham, NJ) with right angle detection 




recorded using a Chirascan CD Spectrometer equipped with a thermostated cuvette holder. The 
inhibition of Capthesin B experiments were performed by Reaction Biology Corporation. 
 







-p-cymene)Ru(μ-Cl)Cl]2 (0.15 g, 0.25 mmol) was dissolved in CH3OH (15 mL) and  
Ph3P=N(CO)(C5H5-2-N) (0.19 g, 0.5 mmol) was added. To the resulting mixture KPF6 (0.10g, 
0.55 mmol) was added. The mixture was stirred for 4 h. The suspension was then filtered and 
washed 3 times with Et2O (10mL). The solution was then concentrated and the precipitate was 
collected by filtration and dried in vacuo. 
 
Yield:  0.36 g (90%). Anal. Calc. for C34H33N2OP2F6ClRu (798.07): C, 51.17; H, 4.17; N, 3.51. 
Found: C, 50.95; H, 4.20; N 3.56 %.  ESI-MS: m/z: 653.10 (100%, [M-PF6]
+





H} NMR  (CDCl3): δ 25.72 (s), -148.26 to -140.19 (septet,  PF6), (DMSO-d6): 24.27 (s), -
152.87 to -130.98 (septet, PF6
1
H NMR (CDCl3): δ 1.10  (6H, dd, J = 6.9, 18.9 Hz, CH3, η
6
-p-
cymene), 1.69 (3H, s, CH3, η
6
-p-cymene), 1.65 (3H, s, CH3, η
6
-p-cymene),  2.30 (1H, m, CH, η
6
-
p-cymene), 5.48-5.59 (4H, m, CH, η
6
-p-cymene), 7.64-7.78 (16H, m, H5, Hm + Ho + Hp), 8.03 





H} (CDCl3): δ 18.10 (s, CH3, η
6
-p-cymene), 21.87 (s, CH3, η
6
-p-cymene), 
22.18 (s, CH3, η
6
-p-cymene), 30.79 (s, CH, η
6
-p-cymene), 81.00 (s, CH, η
6
-p-cymene), 82.09 (d, 
CH, J = 8.3 Hz,  η
6
-p-cymene), 82.41 (s, CH, η
6
-p-cymene), 83.92 (s, C, η
6
-p-cymene), 124.5 (s, 
C2, η
6
-p-cymene), 125.5 (d, Cipso, J = 100.4 Hz), 127.7 (s, C3, C5H4N), 129.5 (d, Cm, J = 13.0 
Hz), 129.8 (s, C5, C5H4N),  133.2 (d, Co, J = 10.4 Hz), 133.8 (s, Cp), 139.3 (s, C4, C5H4N), 153.7 




):  524 (Ru-N), 
834 (v br, PF6
-















-p-cymene)Ru(μ-Cl)Cl]2 (0.15 g, 0.25 mmol) and Ph3P=N(CO)(C5H5-2-N) (0.19 g, 0.5 
mmol) were stirred in acetone (20 mL) for 3 h. The brown solution was concentrated and 30 mL 
of Et2O added dropwise. The orange solid that formed was collected by filtration and dried in 
vacuo. 
 
Yield: 0.33 g (94%). Anal. Calc. for C34H33N2OPCl2Ru·2H2O (724.62): C, 56.36; H, 5.15; N, 
3.87. Found: C, 56.41; H, 4.99; N 3.87 %. ESI-MS: m/z: 653.1 (100%, [M-Cl]
+
, calc. 653.01), 
618.1 (100%, [M-2Cl]
2+
, calc. 618.1), 519.0 (100%, [M-p-cymene-Cl]
+





NMR (CDCl3): δ 25.18 (s), (DMSO-d6): 28.99 (s); 
1
H NMR (CDCl3): δ 1.00  (6H, dd, J = 7.0, 
24.8,  Hz CH3, η
6
-p-cymene), 2.01 (3H, s, CH3, η
6
-p-cymene), 2.25 (1H, m, CH, η
6
-p-cymene), 
5.51-5.71 (4H, m, CH, η
6
-p-cymene), 7.57 (6H, m, Hmeta), 7.68 (9H, m, Hortho + Hpara),  7.87 (1H, 
d, J = 6.0 Hz, H5, C5H4N), 8.03 (1H, d, J = 7.7 Hz, H4, C5H4N), 8.32 (1H, d, J = 7.4 Hz, H3, 




H} (CDCl3): δ 18.47 (s, CH3, η
6
-p-cymene), 
21.82 (s, CH3, η
6
-p-cymene), 22.39 (s, CH3, η
6
-p-cymene), 30.75 (s, CH, η
6
-p-cymene), 81.20 (s, 
CH, η
6
-p-cymene), 82.60 (d, CH, J = 8.3 Hz,  η
6





-p-cymene), 102.5 (s, C, η
6
-p-cymene), 125.6 (d, Cipso, J = 101.2 Hz), 127.2 (s, C3, 
C5H4N), 129.5 (d, Cm, J = 12.8 Hz), 130.3 (s, C5, C5H4N), 133.3 (d, Co, J = 10.2 Hz), 133.9 (s, 
Cp), 139.0 (s, C4, C5H4N), 151.6 (d, C2, J = 24.0 Hz), 156.3 (s, C6), 176.8 (d, C=O, J = 24.14 Hz) 
ppm. IR (cm
-1
):  527 (Ru-N), 1114 (N=P), 1535 (C=O). Conductivity (acetone): 124.20 μS/cm 
(1:1 electrolyte). Solubility: 145.3 mM or 100 mg/mL (H2O). pH (5 x 10
-5
M in H2O): 5.76. 
 







- p-cymene)Ru(μ-Cl)Cl]2 (0.092 g, 0.15 mmol) was dissolved in CH2Cl2 (15 mL) and 
Ph3P=N-8-C9H6N (0.12 g, 0.3 mmol) was added. The mixture was stirred for 3h. The solution 
was concentrated to 2 mL and 20 mL of Et2O added to precipitate an orange solid, which was 





Yield: 0.18 g (84%). Anal. Calc. for C37H35N2PCl2Ru.2.5H2O (755.68): C, 58.81; H, 5.34; N, 
3.71. Found: C, 58.95; H, 4.81; N 3.82 %.   ESI-MS: m/z: 675.13 (100%, [M-Cl]
+
, calc. 675.13), 
540.0 (100%, [M-p-cymene-Cl]
+




H} NMR (CDCl3),: δ 37.68 (s), (DMSO-
d6): 37.84 (s); 
1
H NMR (CDCl3): δ 0.73 (3H, d, J = 6.7 Hz, CH3, η
6
-p-cymene), 1.01 (3H, d, J = 
6.6 Hz, CH3, η
6
-p-cymene),  1.98 (3H, s, CH3, η
6
-p-cymene),  2.44  (2H, m, CH, η
6
-p-cymene), 
5.43 (2H, s, CH, η
6
-p-cymene), 5.72 (2H, s, CH, η
6
-p-cymene), 6.40 (1H, d,  J = 8.0 Hz,  H7, 
C9H6N), 6.91 (1H, d,  J = 8.1 Hz,  H7, C9H6N), 7.15 (1H, d,  J = 8.1 Hz,  H7, C9H6N),  7.66 (9H, 
m, Hm + Hp), 7.68 (1H, s, H3, C9H6N ),  8.00 (6H, m, Ho),  8.21  (1H, d, J = 8.4 Hz,  H4, C9H6N),  




H} (CDCl3): δ 19.20 (s, CH3, η
6
-p-cymene), 21.02 (s, CH3, η
6
-
p-cymene), 22.96 (s, CH3, η
6
-p-cymene), 31.62 (s, CH, η
6
-p-cymene), 118.4 (s, C5, η
6
-p-
cymene), 121.7 (d, C7, J = 10.3 Hz, η
6
-p-cymene), 124.6 (s, C3, η
6
-p-cymene), 125.8 (s, C6), 
129.4 (s, C8), 129.6 (d, Cm, J = 12.7 Hz), 130.0 (s, Cipso), 134.1 (s, Cp), 134.9 (d, Co, J = 9.8 Hz), 
138.4 (d, C4), 144.7 (s, C9H6N), 144.9 (s, C9H6N), 149.2 (s, C=NP) ppm.  Signals due to the 
quaternary C atoms were not observed. IR (cm
-1
):  519 (Ru-N), 1268 (N=P). Conductivity 
(acetone): 125.60 μS/cm (1:1 electrolyte). Solubility: 112.6 mM or 80 mg/mL (H2O). 
 





To a solution of  [(η
6
-p-cymene)Ru(μ-Cl)Cl]2 (0.16 g, 0.26 mmol) in CH2Cl2 (10 mL), [{Cp-
P(Ph2)=N-CH2-2-NC5H4}Fe(Cp)] (0.25 g, 0.52 mmol) in CH2Cl2 (10 mL) was added and stirred 
for 40 min. The solvent removed to dryness under reduced pressure. The solid was dissolved in 
CH2Cl2 and 25 mL of Et2O were added. The solid formed was then filtered and dried in vacuo. 
 
Yield: 0.30 g (81%). Anal. Calc. for C38H39N2FePCl2Ru·3.5H2O (845.59): C, 53.98; H, 5.48; N, 
3.31. Found: C, 54.02; H, 5.30; N 3.47 %. ESI-MS: m/z: 747.0 (100%, [M-Cl]
+
, calc. 747.1), 




H} NMR (CDCl3): δ 46.40 (s), (DMSO-d6): 
45.99 (s), (D2O): 46.95 (s); 
1
H NMR (CDCl3): δ 0.99 (3H, d, J = 5.4 Hz, CH3, η
6
-p-cymene), 
1.23 (3H, m, CH3 + CH2, η
6
-p-cymene, NCH2C), 2.03 (3H, s, CH3, η
6






-p-cymene), 3.98 (5H, s, C5H5), 4.42-4.78(6H, m, CH2 + C5H4), 4.79 (2H, m, Cp), 5.17-
5.62 (4H, m, CH, η
6
-p-cymene), 7.45-7.68 (10H, m, Hm+o+p), 7.83 (1H, d, J = 7.4 Hz, H5, 





(CDCl3): δ 18.91 (s, CH3, η
6
-p-cymene), 21.99 (d, CH3 + CH3, η
6
-p-cymene), 23.25 (s, CH3, η
6
-
p-cymene), 31.30 (s, CH, η
6
-p-cymene), 70.55 (s, Cp), 72.24 (d, J = 9.9 Hz, Cp), 73.73 (d, J = 
9.9 Hz ,Cp), 75.03 (m, Cp), 83.29 (d, CH, J = 14.4 Hz, η
6
-p-cymene), 85.98 (d, 2CH, J = 8.3 Hz,  
η
6
-p-cymene), 87.09 (s, CH, η
6
-p-cymene), 99.99 (s, C, η
6
-p-cymene), 103.8 (s, C, η
6
-p-cymene), 
124.9 (s, Ph), 128.4-128.8 (m, Ph), 130.2 (s, Cipso), 133.0-133.3 (s, Ph),  133.9-134.0 (d, C3 + C4, 
J = 10.1 Hz, C5H4N), 138.8 (s, C4, C5H4N), 155.1 (s, C2, C5H4N), 164.1 (s, C6) ppm. . IR (cm
-1
): 
 488 (Ru-N), 1116 (N=P). Conductivity (MeCN): 130.37 μS/cm (1:1 electrolyte). Solubility: 
89.5 mM or 70 mg/mL (H2O). 
Synthesis of 5 
[PTA=N-C(O)-2-C6H5] 
 
PTA (0.34 g, 2.18 mmol) and benzamide (0.264 g, 2.18 mmol) were placed in a Schlenk flask 
under nitrogen. Dry, degassed THF (10 mL) was added and to this solution, 
t
BuDAD (N,N-
bis(tert-butyl)1,4-diazabutadiene) (0.503g, 2.18 mmol) in dry and degassed THF (4 mL) was 
added dropwise at 0 °C. The reaction was left stirring at RT for 2.5 h. After this period, the 
solvent was removed to dryness under reduced pressure. The white residue was washed three 
times with Et2O (15 mL) giving a white solid that was filtered and dried in vacuo. 
 
Yield: 0.53 g (88%). Anal. Calc. for C13H17N4OP (276.11): C, 56.52; H, 6.20; N, 20.28. Found: 
C, 55.55; H, 6.16; N 20.69 %. ESI-MS: m/z: 277.12.0 (99.6%, [M]
+





NMR (CDCl3): δ −30.8 (s); 
1
H NMR (CDCl3): δ 4.32-4.63 (12H, m, PTA), 7.38 (2H, t, J = 7.6 





H} NMR (CDCl3): δ 55.10 (d, J = 47.2 Hz, PTA), 72.60 (d, J = 8.9 Hz, PTA), 
128.08 (s, C3 + C5, C6H4), 129.21 (s,C2 + C6, C6H4), 131.47 (s, C4), 136.74 (d, J = 17.7 Hz, C1), 







Synthesis of 6 
[(CO)4Mn(2-C6H4C(O)N=PTA)] 
 
PhCH2Mn(CO)5 (0.43 g, 1.5 mmol) and PTA=NC(O)Ph (5) (0.41 g, 1.5 mmol) were refluxed in 
n-hexane (45 mL) for 4h. The hot solution was filtered and the yellow filtrate reduced in volume 
until signs of crystallization became evident. Storage at -20 ºC gave yellow crystals of 
(CO)4Mn(2-C6H4C(O)N=PTA). 
 
Yield: 0.59 g (90%). Anal. Calc. for C17H16N4O4PMn (442.02): C, 46.07; H, 3.65; N, 12.67. 
Found: C, 45.69; H, 3.56; N 12.72%. ESI-MS: m/z: 443.03 (100%, [M], calc. 443.03), 415.04 





H} NMR (CDCl3): δ −15.27 (s); 
1
H NMR (CDCl3): δ 4.32-4.58 (12H, m, 
PTA), 7.16 (1H, t, J = 7.5, 14.8 Hz, H4, C6H4), 7.38 (1H, t, J = 7.5, 14.5 Hz, H3 , C6H4),  7.68  
(1H, d, J = 7.6 Hz,  H2, C6H4), 7.93 (1H, d, J = 7.4 Hz, H5, C6H4); 
13
C{1H} (CDCl3): δ 53.30 (d, 
J = 43.3 Hz, PTA) ppm. 72.54 (d, J = 9.8 Hz, PTA), 124.02 (s, C4, C6H4), 128.60 (s, C2, C6H4), 
132.55 (s, C3, C6H4), 139.93 (s, C1), 141.25 (s, C5, C6H4), 171.36 (s, C=O), 185.71 (s, C=O), 
213.66 (s, C=O), 215.97 (s, C=O) ppm. Conductivity (acetone): 1.11 μS/cm (neutral).  
 
Synthesis of 7  
[Hg(2-C6H4C(O)N=PTA)Cl] 
 
(CO)4Mn(2-C6H4C(O)N=PTA) (6)  (0.44 g, 1.0 mmol) and HgCl2 (0.54 g, 2.0 mmol) were 
refluxed in CH3OH (55 mL) for 5 h during which time the solution turned yellow and a white 
solid formed. The mixture was cooled in an ice-water bath and subsequently filtered. The white 
solid formed was washed well with cold methanol. The solid was redissolved in CH2Cl2 (<200 
mL) and filtered through celite. The resulting clear solution was reduced in volume (<3 mL) and 
Et2O was added dropwise until the solution became cloudy. Storage at -20 ºC gave white crystals 
of 7, which were filtered off, dried and used without further purification. 
 
Yield: 0.33 g (65%). Anal. Calc. for C13H16N4OPClHg·0.5CH2Cl2 (553.78): C, 29.28; H, 3.09; 






513.05), 535.03 (100%, [M+Na]
+









H NMR (CDCl3): δ 4.40 (12H, m, PTA), 7.39 (2H, t, J = 7.6 Hz, H2 + H4, C6H4), 7.51 




H} (CDCl3):  δ 52.71 (d, J = 45.9 Hz, PTA), 72.76 (d, J = 9.5 Hz, PTA), 128.33 (s, C4, 
C6H4) 129.84 (s, C5, C6H4), 131.98 (s, C3, C6H4), 136.31 (s, C2, C6H4), signals corresponding to 
NC=O ,C1and C6 were not observable. Conductivity (acetone): 0.73 μS/cm (neutral) μS/cm. 
 





[Hg(2-C6H4C(O)N=PPh3)Cl] (0.12 g, 0.2 mmol) and [(η
6
-p-cymene)Ru(μ-Cl)Cl]2 (0.13 g, 0.22 
mmol) were refluxed in CH3CN (20 mL) for 7 days after which a yellow precipitate formed. The 
pale yellow solid was filtered off and discarded and the orange solution was concentrated to 
dryness. The solid was dissolved in CH2Cl2 and filtered through celite. The solvent was removed 
under reduced pressure to a minimum, followed by addition of Et2O (~20 mL). The orange solid 
was filtered off and dried in vacuo. 
 
Yield:  0.049 g (37%). Anal. Calc. for C35H33NOPClRu·2H2O (687.18): C, 61.18; H, 5.43; N, 
2.04. Found: C, 60.97; H, 5.05; N 2.35 %.  ESI-MS: m/z: 616.13 (100%, [M-Cl]
+




H} NMR (CDCl3): δ 20.63 (s), (DMSO-d6): 21.15 (s); 
1
H NMR (CDCl3): δ 1.31 (6H, d, J = 
6.9 Hz, CH3, η
6
-p-cymene), 2.18 (3H, s, CH3, η
6
-p-cymene), 2.95 (1H, sept, J = 6.9 Hz, CH, η
6
-
p-cymene), 5.37 (2H, d, J = 6.0 Hz, CH, η
6
-p-cymene), 5.49 (2H, d, J = 6.0 Hz, CH, η
6
-p-
cymene), 7.42-7.48 (2H, m, H3 + H4), 7.49 -7.53 (6H, m, Hm), 7.56 -7.61 (3H, m, Hp), 7.84-7.89 




H} (CDCl3): δ 19.02 (s, CH3, η
6
-
p-cymene), 22.21 (s, 2CH3, η
6
-p-cymene), 30.68 (s, CH, η
6
-p-cymene), 80.58 (s, CH, η
6
-p-
cymene), 81.32 (s, CH, η
6
-p-cymene), 96.77 (s, C, η
6
-p-cymene), 101.25 (s, C, η
6
-p-cymene), 
127.65 (s, C3 + C4), 127.92 (s, C6), 128.62-128.74 (d, Cm, J = 12.4 Hz), 128.91 (s, Cipso,), 129.51-
129.53 (d, J = 3.02 Hz,  C2 + C5), 130.67 (s, C3 + C4), 132.19-132.22- (d, Cp, J = 2.9 Hz), 133.13-
133.24 (d, Co, J = 9.6 Hz), 138.51-138.72 (d, J = 20.6 Hz, C-Ru), 176.26 (s, C=O) ppm. IR (cm
-
1









[Hg(2-C6H4C(O)N=PTA)Cl] (7)  (0.1 g, 0.2 mmol) and [(η
6
-p-cymene)Ru(μ-Cl)Cl]2 (0.13 g, 0.2 
mmol) were refluxed in CH2Cl2 (20 mL) for 3 days. Subsequently, the solvent was removed to 
dryness and the yellow solid obtained was dissolved in CHCl3 and filtered through celite. The 
solvent was removed under reduced pressure to a minimum, followed by addition of Et2O. The 
yellow solid obtained was collected by filtration and dried in vacuo. 
 
Yield: 0.14 g (66%). Anal. Calc. for C23H30N4OPClRu (546.01): C, 50.59; H, 5.54; N, 10.26. 
Found: C, 50.32; H, 5.20; N 10.53 %.  ESI-MS: m/z: 546.0 (100%, [M-Cl]
+
, calc. 546.06), 412.0 
(100%, [M-p-cymene]
-




H} NMR) (CDCl3): δ -16.3 (s), (DMSO-d6): -11.98 
(s); 
1
H NMR (DMSO-d6): δ 0.61 (3H, d, J = 6.7 Hz, CH3, η
6
-p-cymene), δ 0.99 (3H, d, J = 6.8 
Hz, CH3, η
6
-p-cymene), 2.34 (3H, s, CH3, η
6
-p-cymene), 2.24 (1H, sept, J = 7.1 Hz, CH, η
6
-p-
cymene), 4.47-4.67 (12h, m PTA), 5.81 (d, 2H, CH, η
6
-p-cymene),   6.06 (d, 1H, J = 6.5 Hz, CH, 
η
6
-p-cymene),  6.74 (d, 1H, J = 6.9 Hz, CH, η
6
-p-cymene),  7.11 (t, 1H, J = 7.7 Hz , H4),  7.31 (t, 





d6): δ 18.70 (s, CH3, η
6
-p-cymene), 19.97 (s, CH3, η
6
-p-cymene), 24.13 (s, CH3, η
6
-p-cymene), 
31.00 (s, CH, η
6
-p-cymene), 51.82 (s, PTA), 52.22 (s, PTA), 71.50 (d, J = 40.5 Hz, PTA),  86.72 
(s, CH, η
6
-p-cymene), 87.22 (s, CH, η
6
-p-cymene), 95.97 (s, CH, η
6
-p-cymene), 100.6 (s, C, η
6
-
p-cymene), 127.65 (s, C4), 128.6 (s, C5), 128.6 (s, Cipso,), 132.6 (s, C3), 138.6-138.7 (d, J = 20.6 
Hz, C-Ru), 141.1 (s, C2), 183.9 (s, C=O) ppm. IR (cm
-1
):  562 (Ru-N), 1314 (N=P), 1582  
(C=O). Conductivity (acetone): 25.4 (neutral) μS/cm. Solubility: 0.79 mM or 0.43 mg/mL (H2O). 
 
X-Ray crystallography 
Single crystals of 1 (see details in Table 5 in Appendix) were mounted on a glass fiber in a 
random orientation. Data collection was performed at RT on a Kappa CCD diffractometer using 
graphite monochromated Mo-Kα radiation (λ=0.71073 Å). Space group assignments were based 
on systematic absences, E statistics and successful refinement of the structures. The structures 




refined using the SHELXTL 6.1 software package. All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were assigned to ideal positions and refined using a riding 
model. Details of the crystallographic data are given in Table S1 (SI). These data can be obtained 
free of charge from The Cambridge Crystallographic Data Center via 
www.ccdc.cam.ac.uk/data_request/cif. (CCDC 1008354) or in the supporting information. 
Crystals of 1 (xxx prisms with approximate dimensions 0.26 x 0.24 x 0.21 mm) were obtained 
from a solution of 1 in CH2Cl2 by slow diffusion of Et2O at RT.  
 
Cell culture, inhibition of cell growth and cell death analysis 
Cell culture 
The human T-cell leukemia Jurkat (clone E6.1) and the prostate carcinoma DU-145 were 
routinely cultured in RPMI 1640 medium supplemented with 5% fetal calf serum (FCS), L-
glutamine and penicillin/streptomycin. A549 (lung carcinoma), MiaPaca2 (pancreatic 
carcinoma), MDA-MB-231 (Triple negative breast carcinoma) and 293T (non-tumoral 
embryonic kidney cells) were cultured in DMEM medium supplemented with 10% FCS, L-
glutamine and penicillin/streptomycin.  Media for A549 cells were also supplemented with 2,2 
g/l Na2CO3, 100 µg/ml pyruvate and 5 ml non-essential amino acids (Invitrogen). All these 
media will be referred as ‘complete medium’ hereinafter. Cell cultures were maintained in a 
humidified atmosphere of 95% air / 5% CO2 at 37 ºC.   
MTT toxicity assays 
For toxicity assays cells (5 x104 for Jurkat cells and 104 for adherent cell lines) were seeded in 
flat-bottom 96-well plates (100 µl/well) in complete medium.  Adherent cells were allowed to 
attach for 24 h prior to addition of cisplatin or tested compounds.  Compounds were added at 
different concentrations in triplicate. Cells were incubated with cisplatin or compounds for 24 h  
and then cell proliferation was determined by a modification of the MTT-reduction method.
  
Briefly, 10 µl/well of MTT (5 mg/ml in PBS) was added and plates were incubated for 1-3 h at 
37 ºC. Finally, formazan crystal was dissolved by adding 100 µl/well 
i
PrOH (0.05 M HCl) and 




autoreader (ELISA). In some experiments total cell number and cell viability were determined by 
the Trypan-blue exclusion test.  
Cell culture and XTT assay for RPTC cells 
The human Renal Proximal Tubule Cells (RPTC) a non-tumoral human kidney epithelial cell 
line (obtained from Lifeline Cell Technology, Frederick, Maryland, USA) were cultured in 
Lifeline's RenaLife Medium containing RenaLife LifeFactors with 2.4 mM L-Glutamine, 5 
Î¼g/mL  rh insulin, 1.0 Î¼M epinephrine, 10 nM  triiodothyronine, 0.1 Î¼g/mL hydrocortisone 
hemisuccinate, 10 ng/mL rh EGF, 0.5% FBS and 5 Î¼g/m transferrin PS (all from Lifeline Cell 
Technology), at 37°C in a humidified atmosphere of 95% of air and 5% CO2 (University of 
Hawaii Cancer Center, Honolulu, Hawaii, USA).  For evaluation of cell viability, cells were 
seeded at a concentration of 5×10^3 cells/well in 90 µl Lifeline's RenaLife complete 
medium into tissue culture grade 96-well flat bottom microplates (Thermo Scientific BioLite 
Microwell Plate, Fisher Scientific, Waltham, Massachusetts, USA) and grown for 24 h. Solutions 
of the compounds were prepared by diluting a freshly prepared stock solution (in H2O) of the 
corresponding compound in Lifeline's RenaLife complete medium. Afterwards, the intermediate 
dilutions of the compounds were added to the wells (10 µL) to obtain a final concentration 
ranging from 0.1 to 200 µM, and the cells were incubated for 24 h. Following 24 h drug 
exposure, 50 µL of 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-
Carboxanilide (XTT) (Roche Diagnostics, Indianapolis, Indiana, USA) labeling mixture per 
well was added to the cells at a final concentration of 0.3 mg/ml and incubated for 4 h at 37°C in 
a humidified atmosphere of 95% of air and 5% CO2. The optical density of each well (96-well 
plates) was quantified using EnVision Multilabel Plate Readers (Perkin Elmer, Waltham 
Massachusetts, USA) at 450 nm wavelength to measure absorbance. The percentage of surviving 
cells was calculated from the ratio of absorbance of treated to untreated cells. The IC50 value was 
calculated as the concentration reducing the proliferation of the cells by 50% and is presented as 
a mean (± SE) of at least two independent experiments each with triplicates. 
Cell death analysis 
Apoptosis/necrosis hallmarks of cells treated with compounds 2 and 3 were analyzed by 




treated with different concentrations and at different incubation times as indicated in figure 
legends. In some experiments the general caspase inhibitor z-VAD-fmk was added at 50 µM 1 h 
before compounds.  For mitochondrial membrane potential determination cells (2.5x10
5
 in 200 
µl) after treatment with compounds were incubated at 37ºC for 15 min. in ABB (140 mM NaCl, 
2.5 mM CaCl2, 10 mM Hepes/NaOH, pH 7,4) containing 60 mM tetramethylrhodamine ethyl 
ester (TMRE, Molecular Probes). Phosphatidylserine exposure was quantified by labeling cells 
with AnnexinV-PE or AnnexinV-DY636 (Invitrogen) after treatment with compounds. 
AnnexinV was added at a concentration of 0.5 µg/mL and cells were incubated at room 
temperature for 15 min. In all cases, cells were diluted to 1 ml with ABB to be analyzed by flow 
cytometry (FACScan, BD Bioscience, Spain).  
Intracellular ROS quantification 
Oxidative stress induced by compounds 2 and 3 was analyzed by intracellular staining with the 
fluorescent probe 2-hydroxiethidium (2-HE, Molecular Probes).  After 16 h of culture in the 
presence of compounds 1-3, cells were incubated with 2 µM 2-HE at 37ºC for 15 min.  Red 
fluorescence produced by reduction of 2-HE to ethidium was quantified in a flow cytometer. 
Effect of 2 in the levels of proteins of the Bcl-2 family 
Jurkat cells (5x10
5
 cells/ml) were treated with 2 (1 µM) for 6 h.  At the end of incubations total 
protein extracts from 2x10
6
 cells were prepared in lysis buffer and samples (50 micrograms/lane) 
were resolved by SDS-PAGE and transferred onto nitrocellulose membranes.  Then, levels of 
some members of the Bcl-2 family of proteins were analyzed by Western Blot using specific 
antibodies: Bcl-XL (Cell Signalling, cat 2764), Bcl-2 (Abcam, Cat AB692), Mcl-1 (Santa Cruz 
Biotech, cat. SC819), Bim (Calbiochem, cat. 202000), Puma (Cell Signaling, Cat. 4976) and 
Noxa (Abcam, Cat. 114C307). After incubation with primary antibodies, membranes were 
incubated with appropriate secondary antibodies conjugated with HRP.  Finally, membranes 
were revealed using a chemiluminiscence substrate (Pierce).   
Inhibition of cathepsin B 
Cathepsin B, purified from human liver (Accession # P07858) and substrate Peptide sequence: 




50 mM NaCl, 0.005% Brij35, 5 mM DTT and 1% DMSO with a final concentration of 10 μM. 
The enzyme solution was delivered into the reaction well. 2 (1% DMSO solution) was delivered  
into the enzyme mixture by Acoustic technology (Echo550; nanoliter range), incubate for 10 
min. at room temp. The substrate solution was delivered into the reaction well to initiate the 
reaction. The enzyme activity was monitored (Ex/Em = 355/460 nm) as a time-course 
measurement of the increase in fluorescence signal from fluorescently-labeled peptide substrate 
for 120 min. at room temperature. The data was analyzed data by taking slope (signal/time) of 
linear portion of measurement. The slope is calculated by using Excel, and curve fits are 
performed using Prism software. 
Interaction of compounds 1-4, 8, 9, [(η
6
-p-cymene)Ru(μ-Cl)Cl]2 and cisplatin with plasmid 
(pBR322) DNA by Electrophoresis  
(Mobility Shift Assay) 
10 µL aliquots of pBR322 plasmid DNA (20 µg/mL) in buffer (5 mM Tris/HCl, 50 mM NaClO4, 
pH = 7.39) were incubated with different concentrations of the compounds (1-4, 8, 9, [(η
6
-p-
cymene)Ru(μ-Cl)Cl]2) (in the range 0.25 and 2.0 metal complex:DNAbp) at 37 
o
C for 20 h in the 
dark. Samples of free DNA and cisplatin-DNA were prepared as controls. After the incubation 
period, the samples were loaded onto the 1 % agarose gel. The samples were separated by 
electrophoresis for 1.5 h at 84 V in Tris-acetate/EDTA buffer (TAE). Afterwards, the gel was 
stained for 30 min. with a solution of GelRed Nucleic Acid stain.  
 
Interaction of compounds 1-4 with Calf Thymus DNA by Circular Dichroism 
Stock solutions (5 mM) of each complex were freshly prepared in water prior to use. The right 
volume of those solutions was added to 3 ml samples of an also freshly prepared solution of CT 
DNA (48 µM) in Tris/HCl buffer (5 mM Tris/HCl, 50 mM NaClO4, pH=7.39) to achieve molar 
ratios of 0.1, 0.25, 0.5, 1.0 and 2.0 drug/DNA. The samples were incubated at 37ºC for a period 
of 20 h. All CD spectra of DNA and of the DNA-drug adducts were recorded at 25ºC over a 
range 220-420 nm and finally corrected with a blank and noise reduction. The final data is 





DNA precipitation with compounds 2 and 3 and quantification of ruthenium by ICP-MS 
Stock solutions of compounds 2 and 3 (4 mM in water) and CT DNA (11.56 mM in 5 mM 
Tris/HCl, 50 mM NaClO4, pH=7.39) were freshly prepared prior to use. 216 µl of DNA stock 
solution were diluted in 3.53 mL of buffer and 1.25 mL of compound stock solution were then 
added to achieve 5 mL final volume at concentrations of 500 µM in DNA and 1 mM in metal 
compound. Each sample was incubated at 37ºC for a period of 20 h, then cooled down to room 
temperature and centrifuged at 3000 rpm for 15 min. and at 4000 rpm for extra 40 min. The 
supernatant was separated and analyzed for CT DNA concentration by CD spectroscopy. The 
resulting pellet was washed twice with ice-cold ethanol (1 mL), centrifuged at RT for 1 min. at 
4000 rpm, dried under high vacuum and analyzed for Ru content by ICP-MS. The total amount 
of DNA in each sample was 0.92 mg. Every experiment was run in duplicate. 
Interaction of compounds 1-4, 8, 9, and cisplatin with HSA by Fluorescence Spectroscopy 
A solution of each compound (8 mM) in DMSO was prepared and ten aliquots of 2.5 µL were 
added successively to a solution of HSA (10 µM) in phosphate buffer (pH = 7.4) to achieve final 
metal complex concentrations in the range 10-100 µM. The excitation wavelength was set to 295 
nm, and the emission spectra of HSA samples were recorded at room temperature in the range of 
300 to 450 nm. The fluorescence intensities of all the metal compounds, the buffer and the 
DMSO are negligible under these conditions. The fluorescence was measured 240 s. after each 
addition of compound solution. The data were analyzed using the classical Stern-Volmer 
equation F0/F = 1 + KSV[Q]. 
In vivo tests 
All animal experiments were performed according to the University of Hawaii Cancer Center 
regulations and by approval of the responsible authorities (UH IACUC number: A3423-01).  
Determination of lethal dose (LD) and maximum tolerated dose (MTD) of 2 in mice 
14 female C57/Black 6 from Jackson Laboratory (Bar Harbor, ME and Sacramento, CA, USA) 
ages 8 to 14 weeks and weighing 18–26 g were used for these experiments. Mice were 




groups. At trial end-point the mice were sacrificed and liver, spleen, kidney and blood plasma 
were collected, and then processed for further analysis. Gross and microscopic evaluations of 
liver, spleen and kidney were conducted. The weight of 2 treated mice compared and that of 
vehicle-treated mice as measured twice weekly. 
The lethal dose (LD) was determined by injecting once mouse i.p. once 5 mg/kg/day, 10 
mg/kg/day, 20 mg/kg/day, 30 mg/kg/day, or 50 mg/kg/day, and one vehicle control with 100µl 
Normal Saline (0.9% NaCl)). The dose that killed the mice within 24 hours was set to be lethal 
dose. The lethal dose was confirmed by administering that dose to a second mouse. The 
maximum tolerated dose (MTD) was determined by injecting two mice with 5 mg/kg/day, 10 
mg/kg/day, or 20 mg/kg/day over 6 days, or 20 mg/kg/every other day over 6 days and one 
vehicle control mouse with 100µl Normal Saline (0.9% NaCl). The MTD was confirmed by 
administering the determined dose to 3 mice over 7 days and three vehicle control mice with 
100µl Normal Saline (0.9% NaCl). 
Study of the effects of 2 in MDA-MB-231 xenografts in mice 
12 female NOD.CB17-Prkdc scid/J (non-obese diabetic–severe combined immunodeficiency) 
from Jackson Laboratory (Bar Harbor, ME and Sacramento, CA, USA) for the xenograft 
experiment (ages 8 to 12 weeks and weighing 19–24 g, were used. Each mouse received 5x10
6
 
tumor cells subcutaneously without anesthesia. Exponentially growing oestrogen-receptor alpha-
negative MDA-MB-231 human breast cancer cells were suspended in 1:1 ratio 50 μl phosphate-
buffered saline (PBS; pH 7.4) plus 50 μl of matrigel (BD Biosciences, San Jose, CA, USA) were 
injected subcutaneously on both left and right flank of each mice’. The diameter of the tumors 
was measured once weekly using an electronic digital caliper and the tumor volume (TV) was 
calculated according to the empirical equation TV = (a)(b
2
) x π/6 where a = longest dimension; b 
= largest dimension orthogonal to a. The median volumes of each group were normalized to the 
initial tumor volume resulting in the relative tumor volume. Each six MDA-MB-231-
transplanted animals received compound 2 (5 mg/kg/every other day) or vehicle (0.9% NaCl) 
intraperitoneally (i.p.) Treatment started when tumors were palpable (about 5–6 mm diameter).  
To palliate the weight loss observed in the MTD study the mice were fed a 46% fat-adjusted diet 




subcutaneous injection of 100µl Normal Saline (0.9% NaCl) to improve hydration. Mice were 
randomized to treatment groups based on their starting tumor burden at 12 weeks of age to 
ensure equivalent distribution between the two groups. At trial end-point the mice were 
sacrificed and tumors measured again after excision and then processed for further analysis. 
Histological as well as biochemical evaluations of blood, liver, intestine, kidney, and lung were 
conducted. Tumor volumes were graphed for (2) treated mice compared to vehicle-treated mice, 
based on weekly external digital caliper measurements.  
Pharmacokinetic study: determination of ruthenium content in the organs, entire blood, 
and plasma 
Female NOD.CB17-Prkdc scid/J bearing subcutaneous MDA-MB-231 tumors and treated with 
compound 2 (5 mg/kg/every other day) intraperitoneally were used for pharmacokinetic 
evaluation of the drug in blood and other tissues. Blood was collected retroorbitally using 
heparin coated glass capillary into heparinized blood collection vials on ice at time intervals of 
30 min, 2 h, 6 h, 24 h and 48 h. after the first dose. The blood samples were centrifuged at 2800 
rpm at 4°C for 15 min. and the supernatant plasma was transferred into 1.5 mL micro-centrifuge 
tubes and maintained at -80 °C until analysis.  
Ruthenium content was determined using Inductively Coupled Plasma - Mass Spectrometry 
(ICP-MS). Fifty microliter of plasma was transferred into a glass vial and 1 mL of concentrated 
acid mix (comprising of 75% of 16 N nitric acid and 25% of 12 N hydrochloric acid) was added. 
The mixture was heated at 90 °C for 5 h. After cooling, the samples were diluted with water, 40 
ppb of Indium internal standard was added and analyzed in a Thermo Scientific XSERIES 2 
ICP-MS with ESI PC3 Peltier cooled spray chamber with SC-FAST injection loop and SC-4 
autosampler. All the elements were analyzed using He/H2 collision-reaction mode. Plasma from 
control mice was spiked with the test compound to determine the extraction efficiency.  
At the end of the study, liver, kidney and tumor of the animals were harvested, weighed and 
transferred into glass vials. One ml of water was added to each samples and subjected to 
ultrasonic tissue disruption at 15W power for 1 min. The tissue homogenates were frozen at -80 
°C for 2 h and lyophilized. The lyophilized product was heated at 90 °C with the concentrated 




ICP-MS. Pharmacokinetic estimates were obtained from the plasma concentration–time profiles 







5.8.1. Crystallographic Data for Compound 1. 
 




T [K] 293 (2) 
λ (MoKα)[Å] 0.71073 
crystal system Monoclinic 
space group C2/c 
a [Å] 37.8820(15) 
b [Å] 10.8170(5) 





















R1[I > 2σ] 0.0551 



























H NMR spectra of compound 4 in CDCl3. 
 
 
Figure 16. Variable temperature 
1







Figure 17.  Variable temperature 
1
H spectra of compound 4 in CDCl3 (magnification zone 2.9-
0.1 ppm). 
 
































Compound Time (DMSO-d6) 
2.5 h 1 d 6 d 1 w 2 w 3 w 1 m 1.5 m Half life 
(50%) 
1     >99%  91%  months 
2      >99% 87%  months 
3        >99% months 
4       >99%  months 
8   >99% 58%  25% 0%  ~ 9 days 
9 >99% 85%  50% 27%  6%  ~ 1 week 
 
a) % of decomposition determined by integration of all the signals present in the 31P{1H} 




Compound Time (D2O) 
3 d Half life (50%) 
1  insoluble 
2  2.5 days 
3  b 
4 99% c 
 
a) % of decomposition determined by integration of all the signals 




H} NMR spectra, the sum being set to 100%. 
b) Compound hydrolyzes when dissolved in water (45:55 ratio). 
















































H} NMR spectra of compound 8 in DMSO-d6 ( 21.09 (s) ppm) overtime. 
 
 
















H NMR and 
13









































Figure 33.  
1







































H} NMR spectra of compound 2 in D2O ( 26.48 (s) ppm) after heating at 80
o
C 









H} NMR spectra of compound 3 in D2O ( 37.84 (s) ppm) after heating at 80
o
C 
for one hour. 
5.8.8. Mass spectra (ESI+) of compound 2 in H2O solution overtime (5 days). 
 





Figure 39. Magnification of [m/z] from 600 to 665 of compound 2 in H2O solution at t = 0. 
 






Figure 41. Magnification of [m/z] from 600 to 665 of compound 2 in H2O solution at t = 5 days. 
 
 





 in the MS ESI+ spectrum of compound 2 
in H2O solution at t= 5 days. Insert: theoretical isotopic distribution. 










Figure 43. Effect of 2 in the levels of proteins of the Bcl-2 family. Jurkat cells were left 
untreated (control) or incubated for 6 h with compound 2 (1 µM).  At the end of incubations total 
protein extracts were prepared as described in the Experimental section and analyzed by Western 




5.8.10. Experiments to assess the interaction of compounds 2-4 with CT DNA by circular 
dichroism. 
 
Figure 44.  CD spectra of CT DNA (48 µM) and CT DNA incubated with 0.1, 0.25 and 0.5 
equivalents of compounds 1 (A), 2 (B), 3 (C) and 4 (D) for 20 h at 37 °C. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
_________________________________________________ 
• A series of organometallic and coordination gold(III), platinum(II), palladium(II) and 
ruthenium(II) compounds with water-soluble, ferrocene-based and luminescent 
iminophosphorane ligands have been successfully synthesized and characterized. A synthetic 
method for the preparation of cyclometalated exo derivatives of different metals is described. 
A mercury-free transmetallation with organogold(I) derivatives has been employed for the 
preparation of endo cycloplatinated compounds. 
• In the cases of d8 transition metal complexes it was demonstrated that cyclometallated 
complexes are more stable in physiological media than coordination compounds. Both, 
coordination and cyclometalated IM ruthenium(II) complexes are quite stable in physiological 
media or water. 
• The compounds exhibit important cytotoxic effects in vitro in the low or sub-micromolar 
range in selected human cancer cell lines and in most cases are markedly more cytotoxic than 
cisplatin, while being less toxic on ”healthy” cell lines. 
• Studies of the interactions of the compounds with plasmid (pBR322) DNA and/or Calf 
Thymus DNA indicated in most cases no interaction, or a weak interaction electrostatic in 
nature. In specific cases we were able to demonstrate the formation of left-handed helix of Z-
form DNA through strong electrostatic interactions (for a cyclometalated exo-Pt(II) complex 
(3)) or backbone charge neutralization, further confirmed by ICP-MS analysis of metal 
content in DNA precipitates for ruthenium(II) complexes.  
• Most of the complexes displayed a concentration dependent fluorescence quenching of HSA, 
indicating faster binding compared to cisplatin. 
• Studies of intracellular distribution on human ovarian cancer (A2780) cells with selected 
compounds (e.g. 3, and 7, Chapter I) using fluorescence microscopy failed. 
• Initial mechanistic studies for selected compounds indicated that the cell death type is 




caspase-dependent apoptosis, not dependent on p53 while for apoptotic cycloplatinated 
compound 5, caspase-independent cell death is triggered when apoptosis is blocked). 
• Permeability studies for a selected cycloplatinated compound (5) revealed its high 
permeability profile and an estimated oral fraction absorbed of 100% which potentially makes 
it a good candidate for oral administration. 
• The efficacy of the highly water-soluble Ru(II) complex (2) in vivo on xenografted breast 
carcinoma MDA-MB-231-tumors grown on NOD.CB17-Prkdc scid/J mice demostrated a 
tumor reduction (shrinkage) of 56% after 28 days treatment with low systemic toxicity, and 
accumulation of the complex preferentially in the breast tumor tissues when compared to 
kidney and liver. These results make compound 2 the most promising organometallic p-
cymene ruthenium(II) anticancer agent described so far and a potential candidate for 
subsequent more elaborated preclinical studies. 
• Overall, our results support the idea that non-toxic iminophosphorane molecules are excellent 




 metals (especially cationic 





The results obtained in chapter III will guide us to design new iminophosphoranes 
complexes with better luminescence properties in cells in vitro. We will need to design 
compounds with a better stability in biological media and to increase the fluorescence detection 
limits. A possible direction involves the synthesis of cyclometalated compounds incorporating 
modified luminescent iminophosphorane ligands based on susbtitutions on the 8-aminoquinoline 
scaffold (methyl or fluorine groups).  
The results obtained in chapter IV have made us select endo cycloplatinated compound 5 
as a candidate for further in vivo and mechanistic evaluation. The promising water-soluble 
ruthenium(II) complex (2) will be further evaluated in vivo on different tumors such as prostate, 
colon and pancreas. More detailed mechanistic studies are underway after its evaluation on the 
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